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ABSTRACT OF DISSERTATION 
 
 
 
EXPLORATIONS IN HOMEOVISCOUS ADAPTATION AND MASS SPECTRAL 
ANALYSIS OF MEMBRANE LIPIDS 
 
The focus of this dissertation is centered on the mass spectral analysis of lipids 
and changes occurring in keeping with the concept of homeoviscous adaptation [1].  
Homeoviscous adaptation is the process of modification of membrane lipids in response 
to environmental stimuli [1].  Dissertation investigations applied this concept to 
prokaryotic and eukaryotic organisms, and expanded the perception of environmental 
factors from exogenous organic solvents to intracellular environment.   
The field of lipidomics deals with the analysis of phospholipid and fatty acid 
components of membranes the changes that occur due to environmental stimuli and their 
biological significance [2-6].  The high sensitivity of mass spectrometry (MS) is an ideal 
tool for lipidomics allowing detection, quantification and structural elucidation [6].  
Coupling of a mass spectrometer to a chromatographic system, such as gas 
chromatograph (GC), allows the separation of fatty acid methyl esters analytes prior to 
analysis [7]. 
The research investigations that comprise this dissertation are divided into three 
interrelated projects.  The first project involved the analysis of composition and structure 
of Clostridium thermocellum membranes from wild-type and ethanol-adapted strains in 
response to adaptation of cultures to growth in ethanol.  The hypothesis being that 
adaptation of cultures to growth in ethanol would result in compensatory change to the 
membrane composition. 
Rat mitochondrial fatty acid profiles isolated from brain, liver, kidney and heart 
tissues were compared.  The hypothesis being that differences in cellular environments 
found among various tissues would be reflected in the mitochondrial membrane 
composition.  These data support the concept that variations to the lipid content of 
neurological mitochondria may increase susceptibility to the products of oxidative stress.   
Lastly, changes in neurological mitochondria as a function of Alzheimer’s disease 
progression were studied.  The hypothesis being that changes to the mitochondrial 
lipidome would be significantly reflected during advanced stages of AD, in addition to 
being more prevalent in regions displaying greater pathology.   
The three interrelated projects increased our understanding of the boundaries 
established by the concept of homeoviscous adaptation.  Project specific hypotheses were 
supported by data obtained from these investigations.   
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PART I.  LIPIDOMICS AND MASS SPECTROMETRY 
Chapter 1.1.  Background 
The analysis of lipids and lipid derivatives has been firmly established in the 
literature since Folch et al. developed a procedure to extract lipids from animal tissue.  
From these early days, the evolution of lipid analysis has kept pace with improvements in 
instrumentation [8-10].  Mass spectrometry (MS) is an ideal tool for lipid analysis 
allowing quantification and structural identification of components.  For studies based on 
the analysis of biological samples, where analytes might be at µg or ng/µL 
concentrations, mass spectrometry permits small-volume sample injections and low limits 
of detection [6].  Mass spectrometry coupled to a separation technique, such as gas 
chromatography (GC), facilitates the separation of isomers and relative quantitation can 
be achieved by area count comparisons with an internal standard.   
Not being immune from the -omics revolution, the traditional discipline of lipid 
analysis has evolved into lipidomics.  With previously established -omics based 
disciplines for the study of proteins, nucleic acids and metabolites, lipidomics was a 
natural scientific step in high-throughput analysis [4-5, 11-13].  The field of lipidomics 
originated as an area of study centered on the characterization of lipid molecular species 
and their roles with regard to cellular processes [4-5].  Lipids are linked to numerous 
cellular pathways by functioning mutually as end-products of metabolism and as 
substrates for the generation of signaling molecules [4-5, 11-13].  Each of the studies 
included in this dissertation will be focused on the investigation of derivatizied lipid acyl 
chains followed by analysis using GC/MS. 
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Chapter 1.2.  Introduction 
Lipids 
Glycerophospholipids or phospholipids are classified as complex lipids, meaning 
they can be divided into simpler components through hydrolysis.  The 
glycerophospholipid units can be divided into two general regions: (1) a polar head group 
(PHG), typically a derivatized phosphoric acid group, and (2) a hydrophobic portion 
consisting of long-chain fatty acids esterified to a glycerol backbone (Figure 1.1) [14]. 
Aggregates of phospholipid monomers associate together through non-covalent 
interactions to form membrane layers.  Due to the nature of the two hydrophobic tails 
phospholipids interact in order to maximize van der Waals forces between acyl chains.  
The result is a lipid bilayer formed from the hydrophobic interaction of the acyl chains on 
opposing phospholipid monomers (Figure 1.2).  The associated hydrophilic polar head 
groups end-caping the chains with the inner leaflet PHG interacting with the cytosol and 
the outer leaflet PHG exposed to the extracellular matrix [14].  Biological membranes 
have various proteins and carbohydrates associated with the membrane integrated among 
the glycerophospholipid units.   
The phosphoric acid group is generally modified by a head group bonded through 
a phosphoester to the phosphate group.  The modifying substituent provides the polar 
head group with unique functionally allowing recognition by signaling molecules (Figure 
1.3).  The chemical structure of the various head groups range from amine, sugar, amino 
acid, glycerol, hydroxyl or an additional glycerophospholipid as in the case of cardiolipin 
[14].   
Biological membranes in their native form have two fatty acid chains esterified to 
the glycerol backbone of each glycerophospholipid moiety.  The acyl chains are generally 
attached to the glycerol backbone on carbons 1 & 2, also known as stereospecific 
numbering (sn).  For the most part acyl chains are attached to the glycerol backbone by 
an ester linkage (Figure 1.4a).  Chains that are attached in this manner are known as fatty 
acids (FAs), in reference to their carboxylic acid functionality.  Replacement of the ester 
bond with an α,β-unsaturated ether, or vinyl ether linkage results in a lipid species known 
as plasmalogens (P) (Figure 1.4b) [14-16]. 
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Figure 1.1.  Phospholipid structure. 
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Since the projects contained herein were focused on analysis of FAs and 
plasmalogen chain species obtained from phospholipids, the discussion of lipid synthesis 
and analysis will be targeted to these species. 
It is important to cover a brief background on the synthesis of fatty acids and 
plasmalogens species.  The multienzyme complex involved in FA synthesis, fatty acid 
synthetase, is similar in eukaryotes and bacteria.  Overall the synthesis of fatty chains 
progresses through a series of reactions that serves to lengthen the chain in two carbon 
units (Figure 1.5) [17].  The initial steps involve the formation of acetyl-acyl carrier 
protein (ACP) and malonyl-ACP with dissociation of coenzyme A (CoA) from both 
acetyl and malonyl.  The first condensation step combines acetyl-ACP and malonyl-ACP, 
with the loss of ACP from the acetyl group.  This is followed by a reduction of the acetyl 
carbonyl group by nicotinamide adenine dinucleotide phosphate (NADPH).  Dehydration 
forms a double bond between the acetyl and malonyl bonding carbons.  This is followed 
by a NADPH catalyzed reduction across the double bond [14, 17].  The steps are repeated 
beginning with the synthesized butyryl-ACP condensing with malonyl-ACP then are 
repeated in a polymeric fashion beginning with reduction, dehydration then reduction.  
The elongation reaction proceeds until the chain is sixteen carbons long and no longer a 
substrate for the fatty acid synthetase enzyme [17].  The C16 is then cleaved from the 
ACP portion.  Fatty acids with odd-chain length are formed with propionyl-ACP 
replacing the acetyl-ACP [14].  Unsaturated FA are the result of oxidase enzyme 
complexes that consume NADH and O2 in a oxidation dehydration reaction [17]. 
Much like the synthesis of FA the synthesis of plasmalogens occurs by a 
multistep process (Figure 1.6) [16].  The first step is the esterification of 
dihydroxyacetone phosphate (DHAP) with an acyl CoA molecule.  The enzyme alkyl-
DHAP synthase forms an ether bond by replacement of the fatty acid chain with a long 
chain alcohol species.  Reduction of the carbonyl group forms a hydroxyl group.  The 
next step is the transfer of an acyl fatty acid chain onto the hydroxyl group.  Following 
this the desaturation of the ether bond by the enzyme Δ1’-desaturase completes 
plasmalogen synthesis [16].      
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The nomenclature of FAs used throughout this dissertation will be important for 
understanding background information and later during research projects.  The naming 
system employed followed rules established by the International Union of Pure and 
Applied Chemistry (IUPAC) nomenclature for carboxylic acid and esters when 
discussing derivatizied species [18].  In brief, saturated or substituted carboxylic acids 
were named by modifying the IUPAC name of the root alkane compound by removing 
the final “-e” and replacing it with “-oic acid”.  The carbon chain is numbered starting 
with carbonyl carbon identified as 1.  Substituents along the chain are identified by their 
respective IUPAC nomenclature and named according to the carbon which they are 
attached.  Esters derivatives are again named according to their IUPAC rules.  First the 
substituent group that replaced the hydroxyl of the free acid is identified, (i.e. methyl) 
followed by replacement of the “-oic acid” suffix with “-oate” (Figure 1.7) [19]. 
Unsaturated FAs were named in a similar manner, however instead of using the 
root alkane, the alkene was modified to denote sites of unsaturation.  Conversion of the 
root alkene involves removing the terminal “-e” and replacing it with “-oic acid” for 
naming the free acid [19].  Multiple double bonds along the chain, as in case with 
polyunsaturated fatty acids (PUFAs), are denoted by adding a Greek modifier directly 
before the alkene “-ene” suffix.  This follows the same systematic rules as naming 
alkenes with multiple double bonds.  As with substituents along the chain, sites of 
unsaturation are identified by the number of the initial carbon containing the double 
bond, when counting from the carbonyl carbon (Figure 1.8) [19]. 
Shorthand nomenclature is commonly used during the reporting of results.  This 
abbreviated representation takes the form: x:y; where x denotes the number of carbons 
comprising the chain and y signifies the number of double bonds.  The chain is 
considered carbons from the carbonyl to the terminal methyl group.  For esterified 
species the number of carbons within the chain does not include the substituent added to 
the carbonyl group.  Additional information of double bond location is supplied by 
adding the Greek uppercase delta (Δ) followed the carbon number at which the double 
bond is initiated.  An example of this would be 10-octadecenoic acid, written in 
shorthand translates to 18:1Δ10 [19-20].  Another abbreviation commonly used with 
PUFAs is omega (ω).  The ω denotes the number of carbons from the further double  
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bond, relative to the carbonyl, to the terminal methyl group.  Therefore, a fatty acid with 
six carbons from the terminal methyl group to the first double bond would be symbolized 
in shorthand as ω-6, otherwise known as an omega six fatty acid.  At times within the text 
common names for fatty acids have been used for particular fatty acids as these names 
are more popular than the systematic names.  In these cases the common name is given 
with the IUPAC systematic name [18, 20].               
Analysis of the fatty acid species was achieved by the traditional base-catalyzed 
saponification reaction to break the bonds between the acyl chains and the glycerol 
backbone.  Intact membrane glycerophospholipids were reacted with sodium hydroxide 
forming sodium carboxylates [19-20].  Protonation of the free acid was achieved by 
addition of hydrochloric acid (Figure 1.9).  Following extraction of the free acid an 
esterification reaction converts the free acid to an ester.  Methylation of free acids 
through esterification with acetyl chloride and methanol results in formation of fatty acid 
methyl esters (FAMEs) (Figure 1.10) [19-20].  Although esterification reactions can be 
conducted with a number of reagents, reaction with acetyl chloride was preferred for 
small-scale preparation and mild reaction conditions.    
Derivatization of the fatty acids to an ester increases the volatility and removes 
functionality from the carboxylic acid end improving the amenability to GC analysis [20-
21].  Of course analysis of free acids can be conducted without conversion to esters.  
However, conversion to the ester by reaction with excess alcohol pushes the free acid 
reagents to form predictable derivatives and generates a stable product.  Although nearly 
any reagent with a hydroxyl group would suffice for esterification, methanol was chosen 
because the addition of a methyl group minimally increases the molecular weight of the 
final ester.  This is important when considering GC analysis, as higher molecular weight 
compounds often require increased temperatures for volatility and column elution.  On 
the detection end methyl addition was advantageous because mass analyzers often have 
mass limits, this is generally not a problem except for extreme cases, such as long-chain 
FAs and benzyl-type derivatives.  The other advantage is that fatty acid methyl esters are 
the most common researched derivatives, making results comparable to published mass 
spectra and mass spectral libraries [20]. 
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Figure 1.9.  Saponification reaction scheme. 
15 
 
 
  
Cl
O
CH
3
OH
OH+
O
CH
3
Cl
O
O
CH
3
HCl+ + +
OH
O
HCl+
OH
OH
CH
3
OH
OH
OH
O
CH
3 H
OH
OH
O
CH
3
H
+
O
CH
3
OH
OH
2
O
O
CH
3
+ +
+
+
+
Figure 1.10.  Methylation reaction scheme. 
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During the FA esterification reaction, the vinyl ether bond from the plasmalogen 
is cleaved generating an aldehyde.  Reaction of the aldehyde with methylation reagents 
converts the aldehydes into dimethyl acetals (Figure 1.11) [19-20].  Following 
saponification the vinyl ether bond is converted to an aldehyde.  Due to the acidic nature 
of the esterification reaction the carbonyl group of the aldehyde is protonated.  
Nucleophilic attack by methanol on the activated carbonyl carbon generates formation 
hemiacetal.  Subsequent protonation of the hemiacetal hydroxyl group generates water as 
a leaving group.  The loss of water forms a carbocation that is attacked by another 
nucleophilic methanol.  The result is formation of a dimethyl acetal [19-20].  The 
nomenclature for these compounds follows the IUPAC rules for naming acetals [18-19]. 
Instrumentation 
The analysis of all derivatizied species were preformed on a Varian Saturn 3 
GC/MS system (Figures 1.12 & 1.13).  Discussion on instrumentation will first involve 
the theory and brief background on gas chromatography followed by mass spectrometry 
theory and operation.   
Gas chromatography 
A gas chromatograph (GC) is an instrument that separates compounds based on 
volatility and structure [21].  A gas chromatograph in general has three main components: 
an injector, a column housed inside an oven and a detector.  For GC/MS the detector is a 
mass analyzer, therefore the GC detector is replaced by a transfer line leading to the mass 
spectrometer. 
The chemical composition of the column’s stationary phase is central to the 
analytical performance of the experiment and interaction with the stationary phase has the 
greatest single influence on analyte separation [21].  Differential interaction of analytes 
with the stationary phase is the basis for chromatographic separation in any GC 
experiment.  The column resides within a GC oven and during a chromatographic 
experiment the oven temperature is increased to elute analytes (Figure 1.14).  Heating of 
the column increases the vapor pressure of analytes, so that compounds with a high vapor  
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Figure 1.11.  Dimethyl acetal derivatization scheme. 
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Figure 1.12.  Varian gas chromatograph. 
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Figure 1.13.  Varian Saturn QIT mass spectrometer. 
20 
 
 
  
Figure 1.14. Capillary column inside GC oven. 
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pressure are eluted first.  The slope of the temperature ramp in part determines retention 
time and the separation between peaks.   
Gas chromatography is an analytical separation technique that uses a gas, 
typically He or N2, as the mobile phase and a substituted polysiloxane stationary phase 
[21].  Analyte separation for GC is primarily a factor of column stationary phase, column 
temperature and the compound itself.  Unlike liquid chromatography (LC) analyte 
affinity for the mobile phase is not a factor affecting separation [22].  Helium was used 
for all GC operations because of the large ūopt working temperature range and because it 
presents additional benefits which are important during MS operation [21]. 
Mass spectrometry 
Following chromatographic separation based on the selective retention by the 
stationary phase the carrier gas transfers the analytes to the detector.  In this case the 
detector will be a mass spectrometer (MS) and the interface between the GC and the MS 
is made via a transfer line (Figure 1.15).  The transfer line is little more than a heated 
partition that houses a section of the chromatographic column (Figure 1.).  Usually 
transfer lines are at isothermal temperatures, above the final temperature ramp of the 
column, to prevent condensing the separated analytes back onto the stationary phase, 
which would be counter-productive to the chromatographic phase.  The transfer line 
should function in the background allowing analyte introduction into the mass analyzer 
without compromising peak resolution. 
  The instrumental design used throughout the ensuing studies has elution of 
analytes entering directly into the MS detector from the transfer line.  The mass 
spectrometer (MS) has three general components: ionization source, detector and mass 
analyzer.  Prior to separation of molecules, by a mass analyzer based on m/z, ionization 
must occur.  Projects conducted in this dissertation employed two types of ionization: 
electron-impact (EI) ionization and chemical ionization (CI).  Both of these techniques 
involve different ionization mechanisms producing unique ions that are ultimately 
manifested as distinctive mass spectra.  Although the outcomes are different both 
processes begin with the emission of high-energy electrons, approximately 70 eV, from 
the heating of a tungsten filament (Figure 1.16) [23].  Electrons are directed toward the 
column eluent by means of a negatively charged repeller plate situated behind 
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Figure 1.15.  GC/MS Transfer line. 
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Figure 1.16.  Ionization filament. 
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the filament.  It is at this stage the EI and CI process diverge.  Electron-impact will be 
covered first since many of the same principles are encountered during CI.   In EI, a high-
energy electron will “impact” with an analyte molecule causing ionization.  The term 
“impact” is a misnomer as no actual physical collision occurs.  Ionization is the result of 
the high-energy electron interacting with a resonant electron from the analyte molecule 
[23].  A portion of energy is transferred to the molecule resulting in ejection of an 
electron.  The overall EI process yields a radical cation (M
+·
) and two electrons, one 
ejected from the initial molecule and one the ionizing electron (Figure 1.17). 
The minimum amount of energy absorbed by an analyte to cause ejection of an 
electron, or ionization energy, is molecule dependent, however most ionization energies 
are on the range of 7 to 15 eV [23-24].   The ejection of an electron is a rapid process 
resulting in a Frank-Condon vertical transition [24].  Essentially electron ejection is faster 
that molecular bond vibration, so that when ejection occurs atoms and bonds are static.  
Following ejection the molecule redistributes energy to account for the weakened bond.  
This redistribution is manifest as vibrational energy that results in bond dissociation 
releasing a portion of the incurred internal energy. 
The nature of EI is a “hard” ionization technique, meaning that the process 
imparts a significant amount of energy to the analyte causing excessive bond 
dissociation.  Formation of an odd-electron species, M
+·
, consequentially leads to an 
unstable molecular ion that readily undergoes fragmentation and bond rearrangement.  
Fragmentation from the molecular ion, M
+·
, occurs two ways; producing either an even-
electron ion and a radical, or an odd-electron ion and an even-electron neutral [23-24].  
Spectra generated from EI represent statistical distributions of fragments from the 
molecular ion with the most stable fragments having greater abundance [19].   
The most prominent diagnostic ion for fatty acid methyl esters is the McLafferty 
rearrangement (Figure 1.18).  The McLafferty rearrangement is a cyclic hydrogen 
transfer process occurring between a carbonyl and gamma methyl group [19, 23].  
Rearrangement is a two step process, first generating the enol intermediate.  In the second 
step the hydrogen transfer is completed and the bond between the β and γ carbons is 
broken to produce a cation radical and an alkene.  The radical cation is the diagnostic ion.  
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Figure 1.17.  Electron-impact ionization scheme. 
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For methyl ester species this results in the m/z 74 ion.  Other diagnostic ions for fatty acid 
methyl esters would include: m/z 87, [M-31]
+
 and [M-74]
+ 
[19, 23].   
In contrast to EI, the process of chemical ionization (CI) is a gentle “soft” 
ionization technique [19, 23].  As with EI a high-energy electron is used to initiate 
ionization, however instead of impacting with an analyte molecule, ionization first occurs 
with a reagent gas.  The secondary reaction of reagent gas with analyte molecules 
provides further ionization.  The abundance of reagent gas molecules must be 
significantly higher than analyte molecules to ensure CI and not the competing EI 
process.   
 The CI process is highly dependent on the eventual interaction between reagent 
gas and analyte.  Interactions between the two generally involve transfer of a hydrogen, 
hydride or other charged species.  Therefore, the acid/base or proton affinity relationship 
between the charged reagent gas and analyte is critical to the CI process [19, 23-24].  
This relationship determines the eventually molecular species formed.  To this end, a 
variety of reagent gases have been employed depending on the analyte under 
investigation.  Studies contained herein were conducted with acetonitrile as a reagent gas 
(Figure 2.2), however methane is probably the most frequent reagent gas utilized (Figure 
1.19) [23]. 
 Chemical ionization experiments conducted during the course of studies used the 
selected-ejection CI (SECI) technique [25].  Due to features of the particular mass 
analyzer utilized, discussed below, CI reactions occur at low pressure instead of high 
reagent gas pressure usually required.  The SECI process allows reagent gas to fill the 
mass analyzer for a period of time, termed the automatic-reaction control time.  
Ionization of the reagent gas then occurs followed by reaction of the reagent gas with the 
analyte molecules.  The selected-ejection refers to the process that removes all ions with 
m/z lower than the background mass prior to an analytical scan [25].  The advantage is 
that during mass analysis only ions from the predetermined experimental mass range are 
analyzed.   
 The contrast of CI to EI is that the secondary ionization process results in less 
energy transferred to the analyte and the eventual molecular ion, [M+H]
+
, is an even-
electron cation which in intrinsically more stable than the odd-electron radical  
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Figure 1.19.  Chemical ionization scheme. 
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cation [23-24].  As a consequence CI spectra exhibit a greater relative abundance of 
molecular ion.  However, the trade-off is CI leads to less fragmentation which can be 
used for structural identification. 
Electron-impact and CI are ion forming pathways that can be employed 
complimentary during analysis.  The nature of EI is largely analyte independent, making 
it applicable to quantitation.  Chemical ionization on the other hand is highly analyte and 
reagent gas dependent, therefore quantitation with CI can be difficult for unknowns.  The 
stability of the molecular ion in CI permits identification of the parent molecule, which is 
sometimes absent from EI spectra.  Whichever ionization method is employed the 
formation of ions is critical to analysis with a mass analyzer. 
 Discussion of mass analyzers will focus on the particular analyzer used 
throughout each of the projects, a quadrupole ion trap (QIT).  The QIT, sometimes called 
a Paul trap in honor of it’s inventor Wolfgang Paul, is composed of three main parts: a 
ring electrode and two endcap electrodes (Figure 1.20) [26].  When assembled the three 
hyperbolic electrodes are electrically isolated from one another which is vital for 
operation (Figure 1.21).  As the name implies the QIT is a trapping mass analyzer 
presenting several advantages during analysis, such as tandem mass spectrometry 
(MS/MS) and low pressure CI as previously discussed.   
 The arrangement of the QIT electrodes creates a trapping volume that is twice as 
wide along the horizontal axis, 0r , as the vertical axis, 0z  (eq. 1.5). 
2
0
2
0 2zr           eq. 1.5 
A fundamental radio frequency (rf) is applied to the ring electrode creating the trapping 
field.  For current commercial instruments the fundamental rf is applied at a frequency of 
1 megahertz (MHz) [26-29].  In response to this fundamental rf, ions within the trap 
assume cyclic oscillations that have a frequency based on their particular m/z, otherwise 
known as a secular frequency.  It should be noted that during normal operation the trap is 
filled with a buffer gas, normally He, to a pressure of 1 mTorr that assists in reducing the 
kinetic energy of the ions following ionization.  The buffer gas aids in focusing the ions 
to the center of the trap so that they assume predictable movements with the fundamental 
rf [22].  The buffer gas will also be important later during tandem mass spectrometry 
(MS/MS). 
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Figure 1.20.  Quadrupole ion trap anatomy. 
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Figure 1.21.  Quadrupole ion trap assembly. 
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The motion of ions within this quadrupolar field is described by the Mathieu 
equation [26-29].  There are two general solution categories for the Mathieu equation: (1) 
periodic and stable and (2) periodic but unstable.  Together these represent the Mathieu 
stability diagram (Figure 1.22).  Ions adopting a periodic and stable trajectory are 
successfully trapped within the QIT, whereas the periodic but unstable solutions form the 
boundaries.  In order for an ion to be successfully trapped the trajectory must be stable in 
the radial (eq. 1.6 & 1.7) and axial planes (eq. 1.8 & 1.9).  The stable solutions to the 
Mathieu equations describing these boundaries are [26-29]: 
22
0
2
0 2
8
zrm
eU
ar              eq. 1.6 
22
0
2
0 2
4
zrm
eV
qr          eq. 1.7 
Where ra and rq are radial space within the trap, m is the mass of a particular ion, e  is 
the charge of an electron, 0r  is the radius of the ring electrode, 0z  is the distance between 
the endcap electrodes,  is the frequency of the fundamental rf, V  is the amplitude of 
the rf and U is the DC potential applied to the ring electrode. 
22
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qz          eq. 1.9 
Where za and zq are axial space within the trap, all other symbols are the same in eq. 1.6 
and 1.8.  Current commercial QIT mass analyzers do not provide the option of applying a 
DC potential to the ring electrode.  The implications of this are that the U  term is always 
zero, making eq. 1.5 and 1.7 equal to zero, and ion positioning within the Mathieu 
stability diagram is always at zero along the za  axis. 
 The operation of a QIT during a mass analysis experiment involves trapping ions, 
as discussed above, and then ejecting those ions in a mass dependent manner.  The 
ejection of ions is accomplished by increasing the amplitude, V , of the fundamental rf.   
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Figure 1.22.  Mathieu stability diagram. 
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Ion movement in the trap is a function of the fundamental rf and an ions m/z ratio.  
Interaction with the fundamental rf causes ions to adopt regular oscillations, known as 
secular frequency.  An ion’s secular frequency is dependent on its m/z ratio, small ions 
will have a larger secular trajectory than larger ions [26-29].  As the rf amplitude 
increases the secular frequency of the ions increases causing the trajectory to expand 
along the axial plane.  A graphical representation of this increased oscillation would be 
an ion moving to the right along the y-axis in the Mathieu stability diagram (Figure 1.).  
The trajectory of an ion increases until it becomes unstable and is ejected from the trap.  
This point of instability occurs at approximately a zq = 0.908, which is where the stability 
boundary intersects the zq axis [26-29].  This type of scanning is known as a mass-
selective instability scan. 
 The mass-selective nature of ion ejection is due to the relationship between 
secular frequencies and m/z of ions.  Ions with a small m/z will have greater secular 
frequency, therefore when the rf amplitude is ramped their oscillations increase to the 
ejection boundary faster than larger ions with lower secular frequencies.  The slope of the 
rf amplitude ramp determines the number of oscillation cycles an ion makes before 
reaching the critical ejection boundary [26-29].  The ramping of the fundamental rf from 
low to high amplitude, and the subsequent ejection of ions in a mass dependent manner 
from low m/z to high m/z, is termed an analytical scan.  Data collected from the 
analytical scan produces a mass spectrum. 
 The endcaps assist during the mass-selective instability scan in supplying a 
supplemental rf potential to an ions secular frequency [26-29].  As the secular oscillations 
of ions increase during the rf ramp their trajectory places them incrementally closer to the 
endcap electrodes.  At a critical point an ion’s trajectory will place them close enough to 
an endcap electrode that the ion will come into resonance with the supplemental rf 
potential.  This process, known as resonance ejection or axial modulation, increases the 
kinetic energy of the ion and causes prompt ejection.  Generally, the frequency of the 
supplemental rf is approximately half that of the fundamental rf, or 500 kHz [26-29]. 
 One of the advantages with a QIT is the ability to perform tandem mass 
spectrometry (MS/MS).  This is the process where after trapping ions, all ions are ejected 
except for one m/z ratio.  This isolated m/z ratio, also called a parent or precursor ion, is 
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then fragmented a second time in a process known as collisionally-induced dissociation 
(CID) to provide further structural or chemical data on the particular m/z [26-29].  
Because the m/z is isolated prior to fragmentation the product ions should provide unique 
data relevant to the parent molecule. 
 Tandem mass spectrometry in a QIT is a tandem-in-time process meaning the 
events occur within the same space, the trap, during discrete times [23].  The events 
leading to a MS/MS experiment are the same as a MS experiment.  Following ionization 
the trap is full of ions with various m/z ratios.  Isolation of the parent ion for Varian 
Saturn QIT occurs via a two step process.  Ions with m/z lower that the parent ion are 
ejected by ramping the supplemental rf on the endcap electrodes.  Next a broadband 
waveform is applied to the endcap electrodes to eject ions with m/z greater that the parent 
ion.  The two events work together to isolate a particular m/z ratio.  After isolation the 
amplitude of the fundamental rf is decreased in order to “place” the parent ion at a 
particular point along the za axis in the stability diagram.  There are two main reasons for 
doing this: the first is to restrain the kinetic energy of the parent ion so that fragmentation 
can occur under a controlled process; the second is to manage the product ions formed.  
For organic molecules CID is usually performed at a zq = 0.4, because this is the deepest 
point in the pseudo-potential well along the stability diagram [26-29].  Usually organic 
molecules require greater CID voltages to fragment, thus at lower points in the well 
greater voltages would result in immediate ejection without fragmentation. 
 The CID process is conducted by applying a low-energy rf waveform across the 
endcaps, this is known as an excitation or tickle voltage [26-29].  There are two types of 
CID waveform that can be applied: resonant and non-resonant.  A resonant waveform is 
applied at a frequency that is resonance with the parent ion’s secular frequency.  The 
advantage is that only the parent ion is excited to undergo the CID process and not the 
resulting fragment ions.  A non-resonant waveform is a broadband waveform with a 
range of frequencies.  This procedure excites the parent ion and the resulting fragments.  
The disadvantage with non-resonant CID is that spectra are complicated due to fragments 
of fragments.  All experiments contained herein use resonant CID methods. 
 With the excitation voltage applied to the endcaps the motion of the parent 
molecule is increased so that it collides with the He buffer gas.  The low-energy CID 
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process causes multiple collisions between the parent ion and the buffer gas.  With each 
collision the translational kinetic energy of the parent molecule is transferred into 
vibrational energy [26-29].  As the vibrational energy of the parent ion increases 
fragmentation occurs.  Collision-induced dissociation excitation occurs for a period of 
time, usually on the order of milliseconds, then the product ions are scanned out the QIT 
in a typical analytical scan. 
 One potential disadvantage with performing MS/MS in a QIT is the limited mass 
range of trapped product ions, because of the low-mass cut-off (LMCO) [26-29].  The 
low-mass cut-off is the lowest mass that can be successfully trapped at a given zq  value 
(eq. 1.10).  
908.0
zqzmLMCO         eq. 1.10 
Where zm is the parent ion m/z ratio, zq fundamental rf amplitude at which CID occurs 
and 0.908 is the stability boundary along the zq  axis.  Of course the mass range can be 
extended by performing CID at a zq  value, however this limits the CID voltage that can 
be applied without causing parent ion ejection.  Generally, the LMCO does not present a 
problem during analysis of volatile lipid species by GC/MS. 
 Following ion ejection through the endcap electrode during the analytical scan, 
the ion strikes the detector.  The type of detector employed throughout studies was an 
electron multiplier, which was located directly below the bottom endcap electrode 
(Figure 1.23).  The advantage of the electron multiplier is that it provides amplification of 
the incident ion [23].  The result of amplification is an increased signal per incidence 
which in turn translates to greater sensitivity.  
The analysis of methyl derivatizied species by GC/MS allowed the separation, 
quantification and structural elucidation of geometric isomers.  The QIT mass analyzer 
provided versatility during analysis that allowed identification of  unknown lipid 
analytes.  Mass analysis techniques, such as MS/MS and low-pressure CI, were 
developed to take advantage of the unique features provided by the QIT.  Analytical and 
biological procedures developed during the course of investigations aided in directing 
subsequent projects.   Projects conducted for this dissertation are linked by the foundation  
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Figure 1.23.  Electron multiplier ((a) front, (b) back). 
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of lipid modification to environmental stimuli.  Gas chromatography coupled with MS 
demonstrated to be the instrument of choice for the analysis of volatile methyl 
derivatizied lipid species.  
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PART II.  PROKARYOTIC LIPIDOMICS 
Chapter 2.  The Analysis of Composition and Structure of Clostridium thermocellum 
Membranes from Wild-type and Ethanol-adapted Strains 
 
Chapter 2.1.  Introduction 
 
Ethanol derived from fermentation of lignocellulosic biomass is a renewable 
alternative to petroleum-based transportation fuels.  Virtually all bio-ethanol is currently 
produced from fermentation of starch by yeast, but these organisms are unable to directly 
degrade saccharify lignocellulosic feedstocks.  Enzymatic, chemical, and physical pre-
treatments are needed to saccharify the structural carbohydrates and this increases the 
complexity and expense of the overall process.  Consolidated bioprocessing by 
celluloytic bacteria has been proposed as an alternative technological platform for bio-
conversion of lignocellulose to ethanol [30].   
Fermentation with microbes that produce ethanol from cellulose reduces the raw 
material cost.  However, most microbes are unable to directly metabolize cellulose.  
Conventional enzymatic saccharification uses enzymes to break down cellulose and 
hemi-cellulose into sugars which yeast can then metabolize, producing ethanol [31].  
Consolidated bioprocessing by cellulytic microorganisms for the production of ethanol 
has advantages over conventional methods [31].  However, in order to be commercially 
viable, strains with high ethanol-tolerance are required.     
Clostridium thermocellum is an anaerobic, thermophilic bacterium that 
metabolizes cellulose to ethanol and has been proposed for use in consolidated bio-
processing [30-31].  There are many potential advantages to such a strategy.  The optimal 
growth temperature for C. thermocellum is between 55°C to 60°C, and these 
temperatures provide a convenient means for removal of ethanol.  Issues of fermentor 
contamination by ubiquitous microbes is also lessened at higher temperatures.  However, 
a current limitation is the relatively low ethanol tolerance of cellulolytic bacteria.  Most 
strains tolerate less than 1% (w/v) ethanol while yeast tolerate concentrations that are up 
to 20% (w/v) [32-33].    
 Although the wild-type strain is sensitive to ethanol concentrations greater than 
1% (w/v), certain ethanol-adapted cultures tolerate concentrations as high as 8% (w/v) 
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[30-32].  Herrero et al. described membrane lipid changes in an alcohol tolerant strain 
and showed an increased percentage of shorter (<C14) chain fatty acids and 
monounsaturated fatty acids when compared to the ethanol-sensitive wild-type [34].  In 
addition, n- and anteiso-branching was higher in the ethanol-adapted strain at the expense 
of iso- branching. However, there is little detailed information beyond this earlier work 
concerning the mechanism of ethanol tolerance in C. thermocellum. 
   The membrane functions as a protective barrier for the cell and serves a vital role 
in energy-generating pathways.  It should not be surprising that regulation of membrane 
properties is essential to cell proliferation.  The volume of literature concerned with 
membrane adaptation is vast, covering a variety of strains and different modes of 
perturbation.  For instance, studies conducted on Saccharomyces cerevisiae found that 
the degree of monounsaturation and fatty acid chain length increased with ethanol 
exposure [32].  Experiments with Kloeckera apiculata showed an increase in 18:1 with a 
concurrent decrease in 16:1, thus the unsaturation index remained unchanged when 
grown in the presence of ethanol [32].  On the other hand, bacterial studies with Bacillus 
subtilis and Clostridium acetobutylicum revealed an increase in long-chain fatty acids as 
a response to ethanol treatment [35].  The entire body of literature concerned with the 
process of lipid adaptation varies between different genera of bacteria and is therefore 
beyond the scope of this dissertation, however there are reviews dedicated to this topic 
[35-38].  As shown by the given examples, discrepancies in the result of adaptation have 
led to different models for explaining ethanol tolerance.  Models of adaptation to various 
insults usually speculate on changes to the membrane physical properties such as 
membrane fluidity [32, 35].   
The concept of homeoviscous adaptation popularized by Sinensky, established a 
relationship between membrane fatty acid composition and growth temperature [1].  The 
theory was based on the belief that bacteria alter their lipids to maintain an optimum level 
of fluidity.  Bacteria have been shown to alter the degree of unsaturation, position of 
branching, and chain length of their fatty acids in response to environmental stimuli.  As 
a general rule, increasing the unsaturation index and decreasing the average fatty acid 
chain length both serve to increase fluidity of the membranes.  Methyl branching of the 
alkyl chain is another modification that bacteria use to modify the fluidity of the 
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membrane.  The most frequent branch points encountered are anteiso- (ω-3) and iso- (ω -
2), with the latter imparting a greater degree of fluidity [38].  McElhaney proposed that 
changes within the membrane are the result of a desire to maintain lipid phases, rather 
than a specific fluidity [39].  Both theories propose that alterations in membrane 
composition and structure change the physical properties of the membrane, fluidity and 
phase transitions respectively [32].   
 It is widely accepted that ethanol has an effect on increasing membrane fluidity 
[40].  Previously conducted studies on ethanol-adapted strains have concluded that 
membrane fluidity increases as a result of the adaptation process [40-41].  Chu-Ky et al. 
conducted fluorescence anisotropy studies on Oenococcus oeni and reported that ethanol 
produced an immediate increase in membrane fluidization that was concentration 
dependent.  The study also reported that anisotropy numbers returned to previous values 
following incubation with ethanol [42].  Studies with Schizsosaccharomyces pombe and 
Saccharomyces cerevisiae reported that anisotropy values decreased, corresponding to an 
increase in membrane fluidity, proportionally with increasing concentrations of ethanol 
[43].   
In order to gain a more direct understanding of the relationship between fatty acid 
profiles and membrane fluidity, steady-state fluorescence anisotropy experiments were 
conducted as part of this study.  Anisotropy is a measure of rotation by comparing the 
ratio of fluorescent emission in parallel and perpendicular polarizations.  Within the 
context of this study, anisotropy correlates to the order of the fatty acid alkyl chains 
which is inversely related to fluidity, thus as the anisotropy value decreases the fluidity of 
the membrane increases [44].  The rotation is a function of the fatty acid phase transition 
temperature, Tm.  Longer saturated-chain fatty acids have a higher Tm, as a result of 
greater Van der Waals interactions between acyl chains.  Unsaturated fatty acids have 
lower transition temperatures, than saturated fatty acids of similar length, as a result of 
the strained geometry caused by the double bond [45].  Below the Tm the alkyl chains are 
in an ordered state and rotation of the DPH probe is restricted.  With increased 
temperature the alkyl chains become disordered allowing rotation.  Rotation of the 
fluorescent probe lowers the ratio of horizontal and vertical intensities, translating to a 
lower anisotropy [40].  Above the Tm of fatty acids a phase transition occurs which is 
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reflected by a sudden increase in membrane fluidity [46].  Due to non-discriminate 
integration between acyl chains, a decrease in anisotropy represents an increase in bulk 
flow across the bilayer [44, 46-47]. 
Membrane fluidity is highly regulated by the fatty acid composition of the bilayer.  
Fatty acids have a distinct phase transition temperature (Tm) that is characteristic of their 
chain length and degree of unsaturation.  The Tm signifies the temperature at which the 
alkyl chains transition from an ordered, less fluid, state to a disordered, more fluid, state, 
and it is a function of the non-covalent interactions between alkyl chains.  Therefore, 
longer fatty acid chains have a higher Tm due to more non-covalent interactions.  
Unsaturation decreases the Tm due to the bend introduced into the alkyl chain by the 
double bond [45].   
The molecular probe, 1,6-diphenyl-1,3,5-hexatriene (DPH), is an extremely 
hydrophobic molecule that will insert itself among the fatty acid acyl chains of the 
membrane bilayer.  The DPH probe is excited with polarized light and the anisotropy is a 
ratio of emission intensities between the horizontal (0°) and vertical (90°) polarizations.  
Anisotropy is the inverse of fluidity, thus as the anisotropy value decreases the fluidity of 
the membrane increases [44].         
The main objective of this project was to compare the membrane composition of 
C. thermocellum wild-type and an ethanol-adapted strains.  Quantitative lipid analysis 
was achieved by analysis of fatty acid methyl esters and structural analysis was obtained 
through derivatization to picolinyl esters.  Mass spectrometry was used to determine fatty 
acid structure and a quantitative lipid profile.  In addition, functional aspects of the 
membrane were measured using steady-state fluorescence anisotropy.  These experiments 
showed that ethanol adaptation was the result of fatty acid changes that increased 
membrane rigidity and counter-acted the fluidizing effect of ethanol.  
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Chapter 2.2.  Experimental 
Reagents 
Potassium t-butoxide (1.0 M) in tetrahydrofuran (THF), 3-hydroxymethyl 
pyridine, tridecanal, and hexane were purchased from Sigma (St. Louis, MO, USA).  
Methanol, methylene chloride, and hydrochloric acid were obtained from Fisher 
(Pittsburg, PA, USA).  Acetyl chloride was obtained from Fluka (Buchs, Switzerland).  
Sodium hydroxide, sodium bicarbonate, and potassium carbonate were purchased from 
J.T. Baker (Phillipsburg, NJ, USA).  Ethyl ether was obtained from EMD (San Diego, 
CA, USA).  Anthracene was purchased from Acros (Morris Plains, NJ, USA).  Ethanol 
was purchased from Decon Laboratories, Inc. (King of Prussia, PA, USA).  GLC-411 
lipid standard, 5,8,11,14-eicosatetraenoic acid, and 4,7,10,13,16,19-docosahexaenoic acid 
was purchased from Nu-Chek Prep, Inc. (Elysian, MN, USA), and 1,6-diphenyl-1,3,5-
hexatriene (DPH) was purchased from Molecular Probes (Eugene, OR, USA).    
Equipment and supplies 
Savant instruments (Holbrook, NY, USA) speedvac concentrator (model 
SC110A) with refrigerated condensation trap (model RT490).  Eppendorf (Hauppauge, 
NY, USA) centrifuge (model 5415A) with a F45-24-11 fixed angle rotor.  Fisherbrand 
2.0 mL polypropylene microcentrifuge tubes (Thermo Fisher Scientific Inc., Waltham, 
MA, USA).  Eppendorf (Hauppauge, NY, USA) Research Adjustable-volume pipettes.  
Bacterial cultures and growth 
 Clostridium thermocellum ATCC 27405 was obtained from the American Type 
Culture Collection.  The wild-type (ethanol-sensitive) strain was adapted to ethanol as 
previously described [48].  Cultures of wild-type and ethanol-adapted cells (13 L each) 
were grown in a basal medium as previously described [48].  Briefly, the media consisted 
of the following ingredients: 10.8 mM Na2HPO4, 11.05 mM KH2PO4, 9.35 mM NH4Cl, 
3.79 mM (NH4)2SO4, 0.44 mM MgCl2
.
6H2O, 0.27 mM CaCl2, 2.0 g/L yeast extract, 0.5 g 
cysteine, 1 mg resazurin, 10 mL vitamin standard mixture, and 5 mL of modified 
micromineral mixture stock supplemented with 10 mg of Na2WO4·2H2O and 1 mg 
Na2SeO4 L
-1
 stock.  The media was adjusted with 10% NaOH to pH 6.7, then autoclaved 
for 10 minutes.  The solution was sparged with CO2 until reaching room temperature.  An 
anaerobic solution of Na2CO3 was added for a final concentration of 4 gL
-1
.  The solution 
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was autoclaved for an additional 20 minutes then supplemented with cellobiose for a final 
concentration of 4 gL
-1
.  Both strains were harvested during their respective growth 
phases, washed with 50 mM Tris (pH 7.5) and stored at -80°C until analysis. 
Saponification of fatty acids 
 Aliquots (approximately 15 mg cell dry weight) of C. thermocellum whole cells 
were washed three times with 1 mL portions of diH2O, centrifuged (16,100xg, 5 min, 
25°C) and the supernatants discarded.  The cell pellets were placed at 0°C overnight and 
then vacuum-dried for 24 hrs at 25°C.  The saponification methods were based on a 
previous description [49].  Sodium hydroxide (1 mL of 3 M) was added to the dried cells.  
The mixture was vortexed and heated to 90°C for 1 hr, cooled to room temperature, and 2 
mL of 3.25 M HCl was added and reheated at 90°C for 10 min.  After cooling to room 
temperature, the lipids were extracted three times with 1 mL portions of 1:1 (v/v) 
hexane:diethyl ether.  The organic phases were combined and evaporated to dryness 
under a stream of N2 at room temperature. 
Fatty acid derivatization methods 
 Fatty acid methyl ester (FAME) procedures were adapted from previous studies 
[50].  Methanol:acetyl chloride (50:1 (v/v), 5 mL total) was added to the extracted free 
fatty acids.  The solution was mixed and heated at 60°C for 1 hr.  After heating, 3 mL of 
6% K2CO3 was added, and the FAME products were extracted 1 mL of hexane 
containing 0.1 mg anthracene (internal standard).  Extracted material (1 L) was used for 
GC/MS analysis.  An overview for fatty acid analysis is provided as a work-flow diagram  
(Figure 2.1).   
 Fatty acids were trans-esterified to picolinyl esters using a method adapted from 
Destaillats et al. [51].  The hexane phase from the FAME procedure was evaporated to 
dryness under a stream of N2 at room temperature and 1 mL of methylene chloride was 
added to resolvate the methyl esters.  A mixture of 200 µL 3-hydroxymethylpyridine and 
100 L of 1.0 M potassium tert-butoxide in THF were allowed to react for 2 min.  This 
mixture was then added to the FAME methylene chloride solution.  The reaction was 
mixed and heated at 45°C for 1 hr.  After cooling to room temperature, 1 mL of 2.5%  
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Figure 2.1.  Schematic representation of derivatization procedures. 
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NaHCO3 was added and the methylene chloride layer removed.  The organic layer was 
reduced to approximately one-quarter original volume under a stream of N2 at room 
temperature and 1 L was injected for analysis.  All derivatization methods were 
validated by analysis of 5,8,11,14-eicosatetraenoic acid (arachidonic acid), 
4,7,10,13,16,19-docosahexaenoic acid, and Escherichia coli (E. coli) whole cells. 
Gas chromatography/mass spectrometry 
Fatty acid methyl and ethyl ester derivatives were analyzed using a Varian Saturn 
3 GC/MS system equipped with a ZB-5ms capillary column 30 m x 0.25 mm i.d., 0.25 
μm film (Phenomenex USA, Torrance, CA).  The temperature program was: 130°C to 
170°C at 4°C/min, 170°C to 215°C at 2.7°C/min, 215°C for 3.34 min, with a total 
analysis time of 30 min.  Carrier gas head-pressure was set to give a flow rate of 1 
mL/min, with a 50:1 split.  The injector and transfer line were maintained at 240°C and 
the manifold temperature was 210°C.  Ionization was accomplished by electron impact 
(EI) at 70 eV, with a 3 minute filament delay.  Spectra were generated from full scans 
m/z 50 to 650, at a scan rate of 1 analytical scan per second and the background mass was 
set at m/z 49.  The GC/MS method was optimized to provide peak resolution for FAMEs 
from the GLC-411 standard.   
Fatty acid picolinyl ester derivatives were analyzed on the same instrument with 
the following temperature program: 150°C for 4 min., 150°C to 280°C at 20°C/min, 
280°C for 19.5 min with a total analysis time of 30 min.  All other parameters were as 
described above except that the filament delay was 10 min and spectra were generated 
from full scans from m/z 50 to 500.  
Chemical ionization (CI) experiments were conducted on the same instrument 
using the FAME GC/MS program, except the manifold temperature was reduced to 
160°C.  The MS parameters were as follows: selected-ejection chemical ionization 
(SECI) mode with acetonitrile as the reagent gas (Figure 2.2)[52], 100 μsec automatic-
reaction control (ARC) time, 1000 μsec ionization time, 128 msec reaction time, m/z 15 
ionization storage level, 7.5 V0-p reagent gas ion ejection amplitude, m/z 37.0 CI reaction 
storage level.  Spectra were generated by full scans from m/z 80 to 650.  All 
chromatograms were analyzed using Wsearch32 2005 software (version 1.6.2005; 
Melbourne, Australia).   
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Figure 2.2.  Chemical ionization of acetonitrile. 
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Calculations  
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F-test for comparison of two variances 
 The null hypothesis is stated that there is no significant difference between the 
two variances.  If Fcalc > Ftable, p, v1, v2 then the null hypothesis is rejected and there is a 
significant difference between the two populations.  Fcalc > 1, v1 = n1-1, v2 = n2-1 
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t-Test for comparison of two experimental means 
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 Quantification of FAMEs (Conc.FAME) was performed by comparing the area 
counts of the various fatty acid species (AreaFAME) with that of the internal standard, 
anthracene (AreaIS): 
IS
ISFAME
FAME
Area
ConcArea
Conc
.
.        eq. 2.8 
The calculated Conc.FAME value is then divided by the dry cell weight (DCW) to obtain a 
concentration of FAME species normalized to the starting concentration of cells. 
DCW
mgFAME
Conc DCWFAME /.
        eq. 2.9
 
The distribution of FAMEs per C. thermocellum strain was determined by dividing area 
counts for each FAME species by the total observed FAME area count: 
100
.
%
Area
FAME
FAME
Area
FAME
      eq. 2.10
 
 Statistical analysis for comparison of fatty acids between the two strains 
employed the paired t-test.  Comparisons were limited to equivalent fatty acids between 
the two species, i.e. WT n-14:0 vs. EA n-14:0.  If calct  > tablet  ( p<0.05, two-tailed), then 
the null hypothesis (HO), HO = μ1 + μ2, was rejected and there was a significant 
difference between the means of the two fatty acid species (Table 2.1). 
DPH-labeling of whole cells and anisotropy 
 The anisotropy method was adapted from a previously described procedure [53].  
Approximately 15 mg of concentrated whole cells were washed with three 1 mL aliquots 
of 50 mM Tris-HCl (pH 7.5) by centrifugation (16,100xg, 5 min, 25°C) and the 
supernatants discarded.  After the final washing, the cells were resuspended in 1.5 mL of 
50 mM Tris (pH 7.5) and 100 L 0.1 mM 1,6-diphenyl-1,3,5-hexatriene (DPH) in THF.  
The mixture was incubated at 65°C for 1 hr and then at 4°C overnight.  The cells were  
50 
 
Table 2.1.  Fatty acid composition and distribution of C. thermocellum cells. 
Species  
(Structure)
a
 
FAME (μg/mg DCW)c FAME (%)c Percent         
   Change
d,e
 WT EA WT EA 
13-Methyl-tridecanoic 
acid (i-14:0) 
1.02±0.1 0.46±0.2 1.06±0.3 0.46±0.1 44.04* 
Tetradecanoic acid  
(n-14:0) 
1.26±0.2 0.68±0.4 1.38±0.4 0.65±0.2 47.09* 
Plasmalogen i-14:0  
(P i-14:0) 
1.06±0.02 0.49±0.1 1.10±0.3 0.60±0.3 54.69* 
Plasmalogen n-14:0  
(P n-14:0) 
1.16±0.2 0.38±0.2 1.29±0.3 0.66±0.2 50.88* 
Plasmalogen 15:0  
(P 15:0) 
1.01±0.2 0.84±0.3 1.11±0.4 1.00±0.2 90.43 
14-Methyl-
pentadecanoic acid  
(i-16:0) 
23.99±1.7 13.28±1.2 
28.21 
±1.9 
20.98 
±1.3 
74.38* 
Hexadecanoic acid  
(n-16:0) 
18.73±3.2 9.69±0.6 
21.77 
±0.6 
16.22 
±1.2 
74.51* 
Plasmalogen i-16:0  
(P i-16:0) 
12.65±2.4 10.99±1.0 14.540.4 
18.75 
±3.5 
128.98 
Plasmalogen n-16:0  
(P n-16:0) 
8.70±1.8 8.37±0.7 9.94±0.4 
13.46 
±1.2 
135.53* 
15-Methyl-
hexadecanoic acid  
(i-17:0)  
3.89±0.6 4.46±0.3 4.43±0.4 7.61±0.9 171.91* 
Heptadecanoic acid  
(n-17:0) 
2.52±1.0 2.02±0.4 2.93±0.6 2.98±0.5 101.68 
Plasmalogen i-17:0  
(P i-17:0) 
1.29±0.3 1.55±0.4 1.51±0.3 2.22±0.5 147.17 
Plasmalogen n-17:0  
(P n-17:0) 
1.03±0.4 0.90±0.3 1.19±0.2 1.45±0.3 122.36 
16-Methyl-
heptadecanoic acid  
(i-18:0) 
6.62±3.0 5.47±0.5 7.38±2.29 9.42±0.4 127.62 
Octadecanoic acid  
(n-18:0) 
1.91±0.5 1.73±0.1 2.17±0.5 3.52±0.7 162.40 
Total lipid  
(μg/mg DCW)b 
86.84±2.1 61.32±0.8 
a
 Number of carbons:degree of unsaturation. i- denotes iso-branching and n- denotes 
normal or straight chain. 
b
 Comparisons made on % FAME basis due to differences in μg/mg DCW between WT 
and EA.  
c
 Values are averages of four replicates ± SEM. 
d
 Values represent change in EA relative to WT cells. 
e
 
 
Values with asterisks (*) are statistically significantly different (p≤0.05, n=4). 
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then centrifuged (16,100xg, 5 min, 25°C) and the supernatant discarded to remove any 
residual DPH.  The pellet was resuspended in 10 mL of 50 mM Tris (pH 7.5) or 10 mL of 
50 mM Tris (pH 7.5) with 5% (w/v) ethanol. 
 The fluorescence anisotropy of DPH-labeled cells was measured with a Varian 
Cary Eclipse fluorescence spectrophotometer (Walnut Creek, CA, USA), equipped with a 
custom view cell (Thar Technologies, Pittsburg, PA, USA) and manual polarizer 
accessory (part #00-100761-00) for both excitation (350 nm, slit width of 5 nm) and 
emission (452 nm, slit width of 10 nm) (Figure 2.3) [54].  The source was a Xenon pulse 
lamp (200-900 nm operating wavelength range with ±1.5 nm accuracy and ±0.2 nm 
reproducibility) and one second average sampling time was employed.  Temperature of 
the view cell was modulated with heating tape and an Omega controller (model 
CN9000A).  Each sample was heated from 24°C to 70°C with five readings taken every 
2°C over the temperature ramp cycle.  These five readings were averaged together to 
represent the average anisotropy ( r ) for the corresponding temperature.  The reported 
data are the average and relative standard deviation from the average of three analytical 
replicate samples.  The anisotropy ( r ) was calculated: 
VHVV
VHVV
gII
gII
r
2
        eq. 2.11 
where VVI  is the intensity when excitation and emission are polarized vertical, VHI  is the 
intensity when excitation is polarized vertical and emission is polarized horizontal, g  is 
the grating factor. 
The grating factor ( g ) was determined for each sample prior to heating:  
HH
HV
I
I
g          eq. 2.12 
where HVI  is the intensity when excitation is polarized horizontal and emission is 
polarized vertical, HHI  is the intensity when excitation and emission are polarized 
horizontal.  Essentially the g  factor is a correction for the monochromator transmission 
efficiency [41].  The g factor is a function of sample and view cell alignment, therefore it 
was determined prior to analysis of each sample. 
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Figure 2.3.  Schematic of anisotropy apparatus. 
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Chapter 2.3.  Results 
 
GLC-411 standard 
 Previous fatty acid studies with C. thermocellum used packed columns which 
resulted in co-eluding peaks that hindered quantification and species identification [34].  
The development of a GC method that provided resolution of a broad range of fatty acid 
species was critical.  The GLC-411 standard was chosen to give a wide range of FAMEs 
both in chain length, saturation and unsaturation (Table 2.2).  The objective was to 
develop a method that could provide resolution of the thirty-one FAMEs contained in the 
GLC-411 standard.  A number of published GC methods were tested, however 
independently none of these methods provided resolution over the entire FAME spectrum 
[7, 55-57].  However, two established methods provided superior resolution over a 
portion of the GLC-411 standard range.  A method published by the American Oil 
Chemists' Society (AOCS) [58] gave separation of FAMEs C8 to C18, however the later 
compounds had poor peak shape.  A FAME method (application 1774-GC) published by 
Varian (Varian, Inc., Lake Forest, CA, USA) gave poor results with short chain fatty 
acids, but worked well for longer chain fatty acids.  The AOCS and Varian methods had a 
common temperature profile around 215°C, therefore the two methods were coupled at 
this temperature to provide resolution over the entire FAME spectrum.  Although the 
developed GC method provided greater resolution than those previously evaluated, the 
separation of some geometric isomers was not possible (Figure 2.4).  The three geometric 
isomers of 18:1 (methyl oleate (18:1Δ9), methyl petroselinate (18:1Δ6), and methyl 
vaccinate (18:1Δ7); two isomers of 20:3 (methyl eicosatrienoate (20:3Δ11,14,17) and 
methyl homogamma linolenate (20:3Δ8,11,14); and three isomers of 20:1 (methyl 5-
eicosenoate (20:1Δ5), methyl 8-eicosenoate (20:1Δ8) and methyl 11-eicosenoate 
(20:1Δ11) each co-eluted.  Further improvement of the temperature ramp to fully resolve 
these isomers was not undertaken.  
C. thermocellum dry cell weights 
A specific goal of this project was the direct comparison of fatty acids 
composition between WT and EA strains, therefore it was necessary to normalize the 
cellular concentrations for successive reactions.  Reaction standardization based on  
Table 2.2.  List of FAMEs within GLC-411 standard. 
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Common Name Chain FAME Derivative (MW) 
Methyl Octanoate 8:0 158 
Methyl Decanoate 10:0 186 
Methyl 11-Dodecenoate 12:1 212 
Methyl Laurate 12:0 214 
Methyl Myristoleate 14:1 240 
Methyl Myristate 14:0 242 
Methyl Palmitoleate 16:1 268 
Methyl Palmitate 16:0 270 
Methyl Linolenate 18:3 292 
Methyl Gamma Linolenate 18:3 292 
Methyl Linoleate 18:2 294 
Methyl Oleate 18:1 296 
Methyl Petroselinate 18:1 296 
Methyl Vaccenate 18:1 296 
Methyl Stearate 18:0 298 
Methyl Arachidonate 20:4 318 
Methyl 11,14,17-Eicosatrienoate 20:3 320 
Methyl Homogamma Linolenate 20:3 320 
Methyl 11,14-Eicosadienoate 20:2 322 
Methyl 5-Eicosenoate 20:1 324 
Methyl 8-Eicosenoate 20:1 324 
Methyl 11-Eicosenoate 20:1 324 
Methyl Arachidate 20:0 326 
Methyl Docosahexaenoate 22:6 342 
Methyl 7,10,13,16-Doscosatetraenoate 22:4 346 
Methyl 13,16,19-Docosatrienoate 22:3 348 
Methyl 13,16-Docosadienoate 22:2 350 
Methyl Erucate 22:1 352 
Methyl Behenate 22:0 354 
Methyl Nervonate 24:1 380 
Methyl Lignocerate 24:0 382 
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volume was not possible, due to the two strains growing at different rates and the final 
cellular concentration per volume, as measured by optical density at 600 nm (OD600), 
varied at the time of harvest.  Therefore, reactions based on addition of a standard volume 
might lead to erroneous differences, since the number of initial cells in the reaction would 
vary depending on the strain.   
 The solution was to normalize each reaction based on a dry cell weight.  The first 
step was to examine the time frame needed to fully dry an aliquot of cells.  The 
experiment consisted of freeze drying a fixed volume of cells for a period of time and 
measuring the weight loss every 12 hrs.  The cells were deemed fully dry when the 
weight loss between successive measurements decreased to a minimum.  Each weighing 
was done in triplicate, the averages minus the empty tube weight subtracted and standard 
deviations for each set are shown in Tables 2.3, 2.4 and 2.5. 
Micro-centrifuge tubes were set-up with the following contents: tubes 1-3 
contained 100 μL of 50 mM Tris-HCl buffer (pH 7.5), tubes 4-6 had 100 μL of C. 
thermocellum WT whole cells, and 100 μL of C. thermocellum EA whole cells were in 
tubes 7-9.  The dry weight of 50 mM Tris-HCl was required since the cells were solvated 
in this solution.  Thus after drying the buffer salts, would remain on the cells and 
therefore need to be subtracted from the dry cell weight.  The following two tables would 
have the total average Tris-HCl weight subtracted.   
  During sampling it was observed that as a result of cell clumping the aliquots 
could contain an unequal distribution of cells and thus Tris-HCl.  This could introduce 
errors during replicate reactions since it was assumed that the concentration of cells and 
Tris-HCl would be constant in a measured volume.  The solution was to remove the Tris-
HCl washing with diH2O before drying the cells.  Subtraction of Tris salts from the dry 
cell weights was therefore abandoned after cells underwent washings in diH2O. 
Fatty acid structural determination 
Earlier C. thermocellum studies used analytical approaches with limited 
capabilities [34].  To enhance these previous studies, we used mass spectrometry to 
identify and quantify membrane lipids.  Upon analysis of C. thermocellum WT and EA 
strains the developed GC temperature ramp provided separation of FAME analytes,  
Table 2.3.  50 mM Tris-HCl dry weight (mg) per 100 μL. 
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Tube # 12 hr 24 hr 36 hr 
1 0.577±0.133 0.467±0.074 0.520±0.061 
2 0.640±0.082 0.480±0.053 0.483±0.067 
3 0.847±0.095 0.613±0.040 0.550±0.071 
 
Table 2.4.  C. thermocellum WT dry weight (mg) per 100 μL. 
Tube # 12 hr 24 hr 36 hr 
4 2.450±0.140 2.337±0.133 2.240±0.020 
5 2.880±0.030 2.677±0.192 2.677±0.080 
6 3.290±0.106 2.807±0.076 2.850±0.065 
 
Table 2.5.  C. thermocellum EA dry weight (mg) per 100 μL.  
Tube # 12 hr 24 hr 36 hr 
7 5.340±0.032 5.130±0.081 5.193±0.012 
8 6.140±0.072 5.750±0.12 5.853±0.046 
9 4.273±0.115 3.940±0.075 3.977±0.010 
  
58 
 
 
 
  
Figure 2.5.  Chromatogram of C. thermocellum FAMEs. 
59 
 
facilitating accurate quantification the each species (Figure 2.5).  Fatty acid structural 
identification for C. thermocellum was complicated by the presence of multiple pairs of 
peaks that contained nearly indistinguishable mass spectra.  Due to the fact that these 
peaks were chromatographically separated, but displayed identical molecular ions 
masses, they were believed to be geometric isomers of 14:0, 16:0, 17:0, and 18:0 alkyl 
chains. 
Electron-impact (EI) ionization of FAMEs fails to provide characteristic 
fragmentation patterns that provide structural elucidation, because EI spectra that are 
dominated by low molecular weight fragments and contain relatively modest amounts of 
intact molecular ion.  Fragmentation by EI provides a statistical distribution of ions based 
on the stability of the resulting fragments.  Highly stable fragments are represented more 
frequently in mass spectra.  In addition, bond rearrangement regularly occurs to produce 
stable products.  For these reasons alternative methods of derivatization were necessary 
for structural identification.  
A variety of derivatization reagents are available that provide characteristic 
fragmentation patterns [59-63].  Since no prior mass spectral data about the structure of 
the C. thermocellum fatty acids was available, a derivatization method applicable to a 
broad range of compounds was necessary.  Transesterification with 3-
hydroxymethylpyridine, to form picolinyl esters, was chosen for derivatization in the 
hopes that it might provide insight into the structure of the punitive plasmalogen 
compounds, in addition it provided a simple method for derivatization and the mild 
reaction conditions helped minimize fatty acid degradation.  The nature of the picolinyl 
ester resulted in charge remote fragmentation products allowing structure elucidation of 
the fatty acid alkyl chains.   
 Mass spectra for the picolinyl ester products from the 16:0 FAME reactants 
(Figures 2.6 & 2.8).  Each mass spectrum gives a moderately abundant molecular ion m/z 
347, allowing proper fatty acid identification.  Picolinyl fragmentation of straight-chain 
fatty acids provides a repeating pattern of [M]
+
-(CH2)n mass units, after loss of the 
terminal methyl group [M-15]
+
.  The spectrum represents the successive loss of 
methylene groups, 14 atomic mass units (amu) down to the McLafferty ion at m/z 151.  
Figure 2.7 illustrates common fragmentation pathways for straight-chain picolinyl esters. 
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Figure 2.7.  Common fragmentation pathways for straight-chain picolinyl esters. 
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The mass spectrum for picolinyl 14-methyl-pentadecanoate (Figure 2.8), the iso-
methyl is lost to produce m/z 332, however the next mass in the series is m/z 304 which 
represents a loss of 28 amu.  The loss of 28 amu, as opposed to the regular 14 amu, 
indicates a methyl branch point along the alkyl chain.  The absence of an ion at m/z 318 
is indicative of an iso- branch point.  Fragmentation mechanisms for iso-methyl branched 
fatty acid picolinyl esters are shown in Figure 2.9.  This approach was used to identify the 
structures of fatty acids with other chain lengths for both WT and EA C. thermocellum 
strains (data not shown).  Analysis of both C. thermocellum strains through picolinyl 
transesterification yielded equivalent fatty acid structural profiles, consisting of iso- and 
normal branched alkyl chains. 
 In order to confirm the formation of these dimethyl acetals an aldehyde, 
tridecanal, was reacted through the FAME procedure.  Synthesizing a dimethyl acetal 
standard in this manner should produce mass spectra analogous to those observed from 
the plasmalogens.  The resulting mass spectrum from the dimethyl tridecacetal exhibits a 
peak at m/z 213, representing [M-31]
+
 loss of a methoxy group and a base peak at m/z 
75, the fragment of the dimethyl head-group (Figure 2.10).  Comparison of published 
mass spectra from dimethyl acetals generated from plasmalogens provided further 
support for the fragmentation pattern and the presence of plasmalogens within the C. 
thermocellum membrane [64].   
 To further verify the formation of acetals from plasmalogens, chemical ionization 
(CI) experiments were conducted using acetonitrile as a reagent gas [65-68].  
Comparisons of mass spectra from the punitive plasmalogen (P 16:0) observed from C. 
thermocellum reactions, to those generated from methylation reactions with tridecanal 
were made.  The resulting mass spectra from hexadecan-1-al (P 16:0) and tridecanal 
provide analogous fragmentation patterns (Figure 2.11).  Since CI imparts a softer 
ionization process to the analyte, than EI, it should facilitate less fragmentation and 
provide greater structural information.  Both spectra contain minor molecular ion peaks, 
[M+H]
+
, at m/z 287 and 244 respectively.  As with EI generated spectra, fragments 
generated from the loss of a methoxy group, [M-31]
+
, are present at m/z 255 and 213.  
The ion from the dimethyl head-group fragmentation discussed in EI spectra was not  
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Figure 2.9.  Common fragmentation pathways for iso-branched picolinyl esters. 
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Figure 2.10.  Mass spectra from EI experiments from (a) dimethyl acetal of 
hexadecan-1-al (P 16:0) and (b) dimethyl acetal of tridecanal. 
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Figure 2.11.  Mass spectra from CI experiments from (a) dimethyl acetal of hexadecan-1-
al (P 16:0) and (b) dimethyl acetal of tridecanal. 
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detected due to instrumental constants during CI which requires a higher background m/z 
cut-off.   
 Additional validation of dialkyl acetal formation, and by extension plasmalogen 
detection, was gained by substituting methanol with ethanol during the esterification 
reaction.  The resulting EI mass spectra of diethyl acetals from reactions with hexadecan-
1-al (P 16:0) and tridecanal provide spectra where ions are shifted by 28 amu, in 
comparison to their dimethyl analogs (Figure 2.12).  The fragmentation pattern from the 
diethyl acetals are the equivalent to the dimethyl versions, [M-45]
+ 
representing loss of an 
ethoxy group and a base peak at m/z 103, from the diethyl head-group fragment. 
Fatty acid profiles 
Results from the FAME comparison between the two C. thermocellum strains are 
presented in two different arrangements (Table 2.1).  Data were first compared on a basis 
of microgram of FAME species per milligram of dry cell weight.  Evaluation of the data 
in this manner allowed comparison of the fatty acid composition between WT and EA 
strains based on cellular concentration in each reaction (Figure 2.13). 
 Data were then compared on a percentage basis of the fatty acids from C. 
thermocellum WT and EA strains (Figure 2.14).  These percentages represent the percent 
area counts of each lipid species compared to the total lipid species detected.  This 
manner of comparison eliminates error resulting from differences in lipid quantities on a 
dry cell weight basis between the two strains.  The t-test established that on a percentage 
basis, the fatty acid profiles had a significant difference indicated on the graph by “*”, at 
the 95% confidence interval, between the means for i-14:0, n-14:0, P i-14:0, P n-14:0, i-
16:0, n-16:0, P n-16:0, and i-17:0.   
Anisotropy Results 
 Utilization of a custom built view cell for anisotropy experiments meant that 
proper alignment must be maintained in order to reduce variation between experiments.  
Optimal alignment of the view cell was defined as adjusting the placement so that the 
xenon excitation source hit the center of the excitation optical window and the center of 
the emission optical window was aligned with the detector.  The Varian Cary Eclipse 
software package includes an Align feature that runs the xenon lamp and detector 
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continuously while allowing adjustment of the view cell placement to achieve maximum 
intensity.  The custom design of the viewing cell allowed adjustment at four positions  
  
69 
 
 
  
Figure 2.12.  Mass spectra from EI experiments from (a) diethyl acetal of hexadecan-1-al (P 
16:0) and (b) diethyl acetal of tridecanal. 
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along the excitation and emission planes to achieve a proper 90° orientation.  The Align 
program was utilized prior to the analysis of each sample to ensure maximum sensitivity. 
 The grating (g) factor, is the ratio of intensity in parallel (IHH) and the intensity in 
perpendicular (IHV) when excitation is polarized perpendicular.  Essentially, the g factor 
is a correction for molecular probes that are not aligned in the proper orientation to 
absorb light in the parallel polarization.  From the anisotropy equation (eq. 2.11), it is 
clear that an increase in the g factor will have an impact on the value of IVH, which will 
subsequently decrease the anisotropy (r) value.  Since the g factor is dependent on the 
alignment of the probe within the sample membrane and the view cell alignment, it was 
determined prior to analysis of each sample.   
 The first hurdle in conducting whole-cell anisotropy experiments dealt with 
incorporation of the DPH into the membrane.  Initial studies, conducted by incubating 
cells with DPH at room temperature, provided sporadic data and lower than expected 
anisotropy values during the heating phase (Figure 2.15).  It was observed that after the 
sample went through the first heating cycle, Tup 1
st
, the cooling portion, Td, gave more 
reproducible numbers and increased anisotropy values.  Subsequent heating, Tup 2
nd
, of 
the sample resulted in an almost identical trend as to that obtained during the cooling 
cycle. 
This reproducible trend was found to be the result of probe integration into the 
bilayer as the temperature increased.  As the DPH probe entered the bilayer and 
associated with the fatty acid alkyl chains it’s rotation was restricted and the absorption in 
the perpendicular polarization (IVH) decreased, which consequently increased the overall 
anisotropy.  The sample preparation method was modified to incubate the whole cells 
with 0.1 DPH in THF at 65°C for 1 hr prior to analysis.  With the optimization of 
integrating the DPH probe into the bilayer, the anisotropy changes, from the temperature 
ramp, were completely reversible when the temperature was decreased from 70°C to 
24°C (data not shown).  
Following method development for incorporation of the DPH probe into the cells 
a series of blanks was designed to ensure that no inherent fluorescence emission occurred 
at 452 nm, by the buffer or cells, as a result of excitation at 350 nm.  The first 
experiments tested C. thermocellum WT and EA whole cells in 50 mM Tris-HCl buffer  
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Figure 2.15.  Anisotropy method development. 
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and 50 mM Tris-HCl with 5% (w/v) ethanol for intrinsic fluorescence.  Wild-type and 
ethanol-adapted C. thermocellum whole cells were prepared in the same manner as 
conventional samples, however no DPH probe was added.  These cellular samples were 
excited at 350 nm while the emission detector was scanned from 400 nm to 600 nm 
without the polarizing lenses applied.  The polarizer was removed to ensure maximum 
transmission of any generated fluorescence.  Neat 50 mM Tris-HCl buffer with and 
without ethanol was also evaluated in this same manner.  No detectable signal was 
generated from any of these samples (data not shown). 
 Evaluation of unincorporated DPH being transferred into the view cell after 
cellular incubation was also tested.  After DPH incubation the samples were centrifuged 
and the supernatant discarded, in an attempt to remove any superfluous probe not 
integrated into the cell membrane.  The cell pellet was then dissolved in fresh 50 mM 
Tris-HCl buffer.  Wild-type and ethanol-adapted C. thermocellum whole cells were 
prepared in the same manner as conventional samples, the normally discarded 
supernatant was tested for fluorescence as well as the cells.  These tests were conducted 
to provide data on whether the DPH remains in solution or associates with the cell.  The 
experiments were excited at 350 nm while the emission detector was scanned from 400 
nm to 600 nm without the polarizing lenses applied.  The supernatant yielded no 
detectable signal, however the cells provided an intense signal, at 452 nm, which 
corresponds to emission by DPH. 
  Anisotropy experiments were designed to simulate the growth conditions of both 
WT and EA strains.  Since the growth temperature for C. thermocellum WT and EA 
batch cultures was 65°C, measurements were recorded while heating the cells up to 70°C.  
C. thermocellum wild-type and ethanol-adapted whole cells were initially evaluated in a 
50 mM Tris-HCl buffer (pH 7.5).  However, to accurately reflect growth conditions of 
EA cultures experiments were conducted with WT and EA whole cells in 50 mM Tris-
HCl buffer (pH 7.5) with 5% (w/v) ethanol. 
Membrane fluidity was assumed to be lowest at 24°C, and this was arbitrarily set 
to correspond to 100% anisotropy.  Subsequent experimental values were reported as the 
percentage decrease in anisotropy (i.e., increase in fluidity) as a function of increasing 
temperature.  The normalized steady-state fluorescence anisotropy of C. thermocellum 
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wild-type cells in 50 mM Tris (pH 7.5) as a function of temperature is shown in Figure 
2.16.  Each data-point (♦) is the average of three analytical replicates and five multiple 
observations, the standard deviation error bars are concealed by the data-point symbols.  
A trend line was fit to the data-points using a 2
nd
 order polynomial function.  The vertical 
dashed-line represents the batch growth temperature of 60°C. 
The anisotropy experiments conducted without ethanol present, allow a 
comparison of the two strains in an environment similar to WT batch culture.  As the 
temperature was raised from 24°C to 70°C in 50 mM Tris-HCl buffer, the anisotropy of 
WT cells decreased by approximately 30% (Figure 2.17).  In contrast, there was only a 
16% decrease in anisotropy for EA cells over the same temperature range.  These results 
indicate that EA cells have a lower fluidity, greater membrane rigidity, than WT cells in 
the absence of ethanol [69]. 
Normalized steady-state anisotropy data from C. thermocellum WT and EA 
experiments in 50 mM Tris-HCl with 5% (w/v) ethanol provide a comparison of the two 
strains in an environment similar to EA batch culture (Figure 2.18).  The data points, 
omitted to reduce clutter, are again the average of three analytical replicates and the 
standard deviation error bars were concealed by the data-point symbols.  A trend line was 
fit to the data-points using a 2
nd
 order polynomial function.  The vertical dashed-line 
represents the batch growth temperature of both strains.  When 5% (w/v) ethanol was 
added to the buffer, WT and EA cells experienced 42% and 30% decreases in anisotropy, 
respectively (Figure 2.18).  In all experiments, the anisotropy changes were completely 
reversible when the temperature was decreased from 70°C to 24°C (data not shown).  
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Figure 2.16.  Normalized steady-state fluorescence anisotropy with 0% (w/v) 
ethanol.  C. thermocellum wild-type cells in 50 mM Tris (pH 7.5) as a 
function of temperature. 
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Figure 2.17.  Normalized steady-state fluorescence anisotropy with 
0% (w/v) ethanol comparison between C. thermocellum WT and EA 
strains. 
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Figure 2.18.  Normalized steady-state fluorescence anisotropy with 5% 
(w/v) ethanol comparison between C. thermocellum WT and EA 
strains. 
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Chapter 2.4.  Discussion 
The prokaryotic cell membrane functions as a protective barrier and serves a vital 
role in energy generating pathways, and so regulation of membrane integrity is essential 
for microbial survival and growth [70].  The concept that microbes modify their 
membrane composition in response to environmental stress has been well established [1, 
33, 37, 71-72].  The theory of homeoviscous adaptation, that cells modify their 
membranes in order to maintain an optimal degree of fluidity, has been supported by 
studies relating fatty acid profiles to temperature changes and solvent insult [35, 71-78].  
The accepted model for C. thermocellum is that it increases the number of unsaturated 
and short chain fatty acids in response to ethanol insult.  Increasing the percent of 
unsaturated and shorter chain fatty acids both serve to increase the overall fluidity of the 
membrane, when compared to longer, saturated alkyl chains.  Therefore ethanol-adapted 
strains increase baseline membrane fluidity in response to selection for alcohol tolerance.   
A number of previous fermentation studies with C. thermocellum have focused 
efforts on improving ethanol production [79-82].  Studies concerned with changes to the 
fatty acid composition during ethanol adaptation, however have been limited [34].  
Herrero et al. found that their ethanol-adapted strain, C9, had a greater proportion of fatty 
acids with less than fourteen carbons and more monounsaturated fatty acids.  There also 
appeared to be an increase in n- and anteiso-branching, with a concurrent decrease in iso-
branching [34].   
Fatty acid study 
Mass spectral fragmentation patterns of picolinyl esters allowed definitive 
identification of fatty acid alkyl chains present within the C. thermocellum membrane. 
Quantification of fatty acids and plasmalogens confirmed changes in cell membrane 
composition following ethanol treatment.  The adaptation process resulted in a shift to 
longer-chain fatty acids, an increase in iso- to n- branching, but did not increase the 
unsaturation index; these results were counter to previously published reports [34].   
It has been previously documented that members of the Clostridia genus and 
some anaerobic bacteria contain ether-linked alkyl chain lipids [83-84].  The Herrero 
study also detected the presence of plasmalogen compounds, however due to co-elution 
with fatty acid methyl esters, plasmalogen quantification was not possible [34].  During 
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acidic esterification reaction the ether bond is broken and aldehydes are generated.  
Methylation reagents convert these aldehydes into dimethyl acetals.  The spectra for 
published dimethyl acetals appear remarkably similar to the unknown spectra from C. 
thermocellum reactions [64].   
 However, picolinyl transesterification failed to provide structural elucidation for 
the plasmalogen species.  The plasmalogen vinyl-ether group forms an aldehyde during 
the esterification reaction, which immediately converts to a dimethyl acetal.  
Unfortunately the resulting dimethyl acetals were not amenable to transesterification into 
picolinyl esters.  Mass spectra generated with EI of these dimethyl acetals fail to provide 
a molecular ion and generally consist of ions with only minor abundances.  The only two 
prominent ions are: m/z 255 representing [M-31]
+
 loss of a methoxy group and m/z 75 
generated by the loss of the dimethyl head-group.   
Chemical ionization (CI) with acetonitrile has been used to elucidate double bond 
location in the analysis of polyunsaturated fatty acids [65-68].  The expectation was that 
CI could provide a softer ionization mechanism capable of producing structural 
characteristic ions for the plasmalogen species.  Experiments conducted utilizing 
chemical ionization did provide [M+H]
+
 ions, which were not observed during EI 
experiments.  The [M+H]
+
 ions did fragment to produce the [M-31]
+
 ions as observed 
during EI, indicating that ions seen during EI were generated from the respective 
dimethyl acetal species.  Data from the diethyl acetal fragmentation patterns corroborated 
spectra from both EI and CI of dimethyl acetals.  The advantage to employing this three-
tiered approach was that the chromatographic separation remains intact during each 
process, allowing peaks to be confidently identified based on mass spectra and retention 
times.  Comparison of spectra generated from reactions with tridecanal via CI and EI lend 
credibility to the generation of dimethyl acetals and thus the presence of plasmalogens. 
 The milligram FAME per cell dry weight data (Figure 2.13) were analyzed 
statistically.  However, it was believed that differences between the two strains were 
exaggerated due to differences in the amount of lipid per DCW between the two strains.  
The disparity in the lipid to DCW ratio was believed to be a result of variations in size 
and non-lipid components between the strains.  This theory was supported by 
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experiments that showed total carbohydrate levels in EA cells were five times greater 
than those of WT cells (data not shown).   
 Therefore it was necessary to compare the fatty acids as area percents (Figure 
2.14).  Presenting the data as area percents, the data were normalized with respect to 
variations due to differences in lipid per DCW.   
In contrast to the previous work, our work revealed that adaptation to exogenous 
ethanol did not change the site of methyl branching or the degree of unsaturation [32, 34, 
75].  The absence of unsaturated fatty acids within the C. thermocellum membrane raised 
concerns about the validity of the derivatization methods.  In order to confirm that 
unsaturated fatty acids were not being deteriorated as a result of the saponification and 
FAME methods, reactions with 5,8,11,14-eicosatetraenoic acid (ARA), 4,7,10,13,16,19-
docosahexaenoic acid (DHA) standards, and Escherichia coli whole cells were 
conducted.  Reactions with ARA and DHA yielded mass balance recoveries and FAME 
molecular ions of m/z 318 and m/z 342, respectively.  Qualitative analysis of the E. coli 
fatty acid profile was consistent with previously published data, which contained both 
unsaturated and cyclopropane fatty acids (data not shown) [49].  Concluding that results 
obtained from our dervitization methods were valid.       
The present work found that the ratio of iso- to n- branched was higher in the EA 
strain for every fatty acid and plasmalogen, with the exception of 14:0 and P 14:0 (Table 
2.1).  Comparison of the WT and EA strains on a percentage basis revealed that WT had 
a greater percentage of fatty acids with chain lengths sixteen carbons or less.  On the 
other hand, the EA strain had a larger percentage of fatty acids and plasmalogens with 
chain lengths sixteen carbons and longer.  These data indicate that growth in 5% (w/v) 
ethanol resulted in the bacteria increasing the chain length of fatty acids.  However, 
ethanol-adaptation did not promote incorporation of unsaturation fatty acids or change 
the location of methyl branching on the fatty acids.  
One plausible reason for differences between the Herrero study and our study 
could be due to growth conditions after ethanol-adaptation.  Both studies selected 
ethanol-adapted strains by serial transfer of viable cells with successive growth cycles 
and increasing exogenous ethanol concentration [75].  The Herrero et al. study implied 
that their ethanol-tolerant strain, C9, after selection was grown in media without ethanol 
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present [34].  If C. thermocellum changes membrane composition in the presence of 
ethanol, it might be plausible that the membrane is further changed when grown in the 
absence of ethanol.   
Another reason for differences could be due to the method of analysis.  Herrero et 
al. used a packed-column GC as the chromatographic method and detection by means of 
a flame ionization detector (FID).  Fatty acid identification was based on retention time 
comparisons between sample and standards.  Therefore, unknown compounds such as 
plasmalogens could be misinterpreted as fatty acids due to similar retention times.  Our 
study employed capillary-column GC/MS with identification and structural analysis 
based on molecular weight and fragmentation patterns, thereby distinctly separating 
plasmalogens and fatty acids. 
Anisotropy Study 
Previous studies conducted on the effect of exogenous solvents added to C. 
thermocellum batch cultures found that solvents impact bacterial proliferation and 
metabolism [79].  Growth inhibition caused by solvents dispersed in culture media is 
known as molecular toxicity, and such toxicity is the result of interactions between the 
solvent and the membrane or membrane components [85-86].  This solvent interaction 
disrupts membrane integrity by causing loss of protein function and increased membrane 
fluidity.  Molecular toxicity is theorized to be responsible for growth inhibition of C. 
thermocellum WT cells at low ethanol concentrations [85].  Based on this theory, 
ethanol-adapted strains of C. thermocellum are believed to change their membrane 
composition in order to counteract the effects of molecular toxicity.   
In order to gain a more direct understanding of the relationship between fatty acid 
profiles and membrane fluidity, steady-state fluorescence anisotropy experiments were 
conducted as part of this study.  Anisotropy is a measure of probe rotation obtained by 
comparing the ratio of fluorescent emission in parallel and perpendicular polarizations.  
Within the context of this study, anisotropy correlates to the order of the fatty acid alkyl 
chains which is inversely related to fluidity, thus as the anisotropy value decreases the 
fluidity of the membrane increases [44].  The rotation of DPH is a function of the fatty 
acid phase transition temperature, Tm.  Longer saturated-chain fatty acids have a higher 
Tm, due to a greater number of van der Waals interactions between acyl chains.  
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Unsaturated fatty acids have lower transition temperatures than saturated fatty acids of 
similar length, due to reduced van der Waals interactions as a result of the distorted 
geometry around the double bond [45].  Below the Tm the alkyl chains are in an ordered 
state and rotation of the DPH probe is restricted.  With increasing temperature the alkyl 
chains become disordered allowing rotation of DPH.  Rotation of DPH lowers the ratio of 
horizontal and vertical intensities, translating to a lower anisotropy [40].  Above the Tm 
of fatty acids a phase transition occurs which is reflected by a sudden increase in 
membrane fluidity [46].  Due to the heterogeneity of the C. thermocellum membrane and 
because DPH integrates non-discriminately between hydrocarbon chains, a decrease in 
anisotropy represents an increase in the average fluidity of the membrane [46]. 
Numerous papers report relationship between fatty acid chain length, ethanol 
exposure, and membrane fluidity [32, 69, 87].  Anisotropy experiments with exogenous 
ethanol provided conformation of the membrane fluidizing effects of exogenous ethanol 
[88].  We hypothesize that the increased fluidity afforded by exogenous ethanol reduced 
the membrane rigidity for WT cells below an optimum level.  This sub-optimum 
membrane rigidity occurred because WT cells have a high percentage of short chain 
length fatty acids.  Increased fluidity is believed to result in growth inhibition due to 
molecular toxicity when in the presence of ethanol.  The EA cells adapted to ethanol by 
producing a higher percentage of longer-chain fatty acids.  Therefore, interaction between 
exogenous ethanol and the more rigid EA membrane together change the fluidity to a 
level that was consistent to that of WT cells without ethanol. The Herrero et al. concluded 
that C. thermocellum responded to ethanol treatment by increasing membrane fluidization 
[34].  The assumption was that ethanol had a rigidifying effect on the membrane.  This 
was based on partition coefficient studies conducted with liposomes and branched-chain 
alcohols [89].   
 Anisotropy experiments on EA cells without ethanol, displays the smallest % 
change, 16%, over the experimental temperature range.  However the effect of 5% (w/v) 
ethanol on the fluidity of EA cells, increases the fluidity, lowering the anisotropy 
approximately 30% over the experimental temperature range.  These results are similar to 
those obtained for WT cells without ethanol.  The addition of ethanol to WT cells 
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increases the membrane fluidity, illustrated by a reduction in anisotropy by more than 
40%, presumably resulting in a less than optimum fluidity barrier.  
  Since the C. thermocellum WT and EA membranes were comprised of 28% and 
37% plasmalogens, their contribution to membrane structure and fluidity may be 
significant, as the vinyl-ether bond imparts different characteristics to the phosphatidyl 
group than the traditional fatty acid ester bond.  The plasmalogens’ role might be to 
modify the Tm of the membrane in a similar manner to that of unsaturated fatty acids 
[16].  Regulating membrane fluidity by means of plasmalogens might provide the cell 
with a more discrete mechanism of changing membrane properties. 
The data from the fatty acid studies combined with the anisotropy data provide 
strong evidence for a refined model for acquired ethanol tolerance by C. thermocellum 
(Figure 2.19).  Adaptation was the result of changes to the fatty acid profile that increased 
membrane rigidity, allowing the integrity of the membrane to be maintained during 
growth in the presence of exogenous ethanol.  These data presented in this study support 
the idea that EA cells maintain an optimum level of fluidity by increasing their fatty acid 
chain lengths in response to the increased fluidity provided by growth in media 
containing ethanol. This study provided evidence of an alternative description of the 
route for bacterial survival due to adaptation to exogenous solvent.  Understanding the 
mechanism of membrane adaptation by C. thermocellum to acquire ethanol tolerance 
could be utilized to develop cultures that exhibit resistance to higher concentrations of 
ethanol.  This, in-turn, could lead to more cost-effective ethanol production which would 
be a step closer to consolidated bioprocessing (CBP). 
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Figure 2.19.  Schematic of ethanol-adaptation mechanism.  i- denotes 
iso-branching, n- denotes normal or straight chain, a- denotes anteiso-
branching. 
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PART III.  MITOCHONDRIAL LIPIOMICS 
Chapter 3.  Comparison of Sprague Dawley Rat Mitochondrial Fatty Acid Profiles 
Isolated from Various Tissues 
Chapter 3.1.  Introduction 
As shown by the previous study, bacteria alter their membrane composition as a 
result of adaptation to various environmental stimuli [70, 90-91].  However, modification 
of membrane content is not relegated to prokaryotic organisms.  Mammalian systems 
have also been shown to exhibit variations in their lipid content on a tissue specific basis 
and as a function of diet [92-93].   
In eukaryotes, biological processes are compartmentalized by membranes, this 
segregation gives rise to different inter- and intra-cellular biochemical environments.  
Exposure and interaction of cells, within a macromolecular system, to potential 
differences in metabolomes (i.e. ions, secondary messengers, and/or signaling molecules) 
could further stimulate differentiation in cellular composition [94].  Variations in the 
inter-cellular environments among tissues, has been shown to stimulate changes in the 
lipid content of the plasma membrane [95-97].  Based on this knowledge, our hypothesis 
is that alterations in inter-cellular environments could cause tissue specific changes to the 
fatty acid profiles of sub-cellular organelles such as mitochondria.    
Changes to the fatty acid composition will have a significant impact on the 
physical properties of the membrane [15, 45, 98].  Fluidity is a function of the van der 
Waals interactions between acyl chains, which is in part determined by the chain length 
and degree of unsaturation.  Short-chain saturated fatty acids will have greater fluidity 
than longer-chain saturated fatty acids due to the reduced number of van der Waals 
interactions.  Unsaturation along the acyl chain will also decrease the van der Waals 
interactions as a result of the geometry around the double bond.  Double bonds with cis 
geometry, which comprise the majority of naturally occurring double bonds, result in a 
30° bend along the acyl backbone.  This distortion effectively shortens the fatty acid 
chain length by one methylene group per incident.   
Mitochondrial membranes house many protein complexes involved in the reaction 
cascade of the electron transport chain (ETC) [99-100].  Therefore electrons leaking from 
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the ETP are the greatest source of reactive oxygen species (ROS) within a cell.  Because 
of their proximity to these ROS, mitochondria are considered both the cause and a target 
of oxidative stress [101].  The high oxygen consumption rate of neurological cells and the 
relatively low abundance of antioxidant counter measures would likely require 
compensatory changes to the fatty acid profile in order to minimize susceptibility to 
oxidative damage. 
Oxidative stress, a consequence of ROS proliferation, has been suspected to be 
causal in many neurodegenerative diseases [102-104].  Considerable research is 
dedicated to monitoring ROS mediated damage to nucleic acids [105], proteins [106], and 
lipids [107].  Due to the mitochondrial role in the ETP, common targets for these ROS 
are lipid components of the mitochondrial membrane, namely polyunsaturated fatty acids 
(PUFAs).  Previous studies have shown that neurological plasma membranes contain an  
abundance of polyunsaturated fatty acids.  Enzymes required for mitochondrial fatty acid 
synthesis are localized within the mitochondria matrix, whereas fatty acid synthesis for 
other cellular organelles occurs mainly in the cytosol [15].  Therefore mitochondria 
provide a semi-autonomous organelle when studying changes to the FA profile.  Thus, a 
comparison of the fatty acid profiles from brain mitochondria in comparison to other 
tissues may provide evidence for the increased neurological susceptibly to ROS.   
The focus of the project centered on the analysis and variation of mitochondrial 
membrane composition from distinctive cellular environments.  Tissues selected for this 
study represent functioning organs with distinctive biochemical processes.  Mitochondria 
isolated from brain, heart, liver and kidneys were chosen because mitochondrial disorders 
that effect each of these tissues are of interest to researchers [92-94, 108]. 
In order to gain a better understanding of the distinction between each of the 
tissues, a brief description for each is necessary.  The heart is a muscle that is composed 
of short, striated fibers.  The heart functions to maintain and direct the circulation of 
blood throughout the body.  Mitochondria from cardiac cells usually only respire through 
an aerobic pathway, however they commonly utilize a variety of carbon sources for raw 
materials.  Permeability across the cellular membrane in cardiac cells results having a 
biochemistry that vacillates between high concentrations of Ca
2+
, Na
+
 and low K
+
 to 
periods of high K
+
 concentrations and low Ca
2+
 and Na
+
 levels.  Therefore, mitochondria 
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are regularly exposed to fluctuating levels of divalent cations, which have been linked to 
the synthesis of cardiolipin [15]. 
The kidney is responsible for regulating the consistency of fluids throughout an 
organism’s system.  The constant supply of blood and fluids to the kidneys results in cells 
exposed to fluctuating levels of K
+
 and Na
+
, much like cardiac cells, during the 
reabsorption process.  Similar to the kidneys, the liver functions to process nutrients in 
the blood.  The liver produces bile that aids in the digestion of fats and absorption of fatty 
acids.  Metabolically the liver is probably the most active organ within this study.  The 
liver metabolically processes and detoxifies many of the nutrients from external sources.  
In addition, the liver stores vitamins and iron removed from red-blood cells. 
Lastly, the brain, specifically the cerebral cortex, is the processing center for the 
organisms motor, sensory and memory functions.  Unlike the other organs that comprise 
this study, the brain is protected from abrupt changes in cellular environment as a result 
of supplement metabolism.  The brain is surrounded by cerebrospinal fluid (CSF) a 
solution with an abundant concentration of Na
+
, Cl
- 
and Mg
2+
 ions.  The CSF contains a 
reduced amount of Ca
2+
 and K
+
 than found in blood serum, which is in constant contact 
with the heart, liver and kidneys.  The blood-brain barrier allows the diffusion of amino 
acids, electrolytes and fat soluble molecules; while maintaining balanced surroundings 
for neuronal events.   
Comparison of mitochondrial membrane compositions between various tissues 
may provide evidence for neurological tissues having an increased vulnerability to 
oxidative damage.  Gas chromatography/mass spectrometry (GC/MS) techniques were 
used to elucidate fatty acid structures and quantify lipid species.  Our analysis of 
mitochondrial lipids showed a significant increase in acyl chain unsaturation from brain 
mitochondria compared to heart, liver and kidney, perhaps explaining the increased 
vulnerability of the brain to ROS. 
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Chapter 3.2.  Experimental 
Reagents 
Potassium t-butoxide (1.0 M) in tetrahydrofuran (THF), 3-hydroxymethyl 
pyridine, hexane, D-mannitol, sucrose, Triza base, Tween-20, calcium chloride, and 
ethylenediaminetetraacetic acid disodium were purchased from Sigma (St. Louis, MO, 
USA).  Methanol, methylene chloride, and hydrochloric acid were obtained from Fisher 
(Pittsburg, PA, USA).  Acetyl chloride was obtained from Fluka (Buchs, Switzerland).  
Sodium hydroxide, sodium bicarbonate, and potassium carbonate were purchased from 
J.T. Baker (Phillipsburg, NJ, USA).  Ethyl ether was obtained from EMD (San Diego, 
CA, USA).  Anthracene was purchased from Acros (Morris Plains, NJ, USA).  Percoll™ 
was obtained from GE Healthcare (Uppsala, Sweeden).  Porin antibody was purchased 
from Calbiochem (Gibbstown, NJ, USA).  Lamin B was ordered from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA).  MAP2 was purchased from Abcom Inc. 
(Cambridge, MA, USA).  Isothesia (isoflurene) was obtained from Bulter Animal Health 
Supply (Dublin, OH, USA).  GLC-411 lipid standard, 5,8,11,14-eicosatetraenoic acid 
(ARA), and 4,7,10,13,16,19-docosahexaenoic acid (DHA) were purchased from Nu-Chek 
Prep, Inc. (Elysian, MN, USA).    
General equipment and supplies 
Dounce homogenizer (Wheaton Industries, Millville, NJ, USA).  Nalgene brand 
Oak Ridge polypropylene copolymer centrifuge tubes (Thermo Fisher Scientific Inc., 
Waltham, MA, USA).  Beckman Polyallomer centrifuge tube (Beckman Coulter, Inc., 
Brea, CA, USA).  Fisherbrand 2.0 mL polypropylene microcentrifuge tube (Thermo 
Fisher Scientific Inc., Waltham, MA, USA).  Beckman Coulter (Beckman Coulter, Inc., 
Brea, CA, USA) Avanti J-25 series centrifuge equipped with a JA-25.50 fixed angle 
rotor.  Beckman Coulter (Beckman Coulter, Inc., Brea, CA, USA) L-80 Ultracentrifuge 
series equipped with a SW 55 Ti swinging bucket rotor.  Thermo IEC Micromax 
Centrifuge (Thermo Fisher Scientific, Rochester, NY, USA) with a 851 series microtube 
fixed angle rotor.  Eppendorf (Hauppauge, NY, USA) Research Adjustable-volume 
pipettes. 
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Animals 
 Sprague Dawley SD outbred rats were obtained from Harlan Laboratories 
(Harlan Laboratories, Indianapolis, IN, USA) and were housed at the Sanders-Brown 
Center on Aging Animal Facility (Lexington, KY, USA).  All animals were fed a Teklad 
Global 18% Protein Rodent Diet (Harlan Laboratories Inc., Indianapolis, IN, USA) and 
had access to food and water ad libitum.  Animals were kept in plastic cages with wire 
tops containing Sani-Chip bedding (P.J. Murphy Forest Products Corp., Montville, NJ, 
USA).  At four months of age rats were euthanized by exposure to Isothesia (isoflurene) 
followed by cervical dislocation.  Necropsies were performed by trained laboratory 
personnel and harvested tissue was flash frozen in liquid nitrogen and stored at -80˚C 
until processed.  All animal procedures were in accordance with Institutional Animal 
Care and Use Committee (IACUC) regulations at the University of Kentucky under 
approved protocol number 2009-0548. 
Rat mitochondria isolation 
 Mitochondria were isolated using a procedure (Figure 3.1) adapted from previous 
studies [109].  Throughout the procedure all reagents were kept at 4°C, samples and 
equipment were placed on ice.  Tissue samples were homogenized via a manual Dounce 
homogenizer in isolation buffer (IB) (10 mM Tris, 0.32 M sucrose, 0.25 mM Na2EDTA, 
pH 7.4).  The total volume of isolation buffer used during homogenization gave a tissue 
to buffer ratio of approximately 0.1 g/mL (wt/vol).  The tissue was homogenized with 
approximately 8 to 10 up-and-down strokes or until the tissue was completely liquefied.  
The homogenate was centrifuged (2,000xg, 3 min, 4°C).  The supernatant was collected 
and the pellet was dissolved in approximately half the original volume of isolation buffer 
then centrifuged (2,000xg, 3 min, 4°C).  The supernatants were combined and the pellet 
discarded.  The combined supernatants were centrifuged (21,000xg, 10 min, 4°C).  The 
supernatant was discarded and the pellet, containing the crude mitochondria isolate, was 
resuspended in 3 mL 19% Percoll solution.  The crude mitochondria solution was 
carefully layered atop two discrete Percoll concentrations (30% over 50%, 1:1 by vol, 7 
mL total).  The mixture was centrifuged (16,900xg, 30 min, 4°C).  Three bands were 
discernible following centrifugation.  The bottom most band, containing the enriched  
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Tissue homogenization
Nuclear pellet Supernatant
Centrifuge (2000xg, 3 min, 4°C)
Nuclear pellet Supernatant
Centrifuge (2000xg, 3 min, 4°C)
Crude mitochondria pellet
Centrifuge (21000xg, 10 min, 4°C)
Percoll gradient
Centrifuge (16900xg, 30 min, 4°C)
Enriched mitochondria band (4x vol PBS)
Mitochondria (3 mL PBS)
Mitochondria (1 mL PBS)
Centrifuge (17500xg, 30 min, 4°C)
Centrifuge (17500xg, 30 min, 4°C)
Centrifuge (21000xg, 10 min, 4°C)
Purified mitochondria
Figure 3.1.  Mitochondria isolation scheme. 
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free-mitochondria, was extracted with a Pasteur pipette and dissolved in 4 volumes of 
PBS buffer and centrifuged (17,500xg, 30 min, 4°C).  The mitochondrial pellet was 
washed two additional times with 1 mL aliquots of PBS, each washing was centrifuged 
(21,000xg, 30 min, 4°C).  The final pellet was resuspended in deionized H2O and stored 
at -80°C until further analysis.             
Quantification of mitochondrial proteins 
Quantification of mitochondrial proteins was carried out on a Thermo Labsystems 
Multiskan MCC/3340 spectrometer (Pittsburgh, PA, USA) using a Pierce Bicinchoninic 
acid (BCA) assay (Rockford, IL, USA) [105].  A calibration curve was prepared by 
addition of 0, 1, 5, 10, 15, 20 μg BSA standard into separate wells; each concentration in 
duplicate.  Aliquots of isolated mitochondria (5 μL) were added to separate wells; each 
sample in duplicate.  Wells were adjusted to a final volume of 100 μL by addition of 
deionized H2O.  Lastly, 100 μL of a 10 μL/mL CuSO4 in bicinchoninic acid solution was 
pipetted into each well.  The plate was incubated at 37°C for 30 min prior to reading.  
The mitochondrial protein concentration was determined by absorbance at 620 nm. The 
concentration (μg/μL) was calculated by averaging the sample replicates and dividing by 
the addition volume (eq. 3.1):  
L
AA
Lg
5
2
/Protein
21
       eq. 3.1 
 Western blot analysis 
 Mitochondrial isolations were evaluated for purity by western blot (Figure 3.2).  
Isolated mitochondria (20 μg) were separated on a 4-15% SDS-PAGE gradient gel.  
Protein bands were transferred to a nitrocellulose membrane and incubated with 5% milk 
in 0.5% Tween-20/Tris-buffered saline (TTBS) plus goat serum (1:30, 2 hrs, 25°C).  The 
membrane was incubated with primary antibodies: anti-porin (1:5000) specific for 
mitochondria; anti-lamin B (1:3750) a marker specific for nuclei; and anti-MAP2 
(1:3750) a cytosolic specific marker (12 hrs, 4°C).  The membrane was washed three 
times with 0.5% Tween-20/Tris-buffered saline then incubated with horseradish 
peroxidase (1:7500 for lamin B and MAP2; 1:10000 for porin) conjugated secondary 
antibody (1 hr, 25°C).  Following three washings with 0.5% Tween-20/Tris-buffered  
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Figure 3.2.  Mitochondria western blot results.  Protein markers (a) for total 
homogenate (TH), nuclear (Nuc), cytoplasmic (Cyto), and mitochondria 
isolates (Mito) from rat brain and mitochondria protein marker (b) from each 
tissue.   
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saline, the bands were visualized with enhanced chemiluminescence (Amersham 
Pharmacia Biotech, Piscataway, NJ, USA) as per manufacturer’s instructions. 
Saponification of fatty acids 
 Aliquots (250 g) of isolated mitochondrial protein were used for each reaction.  
Saponification methods were based on a previous description by Kurkiewicz et al [49].  
Sodium hydroxide (1 mL of 3 M) was added to the mitochondria solution.  The mixture 
was vortexed and heated to 90°C for 1 h, cooled to room temperature, and 2 mL of 3.25 
M HCl was added and reheated at 90°C for 10 min.  After cooling to room temperature, 
the lipids were extracted three times with 1 mL portions of hexane/diethyl ether (1:1, by 
vol).  The organic phases were combined and evaporated to dryness under a stream of N2 
at room temperature. 
Fatty acid derivatization methods 
 Fatty acid methyl ester (FAME) procedures were adapted from Lepage and Roy 
[50].  Methanol:acetyl chloride (50:1 (v/v), 5 mL total) was added to the extracted free 
fatty acids.  The solution was vortexed and heated at 60°C for 1 h.  After heating, 3 mL 
of 6% K2CO3 was added, and the FAME products were extracted 1 mL of hexane 
containing 50 ng/ L anthracene.  Extracted material (1 L) was used for GC/MS 
analysis.   
 An aliquot of the FAME solution was transesterified to picolinyl esters using an 
adapted method [51].  The hexane phase from the FAME procedure was evaporated to 
dryness under a stream of N2 at room temperature and 1 mL of methylene chloride was 
added to resolvate the methyl esters.  In a separate vial a mixture of 200 µL 3-
hydroxymethylpyridine and 100 L of 1.0 M potassium tert-butoxide in THF were 
allowed to react for 2 min.  This mixture was then added to the FAME methylene 
chloride solution.  The reaction was mixed and heated at 45°C for 1 h.  After cooling to 
room temperature, 1 mL of 2.5% NaHCO3 was added and the methylene chloride layer 
removed.  The organic layer was reduced to approximately one-quarter original volume 
under a stream of N2 at room temperature and 1 L was injected for analysis.  All 
derivatization methods were validated by analysis of 20:4 (arachidonic acid) and 22:6 
(docosahexaenoic acid). 
 
95 
 
Gas chromatography/mass spectrometry 
Fatty acid methyl ester derivatives were analyzed using a Varian Saturn 3 GC/MS 
system equipped with a ZB-5ms capillary column 30 m x 0.25 mm i.d., 0.25 μm film 
(Phenomenex USA, Torrance, CA).  The temperature program was: 130°C to 170°C at 
4°C/min, 170°C to 215°C at 2.7°C/min, 215°C for 3.34 min, with a total analysis time of 
30 min.  Carrier gas head-pressure was set to give a flow rate of 1 mL/min, with a 50:1 
split.  The injector and transfer line were maintained at 240°C and the manifold 
temperature was 210°C.  Ionization was accomplished by electron impact (EI) at 70 eV, 
with a 3 minute filament delay.  Full scan spectra (m/z 50 to 650) were acquired at a scan 
rate of 1 analytical scan per second with a background mass set at m/z 49.  The GC/MS 
method was optimized to provide peak resolution for FAMEs from the GLC-411 
standard.   
Fatty acid picolinyl ester derivatives were analyzed on the same instrument with 
the following temperature program: 150°C for 4 min., 150°C to 280°C at 20°C/min, 
280°C for 19.5 min with a total analysis time of 30 min.  All other parameters were as 
described above except that the filament delay was 10 min and spectra were generated 
from full scans from m/z 50 to 500.   
Chemical ionization (CI) experiments were conducted on the same instrument 
using the FAME GC/MS program, except the manifold temperature was reduced to 
160°C.  The MS parameters were as follows: selected-ejection chemical ionization 
(SECI) mode with acetonitrile as the reagent gas (Figure 2.2) [52], 100 μsec automatic-
reaction control (ARC) time, 1000 μsec ionization time, 128 msec reaction time, m/z 15 
ionization storage level, 7.5 V0-p reagent gas ion ejection amplitude, m/z 37.0 CI reaction 
storage level.  Spectra were generated by full scans from m/z 80 to 650.  All GC/MS data 
were analyzed using the Wsearch32 2005 Software (version 1.6.2005; Melbourne, 
Australia).   
Calculations 
The distribution of FAMEs per tissue was determined by dividing area counts for 
each FAME species by the total observed FAME area count (eq. 3.2): 
100%
Area
FAME
FAME
Area
FAME
      
 eq. 3.2 
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The unsaturation index (u.i.) was calculated by dividing the number of double bonds by 
the total number of bonds on the fatty acid chain (eq. 3.3): 
100
bonds total
bonds double
u.i. %        eq. 3.3  
Plasmalogens were not included in the number of double bonds or total fatty acid chain 
bonds. 
Average ( x ) 
n
n
n
nnnn
x
...321
       eq. 3.4 
Standard deviation (s)  
The standard deviation represents the difference between replicate measurements. 
1
)( 2
n
xx
s
i
         eq. 3.5                         
F-test for comparison of two variances 
 The null hypothesis is stated that there is no significant difference between the 
two variances.  If Fcalc > Ftable, p, v1, v2 then the null hypothesis is rejected and there is a 
significant difference between the two populations.  Fcalc > 1, v1 = n1-1, v2 = n2-1 
2
2
2
1
2
1
s
s
v
v
Fcalc          eq. 3.6 
t-Test for comparison of two experimental means 
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tcalc         eq. 3.7 
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Analysis of Variance (ANOVA) 
2
1
calcF           eq. 3.8  
Where 1  equals the mean square error between the classes and 2 represents the mean 
square error within the classes.  If calcF  > tableF  then the HO is rejected and there is some 
systematic difference among the classes.  
Statistical analysis for comparison of fatty acids between classes employed 
commercially available ABstat software (AndersonBell Corp, Arvada, CO, USA).  
Averages of the fatty acids were compared using a one-way ANOVA and Tukey post hoc 
test (p<0.05, n=3).  Comparisons were limited to equivalent fatty acids between each of 
the tissues compared to brain, i.e. brain 14:0 vs. heart, kidney and liver 14:0 (Table 3.1). 
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Table 3.1.  Mitochondrial fatty acid composition and distribution between various tissues. 
Species 
(Structure)
a
 
FAME (%)
c,d
 
Brain
b
 Heart Kidney Liver 
Dodecanoic acid (12:0) 0.48±0.13 0.66±0.15 0.74±0.07 0.43±0.04 
Tetradecanoic acid (14:0) 0.67±0.12
*,≠
 1.03±0.11 1.35±0.12 0.93±0.03 
Pentadecanoic acid (15:0) 0.47±0.12
≠
 0.57±0.06 0.94±0.05 0.62±0.08 
9-Hexadecenoic acid 
(16:1Δ9) 
1.49±0.61
*
 0 1.89±0.94 1.17±0.15 
Hexadecanoic acid (16:0) 30.49±0.58
*
 15.12±1.3 32.14±0.04 30.01±0.49 
Plasmalogen 16:0 (P 16:0) 2.09±0.34
‡
 2.20±0.14 1.59±0.71 0.31±0.27 
Heptadecanoic acid (17:0) 0.66±0.11
≠
 0.89±0.13 0.97±0.06 0.59±0.01 
9,12-Octadecadienoic acid 
(18:2Δ9,12) 
1.08±0.33
*,≠,‡
 23.92±0.62 10.40±1.2 11.19±0.68 
9-Octadecenoic acid 
(18:1Δ9) 
16.18±0.82
*,≠,‡
 6.49±0.36 8.36±0.34 7.16±0.78 
10-Octadecenoic acid 
(18:1Δ10)  
5.57±0.90
‡
 6.79±0.76 4.16±0.46 3.81±0.15 
Octadecanoic acid (18:0) 21.28±1.1
‡
 25.33±1.1 22.06±1.22 29.77±0.88 
Plasmalogen 18:1a (P 18:1a) 0.87±0.19 0 0 0 
Plasmalogen 18:1b (P 18:1b) 0.86±0.18 0 0 0 
Plasmalogen 18:0 (P 18:0) 2.69±0.92 1.74±0.18 0 0 
5,8,11,14-Eicosatetraenoic 
acid (20:4) 
9.28±0.81
*,≠,‡
 15.25±0.39 15.39±1.4 14.02±0.39 
4,7,10,13,16,19-
Docosahexaenoic acid (22:6) 
3.79±1.4 0 0 0 
7,10,13,16-Docosatetraenoic 
acid (22:4) 
2.13±0.44 0 0 0 
a
 Number of carbons:degree of unsaturation 
b
 
 
Significant differences between brain fatty acids (p<0.05, n = 3) indicated by 
*
 for 
heart, 
≠
 for kidney, and 
‡
 for liver 
c
 Comparisons made on % FAME basis due to differences in μg fatty acid per 
mitochondrial protein concentration between tissues 
d
 Values are averages of three replicates ± sd 
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Chapter 3.3.  Results 
The objective of this project was a membrane composition comparison between 
mitochondria originating from various tissues from Sprague Dawley rats.  An 
impediment in the analysis of sub-cellular organelles is the necessity for high-purity 
isolation from biological samples.  There are numerous procedures for the isolation of 
mitochondria [105, 109-114].  The methods share a common foundation in the isolation 
through differential centrifugation, however they differ in the isolation buffer, 
centrifugation times, speeds, and in the density gradient.  The chosen isolation procedure 
was comparable to a previously employed procedure, therefore little optimization was 
required [105, 109].   The modification in the use of a discontinuous Percoll gradient 
provided greater mitochondria separation from the myelin layer than the previously used 
continuous gradient [115].  The discontinuous gradient also allowed separation of free 
mitochondria from those trapped in lipid vesicles, such as synaptosomes from brain 
tissue.  The results of mitochondrial isolations are represented by western blot analysis 
(Figure 3.2).  The intense porin band signifies an increased concentration of mitochondria 
over the total homogenate.  The absence of MAP2 and lamin B bands verify the purity of 
mitochondrial isolation.   
Fatty acid structure analysis 
A complete description of the fatty acid profile requires structural analysis of the 
acyl chains.  Unfortunately electron-impact ionization, used during quantification of 
FAMEs, fails to provide characteristic fragmentation patterns that provide structural 
elucidation of double-bond or chain-branching locations.  Spectra obtained by EI are 
dominated by low molecular weight fragments and ions generated from fragmentation 
pathways that produce statistical stable products.  Representative EI spectra for 
mitochondrial FAME products, not discussed in detail below, are shown in Figures 3.3 to 
3.9.  Spectra generated through CI provide an abundant [M+H]
+
 ion for proper fatty acid 
recognition, but as with EI fragments for conclusive structural identification are not 
generated due to rearrangement around bond breakage sites.  
For these reasons alternative methods of derivatization were necessary for 
structural identification.  A variety of derivatization reagents are available that provide 
characteristic fragmentation patterns [62].  Derivatization of methyl esters through 
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transesterification with 3-hydroxymethylpyridine, to form picolinyl esters, allowed 
charge remote fragmentation along the fatty acid backbone facilitating structural 
elucidation. 
The process of remote charge fragmentation allows separation of the cation 
charge from the site of fragmentation [51, 60, 63].  The result for straight-chain saturated 
fatty acids is an equal distribution of ions originating from each site along the fatty acid 
chain length.  Picolinyl fragmentation of straight-chain fatty acids provides a repeating 
pattern of [M]
+
-(CH2)n mass units, after the loss of the terminal methyl group [60, 63].  
Examination of the mass spectrum for the picolinyl ester of octadecanoic acid (18:0), the 
presence of the molecular ion, m/z 375, permits conclusive identification of the particular 
fatty acid derivative (Figure 3.11).  The ion at m/z 360 is generated by loss of the 
terminal methyl group, followed by successive loss of 14 amu to m/z 151.  The EI 
spectrum for the methyl ester of octadecanoic acid is provided for comparison (Figure 
3.10)  
The lack of diagnostic fragment ions creates difficultly in determining sites of 
unsaturation along the acyl chain, as seen with the EI spectra of methyl 9,12-
octadecadienate (Figure 3.12).  However, fragmentation of picolinyl fatty acids with 
double bonds have a distinctive pattern indicating the site of the unsaturation, as 
illustrated by 9,12-octadecadienic acid (18:2Δ9,12) (Figure 3.13).  As with the saturated 
fatty acid the molecular ion, m/z 371, loses the terminal methyl group to produce m/z 
356, then the repeating pattern of [M]
+
-(CH2)n mass units is present except for locations 
of double bonds.  Cleavage at the methylene group alpha to the double bond results in a 
26 amu gap between m/z 300 and m/z 274, indicated by * (Figure 3.13).  There is a loss 
of 14 amu from m/z 274 to m/z 260, then a second 26 amu gap from m/z 260 to m/z 234.  
This type of fragmentation pattern is indicative of a methylene interrupted diene acyl  
chain.  The double bond location indicator ions can also be seen by a gap of 40 amu from 
m/z 314 to m/z 274 and m/z 260 to m/z 220 [60, 63-64].  Mechanisms for fragmentation 
of unsaturation fatty acids are shown in Figure 3.14. 
101 
 
 
 
  
m/z
0
10
20
30
40
50
60
70
80
90
100
A
B
U
N
D
A
N
C
E
59
74 87
101
115
129
143
157
171
185
199 228
251236678978493012534045
  <
60 80 100 120 140 160 180 200 220 240
Figure 3.3.  Mass spectrum of methyl dodecanoate (12:0). 
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Figure 3.4.  Mass spectrum of methyl tetradecanoate (14:0). 
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Figure 3.5.  Mass spectrum of methyl pentadecanoate (15:0). 
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Figure 3.6.  Mass spectrum of methyl 9-hexadecenoate (16:1Δ9). 
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Figure 3.7.  Mass spectrum of methyl hexadecanoate (16:0). 
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Figure 3.8.  Mass spectrum of dimethyl acetal of hexadecan-1-al (P 16:0). 
O
OCH
3
H
3
C
[M-31]+ 
107 
 
 
  
m/z
0
10
20
30
40
50
60
70
80
90
100
A
B
U
N
D
A
N
C
E
74
87
101
143
185
213
241
284
321789345645078940231656
  <
50 100 150 200 250 300
Figure 3.9.  Mass spectrum of methyl heptadecanoate (17:0). 
H
3
C
O
O
[M]+ 
108 
 
 
  
Figure 3.10.  Mass spectrum of methyl octadecanoate (18:0). 
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Figure 3.11.  Mass spectrum of picolinyl octadecanoate (18:0). 
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Figure 3.12.  Mass spectrum of methyl 9,12-octadecadienoate (18:2Δ9,12). 
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Figure 3.13.  Mass spectrum of picolinyl 9,12-octadecadienoate (18:2Δ9,12). 
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The EI spectra from the methyl ester derivatives of the two octadecenoic acids 
(18:1) are shown in Figures 3.15 & 3.16.  Spectra from EI of the two octadecenoic acid 
picolinyl esters, reveal the site of unsaturated through the fragmentation patterns (Figures 
3.17 & 3.18).  As with the other two previous examples the molecular ion, m/z 373, loses 
the terminal methyl group to produce m/z 358, and the [M]
+
-(CH2)n mass units trend 
repeats except at the double bond site.  The spectrum for 9-octadecanic acid (18:1Δ9) 
displays a difference of 26 amu between m/z 246 and m/z 220, signifying the double 
bond position (Figure 3.17) [60, 63-64].  The spectrum for 10-octadecanic acid (18:1Δ10) 
has a 26 amu difference between m/z 274 and m/z 248, indicative of a distal shift in the 
double bond position by one methylene unit (Figure 3.18) [60, 63-64]. 
This approach was used to identify the structures of fatty acids with other chain 
lengths.  Analysis of mitochondria from all four tissues through picolinyl 
transesterification indicates that double bond positions are consistent for all tissues. 
Fatty acid profile analysis 
 Methylation reactions were conducted with approximately equal mitochondrial 
protein concentrations as determined by BCA assay.  The fatty acids from brain, heart, 
kidney and liver mitochondria were compared on a percent area count basis (individual 
FAME area count divided by total FAME area count, Figure 3.19).  A significant 
increase in the percentage of 18:1Δ9 was noted in the FA profile between brain compared 
to heart, kidney or liver mitochondria.  Concurrently, significant decreases in the 
percentages of 18:2Δ9,12 and 20:4 were evident between brain FA profiles and the other 
mitochondrial profiles.  Additionally, brain mitochondria contained several FA species 
not present in other tissues: P18:1s, 22:6 and 22:4. 
 The total percentage of saturated fatty acids across brain, kidney and liver showed 
minor variation (Table 3.1).  The lower percentage of saturated FAs in brain 
mitochondria was compensated for by an increase in plasmalogen species (Table 3.2).  In 
keeping with this trend, the percentage of unsaturated fatty acids (both mono- and 
polyunsaturated) was comparable across brain, liver and kidney.  However, heart had  
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Figure 3.14.  Fragmentation pathways for unsaturated picolinyl esters. 
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Figure 3.15.  Mass spectrum of methyl 9-octadecenoate (18:1Δ9). 
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Figure 3.16.  Mass spectrum of methyl 10-octadecenoate (18:1Δ10). 
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Figure 3.17.  Mass spectrum of picolinyl 9-octadecenoate (18:1Δ9). 
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Figure 3.18.  Mass spectrum of picolinyl 10-octadecenoate (18:1Δ10). 
M+ 
O
O
N
274
248
* 
* 
118 
 
 
  
F
ig
u
re
 3
.1
9
. 
 D
is
tr
ib
u
ti
o
n
 o
f 
m
it
o
ch
o
n
d
ri
al
 f
at
ty
 a
ci
d
s 
p
er
 t
is
su
e.
 
05
101520253035
12:0
14:0
15:0
16:1
16:0
P 16:0
17:0
18:2Δ9,12
18:1Δ9
18:1Δ10
18:0
P 18:1
P 18:1
P 18:0
20:4
22:6
22:4
F
A
M
E
s
FAME (%)
B
ra
in
H
ea
rt
K
id
ne
y
Li
ve
r
*,≠
,‡
*,≠
,‡
‡
*
‡
*,
≠
*,≠
,‡
≠
≠
‡
*
119 
 
Table 3.2.  Percent comparison of saturated to unsaturated fatty acids between various 
tissues. 
Tissue SFA
a
 MUFA; PUFA
b
 
SFA/UFA 
ratio
c
 
Unsaturation 
index (%)
d
 
Plasmalogens 
Brain 53.94 23.25; 16.29 1.36 8.41 6.52 
Heart 43.60 13.29; 39.17 0.83 4.81 3.94 
Kidney 58.20 14.42; 25.79  1.45 4.94 1.59 
Liver 62.34 12.14; 25.21 1.67 4.94 0.31 
a
 Saturated fatty acids 
b
 Monounsatured fatty acids; Polyunsaturated fatty acids 
c 
Values represent ratio of saturated/total unsaturated fatty acids 
d
 Number of double bonds divided by total number of bonds in the fatty acid chain 
(calculation does not include unsaturation contributions from plasmalogen species) 
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approximately 12% lower saturated FAs percentage than the other tissues.  As expected 
the percentage of unsaturated fatty acids (both mono- and polyunsaturated) increased for 
heart, as a result of an appreciable higher 18:2Δ9,12 level.   
The distribution of mono- and polyunsaturated FAs provided greater distinction 
between mitochondria from the various tissues (Table 3.2).  Heart mitochondria had the 
largest percentage of polyunsaturated FAs (a total of 39%), due to a disproportionate 
excess of 18:2Δ9,12 (Figure 3.19).  In fact, the percentage of 18:2Δ9,12 from heart 
mitochondria was significantly higher (p<0.01) than the other three tissues.  The 
percentage of monounsaturated FAs in brain was approximately doubles that of kidney 
and liver.  However the polyunsaturated FA percentage from brain was roughly half than 
in kidney and liver, despite the presence of several PUFA species not incorporated in the 
other mitochondrial samples (Figure 3.19).     The percentage of monounsaturated FAs in 
brain was approximately double that of kidney and liver.  However the polyunsaturated 
FA percentage from brain was roughly half than in kidney and liver, despite the presence 
of several PUFA species not incorporated in the other mitochondrial samples (Figure 
3.19).      
 Differences in the fatty acid species from brain, heart and kidney were also 
evaluated on a log scale as normalized to the corresponding liver FAME species (Figure 
3.20).  Normalizing the data to liver, illustrates the change in the brain lipid profile when 
compared to the other three tissues and also emphasizes the homogeneity among the 
heart, kidney and liver mitochondrial profiles.  Positive deviation from the baseline, such 
as 18:1Δ9, signify an increase in relative abundance of FAME species for brain in 
relation to liver.  Negative deviation, as in the case of 18:2Δ9,12 and 20:4, signify a 
reduction in relative abundance of FAME species relative to liver.  Only FAME species 
present in all four tissues have been shown.     
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Chapter 3.4.  Discussion 
Since lipids serve a dual function as membrane components and as secondary 
messengers, changes in the mitochondrial membrane composition might be the result of 
distinctive cellular environments between various tissues.  Diversity in the lipid profile, 
as a function of tissue, could lead to a variety of innate responses as a consequence of 
detrimental species generated in vivo.  Specifically, neurological tissue has an increased 
potential for oxidative stress due to a higher oxygen consumption rate and comparatively 
low level of antioxidant capacity.  Oxidative stress, a hallmark of many 
neurodegenerative diseases, leads to the development of ROS [116].  Common targets for 
ROS are lipid components, namely polyunsaturated fatty acids (PUFAs) [103, 117-119].  
Previous studies have shown that neurological plasma membranes contain an abundance 
of PUFAs.  Most notably, grey matter is highly enriched with docosahexaenoic acid 
(22:6ω3) [118, 120].  The susceptibility of PUFAs to oxidation is theoretically reduced 
by the presence of plasmalogens (P) [121-123].  Plasmalogens are commonly associated 
with PUFAs in the sn-1 position along the glycerol backbone of phospholipids.  They are 
believed to act as endogenous anti-oxidants, providing preferential cleavage sites for 
ROS thus protecting PUFAs [121-123].   
The current study was successful in identifying deviations in the fatty acid profile 
of neurological mitochondria compared to mitochondria from other tissues from Sprague 
Dawley rats.  Data support the premise that variations in brain mitochondrial lipids may 
increase the susceptibility to the products of oxidative stress.  Several researchers have 
linked changes in the proportion of PUFAs to membrane stability as measured by life 
expectancy [124-125].  Pamplona et al. compared the mitochondria membrane 
compositions from liver of rats and pigeons [125].  Their data supported the theory that 
reduced incorporation of PUFAs in the mitochondria from pigeons contributed to an 
increased life expectancy.  Similar conclusions were drawn by Mitchell et al. who 
conducted studies with the naked mole-rat and found a reduction in DHA and an increase 
in plasmalogen content [124].  Their results were believed to contribute to a longer life 
expectancy, inferring that mitochondria containing lower levels of PUFAs will have a 
considerable reduced susceptibility to oxidative damage [124].  Studies conducted by 
Tahin et al. found the fatty acid profiles of rat brain mitochondria were less influenced to 
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dietary changes than the fatty acid profiles of heart and liver mitochondria [126].  It was 
hypothesized that the resilient nature neurological mitochondria to modify their 
membrane composition in response to dietary changes might be the result of the blood-
brain barrier [126].  This pseudo-insulation for the brain may result in long-term health 
implementations. 
Fatty acid structure analysis 
The true measure of membrane variations with the potential to affect the 
susceptibility of lipids to oxidation by ROS would be changes in unsaturation.  The ratio 
of mono- to polyunsaturated fatty acids for the brain mitochondria samples was 
significantly higher than that of the other three tissues (Table 3.2).  The major contributor 
for the increased ratio of monounsaturated over polyunsaturated FAs in brain 
mitochondria stems from the lower abundance of 18:2Δ9,12.  This decrease in 18:2Δ9,12 
may be the result of increased long chain PUFAs synthesis that utilizes 18:2Δ9,12 as a 
precursor.  Conversely, the significant increase in the polyunsaturated FAs in heart 
mitochondria is probably the result of a greater abundance of cardiolipin, which has been 
shown to predominately consist of 18:2Δ9,12 fatty acids [127-128].  Cardiolipin has been 
shown to be highly abundant in the inner mitochondrial membrane and plays a critical 
role in the electron transport chain [129].  This is a noteworthy finding of our study, since 
brain mitochondria had a significantly lower percentage of 18:2Δ9,12 than mitochondrial 
from the other tissues (Table 3.1).  This alteration in fatty acid composition, may impart 
unique physical properties to the membrane of neurological mitochondria [128].   
The attribute with the greatest potential to increase the susceptibility of lipid 
oxidation by ROS would be changes in the unsaturation index.  The percent of double 
bonds per total methylene moieties, unsaturation index (u.i.), presents an interesting 
comparison between the tissues (Table 3.2).  The u.i. associated with brain mitochondria 
was approximately twice that of other tissues.  This increase in u.i. was the result of two 
FAs, 22:4 and 22:6, which were unique FAs to brain samples.  These two PUFAs, 
encompassing ten double bonds between them, more than doubled the number of double 
bonds in brain mitochondria.  In essence, this represents an increased potential for 
susceptibility to ROS.  In addition to greatly increasing the potential targets for ROS, the 
higher percentage of double bonds would significantly alter membrane dynamics [44]. 
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Fatty acid profile analysis 
Results from the current study found that the percentage of total saturated FAs 
was nearly equivalent within brain, kidney and liver mitochondria.  This similarity in 
fatty acid profiles across three of the four tissues studied lends credence to the theory that 
preservation of membrane physical properties are essential for functionality, as changes 
to the fatty acid species will have a significant impact on the physical properties of the 
membrane [2, 15].  The homogeneity of fatty acid saturation echoes results obtained by 
Pamplona et al. in their study of liver mitochondria between species [125].   
Neurological tissue has been reported to have an increased abundance of 
polyunsaturated fatty acids, therefore, it is interesting that brain mitochondria would 
display a greater abundance of monounsaturated fatty acids [130-132].  In fact, the 
distribution of arachidonic acid (ARA; 20:4ω6), showed that brain mitochondria 
contained approximately 5% lower abundance than the other tissues. However, this 
deficiency in ARA was in essence offset by the presence of two other long-chain PUFAs, 
22:6 and 22:4. 
The presence of plasmalogens (vinyl-ether lipids) in neurological membranes has 
been well documented [133-135].  Plasmalogens are distinguished by a vinyl ether bond 
to the glycerol backbone as opposed to the ester linkage of traditional fatty acids [133-
135].  It has long since been recognized that PUFAs and plasmalogens are commonly 
associated along the same phosphoglyceride backbone.  The detection of plasmalogens in 
brain mitochondria that were absent from other tissues would certainly impart unique 
physical characteristics and functionality to the membrane [16].  Since the initial steps of 
plasmalogen synthesis occurs in peroxisomes, their existence within the mitochondrial 
membrane is the result of importation [15-16].  Plasmalogens function within the 
membrane and their role with regard to ROS has been the focus of extensive investigation 
[16, 121-123, 136].  The proposed functionality of plasmalogens as an endogenous anti-
oxidant arises from the preferential oxidation of the vinyl-ether bond [121-123].  These 
unique plasmalogens (P18:0 and P18:1) increase the percentage of ether-linked lipids in 
brain to twice that of heart mitochondria, and four to six times that of liver and kidney, 
respectively (Table 3.2).  The increased proportion of plasmalogens in brain 
125 
 
mitochondria might be a compensatory response to the higher unsaturation index and 
relatively low abundance of antioxidant counter measures [128]. 
Elucidation of the double bond location for the unique plasmalogens found in 
brain mitochondria and the bonding geometry along the glycerol backbone may provide 
insight into the nature of the mitochondria membrane and provide further differences 
between tissue specimens.  The methylation reaction used in forming the FAMEs 
converts the vinyl-ether group to a dimethyl acetal.  Unfortunately, these functional 
groups were not amenable to transesterification to picolinyl esters, and therefore 
alternative structural analysis methods were necessary.  Chemical ionization experiments 
using acetonitrile as a reagent gas has been used for lipidomic structural analysis studies 
[65-66, 137].  Regrettably, these plasmalogens were also not amenable to structural 
elucidation by acetonitrile covalent-adduct CI (CACI), nevertheless isolation and MS/MS 
techniques on the molecular ions provided confidence in molecular classification (Figures 
3.21 & 3.22) [138]. 
   The appearance of unique PUFAs and plasmalogen species in brain 
mitochondria may provide the membrane with a greater susceptibility and protection 
from ROS.  Differences in the mitochondria fatty acid profiles among the tissues may 
also reflect generational life spans of the mitochondria which might vary depending on 
the tissue [139].  Previous lipid studies from brain mitochondria have shown an increased 
turnover rate for phosphatidylethanolamine compared to other phospholipids [139].  The 
significance of phosphatidylethanolamine might be due to the fact that PUFAs and 
plasmalogens are commonly associated this polar head group and mitochondria serve as 
the site of synthesis for this polar head group [15].  This phospholipid species has also 
been shown to decrease in abundance with progression of neurodegenerative disease 
[140].   
This study presents data on the elucidation of tissue specific variations in 
mitochondrial lipid profiles that support the theory of increased susceptibly of 
neurological mitochondria to oxidative stress.  The relative pattern of abundance amongst 
18:2Δ9,12 and 18:1Δ9 fatty acids gave a significantly different FA profile for brain  
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Figure 3.21.  Mass spectra from (a) EI experiments and (b) CI experiments from  
dimethyl acetal of octadecen-1-al (P 18:1). 
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Figure 3.22.  Mass spectra from (a) EI experiments and (b) CI experiments from  
dimethyl acetal of octadecan-1-al (P 18:0). 
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mitochondria compared to liver, kidney and heart.  Even though the total percentage of 
unsaturated fatty acids was lower for brain, the appearance of unique PUFAs led to an 
unsaturation index double that of other tissues.  The appearance of unique PUFAs in 
brain mitochondria increases the potential susceptibility to ROS.  Diversity in the lipid 
profile, as a function of a tissue environment, could lead to a variety of detrimental 
responses as a consequence of the type of ROS generated in vivo.  The characteristic fatty 
acid profile found in brain mitochondrial membranes will be used as a biological 
template for the exploration of changes that occur in the mitochondrial membrane during 
the progression of Alzheimer’s disease. 
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Chapter 4.  Study of Changes in the Mitochondrial Fatty Acids as a Function of 
Alzheimer’s Disease Progression 
Chapter 4.1.  Introduction 
The electron transport chain (ETC), which is vital for cellular energy production, 
is located on the inner mitochondrial membrane.  The ETP is comprised of a multi-
protein transmembrane complex that functions to oxidize hydrogen atoms which in turn 
drives the synthesis of adenosine triphosphate (ATP).  Electron leakage from the ETP 
results in the generation of reactive oxygen species (ROS) and subsequent, ROS 
mediated oxidative damage [141-142].  Increased oxidative damage of cellular 
biomacromolecules has been shown in normal aging and is thought to play a role in the 
pathogenesis of numerous neurodegenerative diseases such as, Alzheimer’s disease (AD) 
[103-104, 141].  Numerous studies report increased ROS mediated damage to nucleic 
acids [105], proteins [106], and lipids [107] during the pathogenesis of AD.   
Oxidative stress, a hallmark of neurodegenerative disease, leads to the 
development of reactive oxygen species (ROS) [103].  Electrons leaking from 
mitochondria are the greatest source of ROS, thus mitochondria are a likely source and a 
target of oxidative stress. The high oxygen consumption rate and comparatively low 
levels of antioxidant capacity in neurological tissue would be expected to cause 
compensatory changes to the lipidome in order to minimize susceptibility to oxidative 
damage.  A common target for these reactive oxygen species are lipid components, 
namely polyunsaturated fatty acids (PUFAs) [143-144].  Previous studies have shown 
that neurological plasma membranes contain an abundance of polyunsaturated fatty acids 
[145].  Most notably, grey matter is highly enriched with docosahexaenoic acid (22:6ω3).  
The susceptibility of PUFAs to oxidation is theoretically reduced by the presence of 
plasmalogens (P).  Plasmalogens are commonly associated with PUFAs in the sn-1 
position along the glycerol backbone of phospholipids.  The vinyl-ether bonds are 
believed to act as endogenous anti-oxidants, providing preferential cleavage sites for 
ROS thus protecting PUFAs [134, 143, 146].   
A diagnosis of AD requires both a clinical and a neuropathologic examination for 
proper disease state classification.  Alzheimer’s disease is diagnosed clinically by 
progressive decline in cognitive aptitude [103].  Cognitive aptitude is generally evaluated 
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by administration of the mini-mental status examination.  The mini-mental status exam 
(MMSE) was developed by Folstein and Folstein in 1975 [147].  The MMSE was 
designed to be an all encompassing exam for neurological disorders including: 
psychiatric, neurologic and geriatric medical populations.  Results from the MMSE are 
normalized to population factors, including years of formal education, to assess an 
individual’s cognitive decline. 
Pathologically, Alzheimer’s disease is distinguished by neuronal deterioration that 
results in widened sulci and contraction of the gyri compared to normal control subjects.  
The gyri are the elevated crests, these features are most commonly associated with the 
wrinkle-like appearance of the brain.  The sulci separate the gyri and are shallow 
indentions along the surface.  The appearance of neurofibrillary tangles (NFT) and 
neuritic plaques (NP) are also two characteristic pathological facets of AD [103, 106, 
148].  Neurofibrillary tangles are intraneuronal deposits which are enriched in 
hyperphosphorylated tau [103].  Tau is associated with microtubules which exhibit an 
increased abundance in neurons.  Assembly of multiple hyperphosphorylated tau subunits 
results in protein aggregations which are believed to be fundamental in the development 
of neurofibrillary tangles [106].  The frequency of NFT are utilized to categorize a 
subject to a particular pathological disease state within the AD scale.  The benchmark 
scale of pathological assessment was established by Braak and Braak [149].  Braak scores 
are based on the quantity and lateral diffusion of NFT across neurological regions [149].  
The scale established by Braak and Braak ranks individuals based on pathology of NFT 
on a scale of I to VI.  Individuals with mild pathology and limited spread of NFT across 
several areas are ranked either I or II.  Prolific expansion of NFT within neuronal tissue, 
such as that seen in late-stage AD (LAD), are assigned a ranking of V or VI.  Assessment 
of neuropathological degradation requires examination of multiple regions and although 
end-points may be easily characterized, differentiation between intermediate stages is 
more difficult [149].  Due to Braak scores being presented as median scores, rather than 
unambiguous values, statistical analysis required the use of non-parametric Kruskal-
Wallis one way ANOVA ranks test with a Dunn’s post hoc method to establish 
significance between disease states. 
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Plaques are extracellular aggregates composed mainly of amyloid beta peptide 
(Aβ) resulting from the amyloid precursor protein (APP) [103].  The amyloid beta 
peptide is formed as a result of proteolytic cleavage from the membrane bound amyloid 
precursor protein [142].  The APP is a transmembrane protein associated with synapses, 
APP is believe to be involved in synapse functionality although its exact role has yet to 
be determined [150].  
The purpose of the study was to examine variations in the mitochondrial fatty 
acids across distinct regions during neuropathological changes associated with 
Alzheimer’s disease.  The areas chosen, cerebellum, superior and middle temporal gyri 
and inferior parietal lobule, represent histological sections functioning in discrete 
neurological processes (Figure 4.1).  Tissue samples from each region were composed of 
gray matter or the outer most cortex layer from each region.  Gray matter is primarily 
composed of nerve cell bodies and slow-twitch unmyelinated neuronal fibers [151].  The 
cerebellum (CER) is the region that regulates the integration of sensory perception, 
coordination and motor control [151].  As with the cerebrum, the cerebellum is 
symmetrically divided bilaterally.  Bodily movement is coordinated across the two 
hemispheres; hence the cerebellum is more associated with motor functions.  Because of 
the lack of memory and cognitive involvement by the cerebellum it is generally devoid of 
AD pathological markers compared to the frontal and temporal lobes. 
The superior and middle temporal gyri (SMTG) are both sections of the temporal 
lobe.  The superior temporal gyrus contains the primary auditory cortex which is 
responsible for processing sound, and a region for speech recognition [151].  The middle 
temporal gyrus is associated with visual processes such as recognition of known faces 
and accessing word meaning while reading [151].  Of the three regions studied the 
SMTG displays the most pathology during the progression of AD.  Data from this area 
provides the examination of changes that occur in relation to the pathology of AD during 
that various stages.   
The inferior parietal lobule (IPL) is a section found in approximately the middle 
portion of the parietal lobe.  This domain is involved with integration of a variety of 
sensory information, including spatial sense, navigation, knowledge of numbers and the 
manipulation of objects [151-152].  Due to the nature of the multimodal processing that  
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Figure 4.1. Neurological regions under study. 
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occurs in the IPL, it has been hypothesized to function in direct relationship to other 
regions [152]. 
For the analysis of the mitochondrial lipidome as a progression of Alzheimer’s 
disease, tissue was chosen based on patient classification by the University of Kentucky 
Alzheimer’s Disease Center (UK-ADC). Age-matched normal control (NC) are 
individuals with no cognitive deficits and limited evidence of pathology at time of 
autopsy.  Generally, they have Braak scores of I at the time of autopsy.  Mild cognitive 
impairment (MCI) marks the transition between normal cognitive decline and rapid onset 
of AD.  Patients falling into this category have pathology with evidence of minor plague 
and neurofibrillary tangle formation.  Braak scores for MCI subjects are usually III or IV.  
Preclinical AD (PCAD) are individuals that have no record of cognitive decline, 
however they exhibit a greater degree of pathology compared to NC subjects.  The 
preclinical designation is thought to be a prodromal stage of AD pathology [153]. 
The final stage of AD is marked behaviorally when individuals lose the ability to 
respond to their environment, speak and control movement.  Late-stage AD (LAD) 
patients have discernible pathology marked by a significant number of plagues and 
neurofibrillary tangles (NFTs).  Braak scores from LAD patients generally rank V or VI.  
On a whole neurological tissue from LAD patients exhibit extensive degradation in the 
form of contracted of gyri and broadening of sulci at the time of autopsy. 
An additional subject set was added consisting of frontotemporal dementia (FTD) 
and dementia with Lewy body (DLB) disease patients.  Both of these are 
neurodegenerative diseases that are linked by a common pathology consisting of protein 
aggregates [154-157].  For DLB pathology, Lewy bodies are enriched in the protein 
alpha-synuclein (α-syn) [156, 158].  Alpha-synuclein commonly exists as a soluble, 
cytoplasmic monomer that is associated with neural tissue [157].  The events of initiating 
Lewy body formation as a result of α-syn aggregation have not been determined, 
however a link between oxidative stress has been hypothesized [154, 157].  In contrast, 
FTD Lewy bodies are enriched in tau, as seen with NFT in AD.  Frontotemporal 
dementia is classified as a tauopathy.  The comparison between AD states and these 
combined pathology groups, aka disease control (DC), provide an evaluation of 
mitochondrial lipids from comparable neurodegenerative disease pathologies [159]. 
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The objective of this study is to provide a comprehensive examination of 
mitochondrial fatty acid composition from various brain regions during the progression 
of AD.  We focused on the mitochondrial membrane because electrons leaking from 
mitochondria are the greatest source of ROS with in a cell, thus mitochondria are a 
potential cause and a target of oxidative stress.  Therefore, compensatory changes to the 
fatty acid profile would be expected in order to minimize susceptibility to oxidative 
damage.  Comparison of mitochondrial membrane compositions between various regions 
may provide an understanding of why certain neurological regions have an increased 
vulnerability to oxidative damage.  
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Chapter 4.2.  Experimental 
Reagents 
Potassium t-butoxide (1.0 M) in tetrahydrofuran (THF), 3-hydroxymethyl 
pyridine, tridecanal, cis-4-decenal, trans-2-tridecenal, hexane, D-mannitol, sucrose, Triza 
base, Tween-20, calcium chloride, and ethylenediaminetetraacetic acid disodium were 
purchased from Sigma (St. Louis, MO, USA).  Methanol, methylene chloride, and 
hydrochloric acid were obtained from Fisher (Pittsburg, PA, USA).  Acetyl chloride was 
obtained from Fluka (Buchs, Switzerland).  Sodium hydroxide, sodium bicarbonate, and 
potassium carbonate were purchased from J.T. Baker (Phillipsburg, NJ, USA).  Ethyl 
ether was obtained from EMD (San Diego, CA, USA).  Anthracene was purchased from 
Acros (Morris Plains, NJ, USA).  Percoll™ was obtained from GE Healthcare (Uppsala, 
Sweden).  Anti-rabbit porin antibody was purchased from Calbiochem (Gibbstown, NJ, 
USA).  Anti-rabbit lamin B was ordered from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA).  Anti-mouse MAP2 and anti-mouse synaptophysin were purchased from 
Abcom Inc. (Cambridge, MA, USA).  10-20% Tris-HCl SDS-PAGE gradient gels were 
purchased from BIO-RAD (Hercules, CA, USA).  Isothesia (isoflurene) was obtained 
from Bulter Animal Health Supply (Dublin, OH, USA).  GLC-411 lipid standard, 
5,8,11,14-eicosatetraenoic acid (ARA), and 4,7,10,13,16,19-docosahexaenoic acid 
(DHA) were purchased from Nu-Chek Prep, Inc. (Elysian, MN, USA).    
General equipment and supplies 
Dounce homogenizer (Wheaton Industries, Millville, NJ, USA).  Nalgene brand 
Oak Ridge polypropylene copolymer centrifuge tubes (Thermo Fisher Scientific Inc., 
Waltham, MA, USA).  Beckman Polyallomer centrifuge tube (Beckman Coulter, Inc., 
Brea, CA, USA).  Fisherbrand 2.0 mL polypropylene microcentrifuge tube (Thermo 
Fisher Scientific Inc., Waltham, MA, USA).  Beckman Coulter (Beckman Coulter, Inc., 
Brea, CA, USA) Avanti J-25 series centrifuge equipped with a JA-25.50 fixed angle 
rotor.  Beckman Coulter (Beckman Coulter, Inc., Brea, CA, USA) L-80 Ultracentrifuge 
series equipped with a SW 55 Ti swinging bucket rotor.  Thermo IEC Micromax 
Centrifuge (Thermo Fisher Scientific, Rochester, NY, USA) with an 851 series microtube 
fixed angle rotor.  Eppendorf (Hauppauge, NY, USA) Research Adjustable-volume 
pipettes. 
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Human subject neuropathological demographics 
Tissue specimens from the superior and middle temporal gyri (SMTG), inferior 
parietal lobule (IPL), and cerebellum (CER) of short post-mortem interval (PMI) 
autopsies of subjects were obtained through the University of Kentucky Alzheimer’s 
Disease Center (UK-ADC).   Samples were flash frozen at autopsy in liquid nitrogen and 
stored at -80˚C until analysis.  Sample demographics consisted of 14 (4 men, 10 women) 
age-matched normal control (NC) patients; 7 (2 men, 5 women) mild cognitive 
impairment (MCI) patients; 14 (3 men, 11 women) preclinical Alzheimer’s disease 
(PCAD) patients; 15 (7 men, 8 women) late-stage Alzheimer’s disease (LAD) patients 
and 11 (7 men, 4 women) diseased control (DC) patients (Table 4.1).  
Human mitochondria isolation 
The method presented here (Figure 4.2) for isolation of enriched mitochondria is 
based on a series of modifications described in previous studies [109, 111-112, 114].  
Throughout the procedure all reagents, samples, and equipment were placed on ice.  
Isolation buffer, Percoll and digitonin solutions were prepared fresh on the day of 
isolation.   
Tissue samples, approximately 1 g wet tissue weight, were homogenized via a 
manual Dounce homogenizer in isolation buffer (10 mM Tris, 0.32 M sucrose, 0.25 mM 
Na2EDTA, pH 7.4).  The total volume of IB used during homogenization gave a tissue to 
buffer ratio of approximately 0.1 g/mL.  The tissue was homogenized with approximately 
8 to 10 up-and-down strokes or until the sample was completely liquefied.  The 
homogenate was transferred into a Nalgene brand Oak Ridge polypropylene copolymer 
centrifuge tube with a polypropylene screw closure.  The homogenate was centrifuged 
(2,000xg, 3 min, 4°C), in a Beckman Coulter Avanti J-25 series centrifuge equipped with 
a JA-25.50 fixed angle rotor set at maximum acceleration and deceleration with the brake 
activated.  The supernatant was collected and the pellet resuspended dissolved in 
approximately half the original volume of IB, re-homogenized and centrifuged (2,000xg, 
3 min, 4°C).  The combined the supernatants, consisting of cytosolic material, were 
centrifuged (20,000xg, 10 min, 4°C).  The supernatant was discarded and the pellet, 
containing the mitochondria, was resuspended in 10 mL isolation buffer and centrifuged 
(2,000xg, 3 min, 4°C).  The pellet was discarded and the supernatant transferred to a new  
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Table 4.1.  Sample demographic information categorized by disease state. 
Sample 
demographic 
Normal 
control (NC) 
Mild 
cognitive 
impairment 
(MCI) 
Preclinical 
AD (PCAD) 
Late-stage 
AD (LAD) 
Disease 
control 
(DC)
a
 
n
b
 14 7 14 15 11 
Gender (M/W) 4/10 2/5 3/11 7/8 7/4 
Avg. age (yrs) 86.4±1.5 91.0±1.9 85.8±1.7 80.8±1.4 71.8±4.2 
Avg. PMI 
(hrs) 
2.79±0.20 2.55±0.21 2.78±0.16 3.57±0.42 3.48±0.39 
Median Braak 
score 
I IV
*
 IV
*
 VI
*
 II 
a
 Represents a combination of Dementia with Lewy body disease (DLB) and 
frontotemporal dementia (FTD) 
b
 Represents the number of samples for each region (cerebellum (CER), superior and 
middle temporal gyri (SMTG) and inferior parietal lobule (IPL)) 
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Tissue Homogenization
Centrifigue (2000xg, 3 min, 4˚C)
SupernatantPellet (Nuclear)
Resuspend in IB & Centrifigue (2000xg, 3 min, 4˚C)
Pellet (Nuclear) Supernatant
Combine Supernatant fraction & Centrifigue 
(20,000xg, 10 min, 4˚C)
Pellet Supernatant 
(Cytosolic Fraction)
Resuspend in IB & Centrifigue (2,000xg, 
10 min, 4˚C)
Pellet (nuclear) Supernatant
Pellet (Crude Mitochondia & 
Synatosomes)
Centrifuge 20,000xg, 10 min, 4˚C)
Supernatant
Resuspend in 19% Precoll:IB & Centrifuge 
(19,600xg, 30 min, 4˚C)
Pellet (Mitochondia & Synatosomes) Supernatant
Wash Pellet & Centrifuge ( 19,600xg, 10 min, 4˚C)
Pellet (Mitochondia & Synatosomes) Supernatant
Resuspend in 1% Digitonin (10 min, 4˚C)
Add 28% Precoll:IB & Centrifuge (19,600xg, 10 min 4˚C)
SupernatantMitochondrial Pellet
Wash with PBS & Centrifuge (19,600xg, 10 min 4˚C)
Resuspend in PBS
Purified Mitochondira
 
  Figure 4.2. Mitochondria isolation procedure. 
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tube and centrifuged (20,000xg, 10 min, 4°C).  The resulting pellet, containing the crude 
free and synaptosomal mitochondria isolate, was dissolved in 3 mL of a 19% (vol/vol) 
Precoll:IB and transferred to a Beckman Polyallomer centrifuge tube.  The solution was 
centrifuged (19,600xg, 30 min, 4°C), in a Beckman Coulter L-80 Ultracentrifuge series 
equipped with a SW 55 Ti swinging bucket rotor set at maximum acceleration and 
deceleration with the brake activated.  The supernatant was discarded and the pellet, 
containing both free and synaptosomal mitochondria, was transferred to a Fisherbrand 2.0 
mL polypropylene microcentrifuge tube and washed in 1 mL PBS and centrifuged 
(19,600xg, 10 min, 4°C) in a Thermo IEC Micromax Centrifuge with a 851 series 
microtube fixed angle rotor set at maximum acceleration and deceleration with the brake 
activated.  The supernatant was discarded and the mitochondrial pellet was dissolved in 
PBS containing 1% digitonin (wt/vol) and placed on ice for 10 min.  Following 
incubation, 3 mL of 28% (vol/vol) Percoll:IB buffer  was added and the samples 
centrifuged (19,600xg, 10 min, 4°C).  The supernatant was discarded and the pellet, 
consisting of free and synaptic mitochondria, was washed two times with 1 mL aliquots 
of PBS, each washing was centrifuged (16,900xg, 10 min, 4°C).  The final mitochondrial 
pellet was resuspended in 500 µL PBS and stored at -80°C until further analysis.             
Quantification of mitochondrial proteins 
Quantification of mitochondrial proteins was carried out on a Thermo Labsystems 
Multiskan MCC/3340 spectrometer (Pittsburgh, PA, USA) using a Pierre Bicinchoninic 
acid (BCA) assay (Rockford, IL, USA) [105].  A calibration curve was prepared by 
addition of 0, 1, 5, 10, 15, 20 μg BSA standard into separate wells; each concentration in 
duplicate.  Aliquots of isolated mitochondria (5 μL) were added to separate wells; each 
sample in duplicate.  Wells were adjusted to a final volume of 100 μL by addition of 
deionized H2O.  Lastly, 100 μL of a 10 μL/mL CuSO4 in Bicinchoninic acid solution was 
pipetted into each well.  The plate was incubated at 37°C for 30 min prior to reading.  
The mitochondrial protein concentration was determined by absorbance at 620 nm. The 
concentration (μg/μL) was calculated by averaging the sample replicates and dividing by 
the addition volume (eq. 4.1):  
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 Western blot analysis 
 Mitochondrial isolations were evaluated for purity by western blot (Figure 4.3).  
Isolated mitochondria (20 μg) were separated on a 10-20% Tris-HCl SDS-PAGE gradient 
gel.  Protein bands were transferred to a nitrocellulose membrane and incubated with 5% 
milk in 0.5% Tween-20/Tris-buffered saline (TTBS) with 3.3% goat serum (1 hrs, 25°C).  
The membrane was incubated with primary antibodies (1:3750): anti-porin, specific for a 
mitochondrial channel protein; anti-lamin B a marker specific for a nuclear envelope 
protein; anti-MAP2 a microtubular associated protein and anti-synaptophysin (12 hrs, 
4°C).  The membrane was washed three times with 0.5% Tween-20/Tris-buffered saline 
then incubated with horseradish peroxidase conjugated secondary antibody goat anti-
mouse for MAP2 and synaptophysin at a dilution of 1:7500 and goat anti-rabbit for porin 
and lamin B at a dilution of 1:7500 (2 hr, 25°C).  Following three washings with 0.5% 
Tween-20/Tris-buffered saline, the bands were visualized with enhanced 
chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ, USA) as per 
manufacturer’s instructions. 
Saponification of fatty acids 
 Aliquots (approximately 100 g of mitochondrial protein) of isolated 
mitochondria were used for each reaction.  Saponification methods were based on a 
previous description by Kurkiewicz et al [49].  Sodium hydroxide (1 mL of 3 M) was 
added to the mitochondria solution.  The mixture was vortexed and heated to 90°C for 1 
h, cooled to room temperature, and 2 mL of 3.25 M HCl was added and reheated at 90°C 
for 10 min.  After cooling to room temperature, the lipids were extracted three times with 
1 mL portions of hexane/diethyl ether (1:1, by vol).  The organic phases were combined 
and evaporated to dryness under a stream of N2 at room temperature. 
Fatty acid derivatization methods 
 Fatty acid methyl ester (FAME) procedures were adapted from Lepage and Roy 
[50].  Methanol:acetyl chloride (50:1 (v/v), 5 mL total) was added to the extracted free 
fatty acids.  The solution was vortexed and heated at 60°C for 1 h.  After heating, 3 mL  
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Figure 4.3.  Representative western blot analysis for mitochondrial 
isolation (a) and digitonin treatment (b).  Total homogenate (TH),  nuclear 
fraction (NF), cytosolic fraction (CF),  and mitochondrial fraction (MF) 
from inferior parietal lobule of brain. 
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of 6% K2CO3 was added, and the FAME products were extracted 1 mL of hexane 
containing 50 ng/ L anthracene.  Extracted material (1 L) was used for GC/MS 
analysis.   
 An aliquot of the FAME solution was transesterified to picolinyl esters using an 
adapted method [51].  The hexane phase from the FAME procedure was evaporated to 
dryness under a stream of N2 at room temperature and 1 mL of methylene chloride was 
added to resolvate the methyl esters.  In a separate vial a mixture of 200 µL 3-
hydroxymethylpyridine and 100 L of 1.0 M potassium tert-butoxide in THF were 
allowed to react for 2 min.  This mixture was then added to the FAME methylene 
chloride solution.  The reaction was mixed and heated at 45°C for 1 h.  After cooling to 
room temperature, 1 mL of 2.5% NaHCO3 was added and the methylene chloride layer 
removed.  The organic layer was reduced to approximately one-quarter the original 
volume under a stream of N2 at room temperature and 1 L was injected for analysis.  All 
derivatization methods were validated by analysis of 20:4 (arachidonic acid) and 22:6 
(docosahexaenoic acid). 
Gas chromatography/mass spectrometry 
Fatty acid methyl ester derivatives were analyzed using a Varian Saturn 3 GC/MS 
system equipped with a ZB-5ms capillary column 30 m x 0.25 mm i.d., 0.25 μm film 
(Phenomenex USA, Torrance, CA).  The temperature program was: 130°C to 170°C at 
4°C/min, 170°C to 215°C at 2.7°C/min, 215°C for 3.34 min, with a total analysis time of 
30 min.  Carrier gas head-pressure was set to give a flow rate of 1 mL/min, with a 50:1 
split.  The injector and transfer line were maintained at 240°C and the manifold 
temperature was 210°C.  Ionization was accomplished by electron impact (EI) at 70 eV, 
with a 3 minute filament delay.  Full scan spectra (m/z 50 to 650) were acquired at a scan 
rate of 1 analytical scan per second with a background mass set at m/z 49.  The GC/MS 
method was optimized to provide peak resolution for FAMEs from the GLC-411 
standard.   
Fatty acid picolinyl ester derivatives were analyzed on the same instrument with 
the following temperature program: 150°C for 4 min, 150°C to 280°C at 20°C/min, 
280°C for 19.5 min with a total analysis time of 30 min.  All other parameters were as 
described above except that the filament delay was 10 min and spectra were generated 
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from full scans from m/z 50 to 500.  All GC/MS data were analyzed using the Wsearch32 
2005 Software (version 1.6.2005; Melbourne, Australia).   
Calculations 
Average ( x ) 
n
n
n
nnnn
x
...321
       eq. 4.2 
Standard deviation (s)  
The standard deviation represents the difference between replicate measurements. 
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         eq. 4.3                         
Standard error of the mean (SEM) 
n
s
SEM           eq. 4.4 
Shapiro-Wilk test for normality 
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Where W is the Wilk statistic, )(ix is the smallest value for test samples, ia  is a constant 
based on )(ix  and x  is the samples mean. 
Skewness test 
n
s
xx
skewness
i
3
        eq. 4.6 
Where ix  are the individual values, x  is the average of all values, s is the standard 
deviation and n is the number of samples. 
Pearson Product-Moment test for correlation 
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Where  is the Pearson’s coefficient, x  and y are variables, ix is an each value of x , x
and y are the means for and y variables, n  is the number of variables and xs  and ys  are 
the standard deviations for x  and y variables. 
F-test for comparison of two variances 
 The null hypothesis is stated that there is no significant difference between the 
two variances.  If Fcalc > Ftable, p, v1, v2 then the null hypothesis is rejected and there is a 
significant difference between the two populations.  Fcalc > 1, v1 = n1-1, v2 = n2-1 
2
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Fcalc          eq. 4.8 
t-Test for comparison of two experimental means 
  
21
2121 )(
nn
nn
sp
XX
tcalc         eq. 4.9 
Analysis of Variance (ANOVA) 
2
1
calcF          eq. 4.10  
Where 1  equals the mean square error between the classes and 2 represents the mean 
square error within the classes.  If calcF  > tableF  then the HO is rejected and there is some 
systematic difference among the classes.  The Tukey post hoc test was then employed to 
compare each group against each other and established significance. 
Kruskal-Wallis One Way Analysis of Variance on Ranks 
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Where N is the total number of observations, in is the number of observations in group i , 
r  is the average rank, ir  is the average for observations from group ir , ijr is the rank of 
observation j  within group i .  If calcH  > criticalH  then the HO is rejected and there is 
some systematic difference among the ranks.  Dunn’s or Tukey post hoc tests were then 
employed to compare each group pairwise and establish significance. 
Statistical analysis employed the commercially available SigmaPlot software 
(Systate Software, Inc, San Jose, CA, USA).  Comparisons were limited to equivalent 
fatty acids between brain regions and/or disease states, i.e. NC vs. MCI vs. PCAD vs. 
LAD vs. DC.  Significant differences (p<0.05) across disease states, within a particular 
brain region, compared to NC are depicted by *.  Significant differences (p<0.05) within 
equivalent disease states, across distinct brain regions, are depicted by ‡. 
Box-and-whisker plots 
 Box-and-whisker plots were utilized to graphically represent much of the data 
acquired.  A diagram of a typical box-and-whisker plot is provided to help illustrate the 
data contained these graphs (Figure 4.4).  The gray area of the box represents the upper to 
lower quartile for the selected data.  Within this gray area are the median line (solid) and 
the mean line (dotted) for the data.  The whiskers proved the data range from lowest to 
highest.  Outliers, greater than 5
th
/95
th
 percentile from either the lowest or highest value, 
are represented by solid circles. 
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Figure 4.4. Box-and-whisker plot anatomy. 
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Chapter 4.3.  Results 
 The characteristic fatty acid profile found in brain mitochondrial membranes from 
experiments with Sprague Dawley rats, was used as a template for the exploration of 
changes that occur in the mitochondrial membrane during the progression of neurological 
diseases.  The objective of this study was designed to examine the changes in the 
mitochondrial lipidome as a function of Alzheimer’s disease (AD) progression.  
Mitochondria isolated from human neurological tissue from three stages of AD 
progression ranging from preclinical (PCAD), mild cognitive impairment (MCI), through 
late-stage (LAD) were compared to lipid profiles from age-matched normal (NC) and 
disease controls (DC).  The scope of this study will also map the changes that occur as a 
function of regional proliferation of AD across three areas of the brain: cerebellum 
(CER), superior and middle temporal gyri (SMTG), and inferior parietal lobule (IPL).  
The hypothesis being that changes to the mitochondrial fatty acids will be reflected 
during advanced stages of AD, in addition to being more prevalent in regions displaying 
greater pathology. 
Subject neuropathological demographics 
 The patient demographics used in these studies were compared statistically to 
determine possible differences between the subjects (Table 4.1).  The average age was 
compared by one way ANOVA and showed no statistical differences between AD states 
compared to NC (Figure 4.5).  However, the disease control subjects were found to be 
significantly younger (p<0.001) than all of the other neuropathologic states.  Analysis of 
the post-mortem interval (PMI) data by one way ANOVA indicated there was no 
statistical difference between the samples (Figure 4.6). 
 Comparisons of the median Braak scores and neuritic plaque (NP) data among the 
disease states provided the main distinction between the subjects.  The Braak scores were 
evaluated by the non-parametric Kruskal-Wallis one way ANOVA ranks test with a 
Dunn’s method post hoc test to establish significance.  Both NC and DC groups were 
significantly different (p<0.05) than MCI, PCAD and LAD states (Figure 4.7). 
 The average neuritic plaques (NP) were compared across disease states for IPL 
and SMTG regions.  The plaque counts were compared statistically by one way ANOVA 
with Tukey post hoc test.  Inferior parietal lobule had a significant increase (P<0.001) in  
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Figure 4.5. Differences in subject age between disease 
states (normal control (NC), mild cognitive impairment 
(MCI), preclinical AD (PCAD) late-stage AD (LAD) and 
disease control (DC)).  Significant differences (p<0.05) 
between disease states, compared to NC are depicted by *. 
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Figure 4.6. Differences in subject post-mortem interval 
(PMI) between disease states (normal control (NC), 
mild cognitive impairment (MCI), preclinical AD 
(PCAD) late-stage AD (LAD) and disease control 
(DC)).  Significant differences (p<0.05) between disease 
states, compared to NC are depicted by *. 
150 
 
 
  
Figure 4.7. Differences in subject median Braak score 
between disease states (normal control (NC), mild 
cognitive impairment (MCI), preclinical AD (PCAD) 
late-stage AD (LAD) and disease control (DC)).  
Significant differences (p<0.05) between disease states, 
compared to NC are depicted by *. 
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NP for LAD compared to all other disease states (Figure 4.8).  For SMTG the LAD 
samples had a significant increase (p<0.001) in NP compared to NC, PCAD and DC; 
however, the LAD comparison to MCI samples resulted in a p<0.05 significant increase 
(Figure 4.9).  
Mitochondria isolation 
The development of a mitochondrial isolation procedure that provided significant 
purity while maximizing yield, from neurological tissue, was essential for lipidomic 
analysis (Figure 4.2).  Protein markers for total homogenate (TH), nuclear fraction (NF), 
cytosolic fraction (CF) and mitochondria fraction (MF) as visualized with enhanced 
chemiluminescence (Figure 4.3a).  The western blot result confirms the purity and 
increased concentration of mitochondria isolation over that of the total homogenate.  The 
absence of MAP2 and lamin B bands verified the purity of mitochondrial isolation. 
Quantification of mitochondrial proteins based on bicinchoninic acid (BCA) 
assay, did not indicate any significant differences in isolation yields across the three brain 
regions studied for the combined disease states (Figures 4.10).  The average 
mitochondrial protein yield per tissue weight, for the entire sample population was 500 
µg/g ± 0.006 (Figure 4.10).  When the data of mitochondria protein quantification is 
separated into individual disease states for the three regions only slight statistical 
differences are present (Figures 4.11).  For inferior parietal lobule there was a significant 
decrease (p<0.05) in yield for MCI and LAD compared to NC, indicated by *.  In 
addition, there was also a significant increase (p<0.05) in yield for LAD from the inferior 
parietal lobule compared to LAD from cerebellum, indicated by ‡.  
Fatty acid structure analysis 
As discussed with the previous project (Chapter 3) a complete description of the 
fatty acid profile requires structural analysis of the acyl chains.  As described previously 
derivatization to picolinyl esters provided charge remote fragmentation along the fatty 
acid backbone facilitating structural elucidation [62].  Results for fatty acid structural 
analysis from human neurological mitochondria yielded equivalent results to fatty acids 
from the preceding study with Sprague Dawley neurological mitochondria (Chapter 3).  
Therefore, the presented results will focus on long-chain polyunsaturated fatty acids not  
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Figure 4.8. Differences in subject neuritic plaques counts 
within IPL between disease states (normal control (NC), 
mild cognitive impairment (MCI), preclinical AD 
(PCAD) late-stage AD (LAD) and disease control (DC)).  
Significant differences (p<0.05) between disease states, 
compared to NC are depicted by *. 
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Figure 4.9. Differences in subject neuritic plaques counts 
within SMTG between disease states (normal control (NC), 
mild cognitive impairment (MCI), preclinical AD (PCAD) 
late-stage AD (LAD) and disease control (DC)).  
Significant differences (p<0.05) between disease states, 
compared to NC are depicted by *. 
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Figure 4.10.  Differences in mitochondrial yield across brain 
regions as measured by BCA assay for combined disease 
states. 
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previously discussed.  For spectra and discussions concerning other fatty acids, the reader 
is referred to Chapter 3.3 and Figures 3.3-3.18. 
Fragmentation of picolinyl esters with double bonds have a distinctive pattern 
indicating the site of the unsaturation, although mass intervals are sometimes difficult to 
determine with long-chain PUFAs.  As before, loses of the terminal methyl group 
produces [M-15]
+
, then the repeating pattern of [M]
+
-(CH2)n mass units is present except 
for locations at double bonds.  Cleavage at the methylene group alpha to the double bond 
results in a 26 amu gap.  Usually, following a loss of 26 amu, there is a loss of 14 amu 
indicating the methylene interrupted site along the chain, prior to another loss of 26 amu 
for PUFAs.  The double bond location indicator ions can also be seen by a gap of 40 amu. 
These methodologies were used to determine the structure of each the PUFAs.  
The EI spectra are presented in two forms, first the methyl ester derivative then the 
picolinyl ester of 5,8,11,14-arachidonic acid (20:4 Δ5,8,11,14) (Figures 4.12 & 4.13).  
Increasing the number of conjugated double bonds along the alkyl chain imparts greater 
difficulty interpreting the spectrum.  Still present is the fragmentation to lose the terminal 
methyl group producing, m/z 380, from the molecular ion, m/z 395.  Following the same 
concept as above the loss of 26 amu from m/z 324 to m/z 298 represents the double bond 
between carbon fourteen and fifteen, confirming that this is an ω-6 fatty acid.  The next 
double bond corresponds to the loss from m/z 284 to m/z 258.  The remaining two double 
bonds adhere to the same pattern of a 26 amu loss from m/z 244 and m/z 204 to m/z 218 
and m/z 178 respectively.  Following each loss of 26 amu, indicated by *’s, the 
subsequent loss of 14 amu before the next 26 amu loss represents the methylene 
separation between double bonds. 
The mass spectrum for the picolinyl ester of 8,11,14-eicosatrienoic acid 
(20:3Δ8,11,14) is shown in Figure 4.14.  The molecular ion, m/z 397, loss of the terminal 
methyl group yields m/z 368.  The ω-6 double bond between carbons 14 and 15, results 
in the first 26 amu gap in the spectrum.  This fragmentation yields m/z 326 to m/z 300, 
however this paticular unsaturation site is probably better illustrated by the 40 amu loss 
from m/z 340 to m/z 300.  The next double bond, located between carbons 11 and 12, 
produces the 26 amu loss between m/z 286 to 260 m/z.  Finally, m/z 246 to m/z 220 
results from the double bond between carbons 8 and 9.  Note that between each double  
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Figure 4.12.  Mass spectrum of methyl 5,8,11,14-eicosatetraenoate (20:4Δ5,8,11,14). 
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  Figure 4.13.  Mass spectrum of picolinyl 5,8,11,14-eicosatetraenoate (20:4Δ5,8,11,14). 
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Figure 4.14.  Mass spectrum of picolinyl 8,11,14-eicosatrienoate (20:3Δ8,11,14). 
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bond is a 14 amu gap, indicating a conjugated triene systems.  For comparison the methyl 
ester EI spectrum of 8,11,14-eicosatrienoic acid is provided (Figure 4.15). 
The mass spectrum for the methyl ester of 4,7,10,13,16,19-docosahexaenoic acid 
(22:6Δ4,7,10,13,16,19) provides little to no molecular ion and is dominated by low 
molecular weight fragments (Figure 4.16).  In addition the picolinyl ester, is difficult to 
interpret due to the increased number of double bonds (Figure 4.17).  Once again the 
[M]
+
 ion, m/z 419, is prominent however the [M-15]
+
 ion is minor compared to other 
spectra.  The ω-3 double bond at carbon 19, results in m/z 390 minus 26 amu to m/z 364.  
The double bond at carbon 16 is indicated by the 40 amu gap between m/z 350 and m/z 
310.  This pattern is also present for the double bond at carbon 7, m/z 244 to m/z 204.  
The remaining double bond locations are indicated by 26 amu breaks between m/z 310 to 
284, m/z 270 to 244 and m/z 204 to 178.  Note that each of the double bonds producing -
26 amu fragments, is separated by 14 amu indicating a methylene interrupted double 
bond.  The two double bonds distinquished by the 40 amu loss, have the methylene group 
as part of the fragment.  
Finally, the mass spectrum for picolinyl 7,10,13,16-docosatetraenoate 
(22:4Δ7,10,13,16) is shown in Figure 4.18.  As with docosahexaenoic acid the increased 
carbon length and double bonds complicates interpretation of the spectrum.  The ω-6 
double bond at carbon 16 is prominently indicated by the loss of 40 amu between m/z 
352 and m/z 312.  Likewise the next double bond location is revealed m/z 312 to m/z 
272, again a difference of 40 amu.  The final two sites of unsaturation result in the 
fragmentation pattern of m/z 272 to m/z 246 and m/z 246 to 220, respectively.  The 
analogous methyl ester derivative spectrum is provided for comparison (Figure 4.19). 
Two unsaturated plasmalogen species (P 18:1a&b) were unique to neurological 
mitochondria.  Mass spectra generated with EI of the derivatizied dimethyl acetals fail to 
provide a molecular ion and generally consist of ions with only minor abundances, as 
seen with saturated plasmalogen derivatives.  The only two prominent ions are: m/z 281 
representing [M-31]
+
 loss of a methoxy group and m/z 75 generated by the loss of the 
dimethyl head-group (Figure 4.20).   
To confirm the formation of these dimethyl acetals and in an attempt to establish 
the unsaturation sites, three aldehydes (tridecanal, cis-4-decenal and trans-2-tridecenal) 
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Figure 4.15.  Mass spectrum of methyl 8,11,14-eicosatrienoate (20:3Δ8,11,14). 
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Figure 4.16.  Mass spectrum of methyl 4,7,10,13,16,19-docosahexaenoate 
(22:6Δ4,7,10,13,16,19). 
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Figure 4.17.  Mass spectrum of picolinyl 4,7,10,13,16,19-docosahexaenoate  
(22:6Δ4,7,10,13,16,19). 
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Figure 4.18.  Mass spectrum of picolinyl 7,10,13,16-docosatetraenoate  
(22:4Δ7,10,13,16). 
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Figure 4.19.  Mass spectrum of methyl 7,10,13,16-docosatetraenoate  
(22:4Δ7,10,13,16). 
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Figure 4.20.  Mass spectra from EI experiments from dimethyl acetals of 
octadecen-1-al (P 18:1a&b). 
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were reacted through the FAME procedure.  Synthesizing a dimethyl acetal standard in 
this manner should produce mass spectra analogous to those observed from the 
plasmalogens.  The mass spectrum from the resulting dimethyl tridecacetal exhibits a 
peak at m/z 213, representing [M-31]
+
 loss of a methoxy group and a base peak at m/z 
75, the fragment of the dimethyl head-group (Figure 4.21).  The mass spectrum from the 
dimethyl acetal of cis-4-decenal displayed a m/z 169 ion from [M-31]
+
 and the dimethyl 
head-group, m/z 75 (Figure 4.22).  The dimethyl acetal mass spectrum from trans-2-
tridecenal, displays an ion at m/z 211 corresponding to [M-31]
+
, and the ever present 
dimethyl head-group at m/z 75 (Figure 4.23).  Comparison of published mass spectra 
from unsaturated dimethyl acetals generated from plasmalogens provided further support 
for the fragmentation pattern of P 18:1a&b [64].   
 To further verify the formation of acetals and attempt to locate unsaturation sites 
from plasmalogens, chemical ionization (CI) experiments were conducted using 
acetonitrile as a reagent gas [65-68].  The resulting mass spectra from the dimethyl acetal 
of octadecen-1-al (P 18:1a&b) CI experiments are shown in Figure 4.24.  Since CI 
imparts a softer ionization process to the analyte, than EI, it should facilitate less 
fragmentation and provide greater structural information.  Both spectra contain minor 
[M+54]
+
 ion peaks, at m/z 366, and a major [M-31]
+
 ion peak, at m/z 281.  The ion from 
the dimethyl head-group fragmentation discussed in EI spectra was not detected due to 
instrumental constants during CI which requires a higher background m/z cut-off.   
Fatty acid profile analysis 
Normality test 
 Fatty acid methyl esters were evaluated for normality by a Shapiro-Wilk test.  The 
normality test indicates whether the data results from a population with a Gaussian 
distribution.  For the Shapiro-Wilk’s test a significance level of p<0.05 indicates the 
sample population was drawn from a non-normally distributed population and therefore 
non-parametric testing would be required for comparisons.  A p>0.05 implies a sample 
population with normal distribution, facilitating the using of parametric testing.  Each 
methyl ester was analyzed for normality based on disease state from combined brain 
regions (Table 4.2).  The data was then further divided based on disease state for each  
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Figure 4.21.  Mass spectrum from EI experiments from dimethyl acetal of  
tridecanal. 
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Figure 4.22.  Mass spectrum from EI experiments from dimethyl acetal of  
cis-4-decenal. 
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Figure 4.23.  Mass spectrum from EI experiments from dimethyl acetal 
of trans-2-tridecenal. 
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Figure 4.24.  Mass spectra from CI experiments from dimethyl acetals of 
octadecen-1-al (P 18:1a&b). 
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Table 4.2.  Shapiro-Wilk normality test results for mitochondrial fatty acid composition 
between various disease states. 
Species 
(Structure)
a
 
p-value
b
 
Normal 
Control 
(NC) 
Mild 
cognitive 
impairment 
(MCI) 
Preclinical 
AD 
(PCAD) 
Late-
stage 
AD 
(LAD) 
Disease 
Control 
(DC)
c
 
Dodecanoic acid (12:0) <0.001 <0.001
†
 <0.001 0.085 <0.001
†
 
Tetradecanoic acid (14:0) 0.072 0.546 <0.001 0.079 0.038 
Pentadecanoic acid (15:0) 0.136 0.011 <0.001 0.033
†
 0.061 
9-Hexadecenoic acid 
(16:1Δ9) 
0.094 0.081 0.047 0.111 0.098
#
 
Hexadecanoic acid (16:0) 0.068 0.166 0.042
†
 0.398 0.195 
Plasmalogen 16:0  
(P 16:0) 
0.094
#
 0.081 0.047
†
 0.111 0.098 
Heptadecanoic acid (17:0) <0.001 0.010† 0.221 0.018† 0.323 
9,12-Octadecadienoic acid 
(18:2Δ9,12) 
<0.001 0.043 0.042 0.038
†
 0.044
†
 
9-Octadecenoic acid 
(18:1Δ9) 
<0.001 0.322 0.548 0.281 0.111
#
 
10-Octadecenoic acid 
(18:1Δ10)  
0.056 0.183
#
 0.591 0.348
#
 0.804 
Octadecanoic acid (18:0) <0.001 0.037 0.235
#
 0.486 0.769 
Plasmalogen 18:1a  
(P 18:1a) 
0.039 0.726 0.752 0.020
†
 0.029
†
 
Plasmalogen 18:1b  
(P 18:1b) 
<0.001 0.920 0.372 0.036 0.034
†
 
Plasmalogen 18:0  
(P 18:0) 
<0.001 0.069 0.918 0.066
#
 0.690
#
 
5,8,11,14-Eicosatetraenoic 
acid (20:4Δ5,8,11,14) 
0.001 0.066 0.343 0.791 0.636 
8,11,14-Eicosatrienoic acid 
(20:3Δ8,11,14) 
0.291 0.016
†
 0.129 0.017
†
 0.143 
4,7,10,13,16,19-
Docosahexaenoic acid 
(22:6Δ4,7,10,13,16,19) 
0.123 0.909 0.004 0.011 0.102 
7,10,13,16-
Docosatetraenoic acid 
(22:4Δ7,10,13,16) 
0.003 0.004† 0.218# 0.032 0.270 
a
 Number of carbons:degree of unsaturation 
b
 Values represent data from CER, IPL and SMTG 
c 
Represents a combination of dementia with Lewy body disease (DLB) and 
frontotemporal dementia (FTD) 
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brain region: CER (Table 4.3), IPL (Table 4.4) and SMTG (Table 4.5).  The overall 
results across each disease state and from each region suggested that the majority of FAs 
were from normally distributed populations.  Although no dominating pattern was present 
for individual disease states, the greatest abundance of non-normally distributed FAs 
were found in the inferior parietal lobule. 
Skewness test 
 Fatty acid methyl esters were evaluated for skewness, which provides a 
measurement of data symmetry around the mean.  A population with a Gaussian 
distribution would have a skewness value equal to zero, indicating perfect symmetry.  
Positive skewness values result when the distribution of data is heavily concentrated at 
lower values, the outcome being a population with a long-tailing peak to the right (Figure 
4.25).  Negative skewness values result from data distributions that are more concentrated 
at higher values, in this case the sample population curve has a long-fronting peak to the 
left (Figure 4.26).  In both cases a larger deviation from zero, positive or negative, 
indicates a greater degree of asymmetry from a Gaussian distribution.  The data from 
each methyl ester was initially examined as a function of disease state from the combined 
brain regions (Table 4.6).  The data was then separated into the various regions: CER 
(Table 4.7), IPL (Table 4.8) and SMTG (Table 4.9) for each disease state. 
 The evaluation of skewness for the combined regions, did not exhibit any 
dramatic shifts, positive or negative, in relation to NC values (Table 4.6).  A handful of 
FA species displayed a difference in magnitude between NC and the other demographics.  
The FA species: 18:2Δ9,12, P18:1b, P18:0 and 20:4 had a large positive skewness value 
for NC patients, but a substantially lower positive skewness for later AD states. 
 Evaluation of skewness as a function of disease population for each brain region 
provided greater disparity between subject demographics, meaning skewness oscillations 
between positive and negative values.  The cerebellum (CER) mitochondrial FA profile 
imparts a change in positive to negative skewness for 20:3 and 22:4 PUFAs, whereas 
P18:1b and 22:6 displayed the opposite trend when comparing NC to LAD (Table 4.7).  
Skewness data from inferior parietal lobule (IPL) was consistent across the disease 
categories with the only major change involving 20:4 for NC and LAD (Table 4.8).   
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Figure 4.25.  Representation of a population with positive skewness.   
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Figure 4.26.  Representation of a population with negative skewness.   
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Table 4.3.  Shapiro-Wilk normality test results for mitochondrial fatty acid composition 
between various disease states for cerebellum (CER). 
Species 
(Structure)
a
 
p-value 
Normal 
Control 
(NC) 
Mild 
cognitive 
impairment 
(MCI) 
Preclinical 
AD 
(PCAD) 
Late-
stage 
AD 
(LAD) 
Disease 
Control 
(DC)
b
 
Dodecanoic acid (12:0) 0.003 0.429 0.005 0.227 0.235 
Tetradecanoic acid (14:0) 0.145 0.697 0.017 0.831 0.270 
Pentadecanoic acid (15:0) 0.545 0.788 0.014 0.379 0.205 
9-Hexadecenoic acid 
(16:1Δ9) 
0.595 0.540 0.024 0.492 0.463 
Hexadecanoic acid (16:0) 0.853 0.380 0.161 0.737 0.106 
Plasmalogen 16:0  
(P 16:0) 
0.023 0.839 0.510 0.858 0.354 
Heptadecanoic acid (17:0) 0.058 0.471 0.836 0.665 0.423 
9,12-Octadecadienoic acid 
(18:2Δ9,12) 
0.315 0.485 0.023 0.112 0.187 
9-Octadecenoic acid 
(18:1Δ9) 
0.390 0.500 0.698 0.358 0.040 
10-Octadecenoic acid 
(18:1Δ10)  
0.102 0.317 0.660 0.601 0.067 
Octadecanoic acid (18:0) 0.064 0.444 0.263 0.605 0.085 
Plasmalogen 18:1a  
(P 18:1a) 
0.624 0.832 0.423 0.647 0.405 
Plasmalogen 18:1b  
(P 18:1b) 
0.495 0.501 0.382 0.026 0.973 
Plasmalogen 18:0  
(P 18:0) 
0.400 0.800 0.850 0.857 0.103 
5,8,11,14-Eicosatetraenoic 
acid (20:4Δ5,8,11,14) 
0.135 0.750 0.332 0.486 0.375 
8,11,14-Eicosatrienoic acid 
(20:3Δ8,11,14) 
0.349 0.544 0.415 0.093 0.202 
4,7,10,13,16,19-
Docosahexaenoic acid 
(22:6Δ4,7,10,13,16,19) 
0.592 0.617 0.409 0.341 0.589 
7,10,13,16-
Docosatetraenoic acid 
(22:4Δ7,10,13,16) 
0.519 0.855 0.592 0.939 0.592 
a
 Number of carbons:degree of unsaturation 
b 
Represents a combination of dementia with Lewy body disease (DLB) and 
frontotemporal dementia (FTD) 
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Table 4.4.  Shapiro-Wilk normality test results for mitochondrial fatty acid composition 
between various disease states for inferior parietal lobule (IPL). 
Species 
(Structure)
a
 
p-value 
Normal 
Control 
(NC) 
Mild 
cognitive 
impairment 
(MCI) 
Preclinical 
AD 
(PCAD) 
Late-
stage 
AD 
(LAD) 
Disease 
Control 
(DC)
b
 
Dodecanoic acid (12:0) 0.005 0.528 0.044 0.318 0.259 
Tetradecanoic acid (14:0) 0.588 0.509 0.022 0.474 0.796 
Pentadecanoic acid (15:0) 0.678 0.337 0.674 0.081 0.098 
9-Hexadecenoic acid 
(16:1Δ9) 
0.918 0.248 0.344 0.881 0.018 
Hexadecanoic acid (16:0) 0.352 0.764 0.217 0.097 0.265 
Plasmalogen 16:0  
(P 16:0) 
0.435 0.861 0.870 0.050 0.745 
Heptadecanoic acid (17:0) <0.001 0.054 0.255 0.856 0.165 
9,12-Octadecadienoic acid 
(18:2Δ9,12) 
<0.001 0.143 0.603 0.933 0.359 
9-Octadecenoic acid 
(18:1Δ9) 
0.013 0.203 0.115 0.855 0.289 
10-Octadecenoic acid 
(18:1Δ10)  
0.914 0.004 0.181 0.837 0.329 
Octadecanoic acid (18:0) 0.785 0.043 0.021 0.749 0.624 
Plasmalogen 18:1a  
(P 18:1a) 
0.737 0.109 0.956 0.869 0.810 
Plasmalogen 18:1b  
(P 18:1b) 
<0.001 0.905 0.630 0.214 0.579 
Plasmalogen 18:0  
(P 18:0) 
<0.001 0.002 0.593 0.028 0.047 
5,8,11,14-Eicosatetraenoic 
acid (20:4Δ5,8,11,14) 
0.420 0.203 0.110 0.819 0.097 
8,11,14-Eicosatrienoic 
acid (20:3Δ8,11,14) 
0.402 0.061 0.845 0.127 0.221 
4,7,10,13,16,19-
Docosahexaenoic acid 
(22:6Δ4,7,10,13,16,19) 
0.086 0.779 0.007 0.249 0.470 
7,10,13,16-
Docosatetraenoic acid 
(22:4Δ7,10,13,16) 
0.026 0.399 0.011 <0.001 0.078 
a
 Number of carbons:degree of unsaturation 
b 
Represents a combination of dementia with Lewy body disease (DLB) and 
frontotemporal dementia (FTD) 
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Table 4.5.  Shapiro-Wilk normality test results for mitochondrial fatty acid composition 
between various disease states for superior and middle temporal gyri (SMTG). 
Species 
(Structure)
a
 
p-value 
Normal 
Control 
(NC) 
Mild 
cognitive 
impairment 
(MCI) 
Preclinical 
AD 
(PCAD) 
Late-
stage 
AD 
(LAD) 
Disease 
Control 
(DC)
b
 
Dodecanoic acid (12:0) 0.005 0.700 0.009 0.052 0.166 
Tetradecanoic acid (14:0) 0.274 0.456 0.525 0.439 0.348 
Pentadecanoic acid (15:0) 0.327 0.104 0.072 0.654 0.898 
9-Hexadecenoic acid 
(16:1Δ9) 
0.124 0.415 0.895 0.650 0.598 
Hexadecanoic acid (16:0) 0.429 0.430 0.498 0.177 0.572 
Plasmalogen 16:0  
(P 16:0) 
0.661 0.718 0.476 0.803 0.364 
Heptadecanoic acid (17:0) 0.408 0.369 0.440 0.090 0.608 
9,12-Octadecadienoic acid 
(18:2Δ9,12) 
0.760 0.584 0.948 0.261 0.917 
9-Octadecenoic acid 
(18:1Δ9) 
0.530 0.577 0.857 0.253 0.415 
10-Octadecenoic acid 
(18:1Δ10)  
0.434 0.292 0.947 0.045 0.365 
Octadecanoic acid (18:0) 0.816 0.608 0.350 0.190 0.208 
Plasmalogen 18:1a  
(P 18:1a) 
0.425 0.953 0.594 0.135 0.389 
Plasmalogen 18:1b  
(P 18:1b) 
0.473 0.382 0.732 0.094 0.612 
Plasmalogen 18:0  
(P 18:0) 
0.876 0.667 0.843 0.730 0.756 
5,8,11,14-Eicosatetraenoic 
acid (20:4Δ5,8,11,14) 
0.871 0.514 0.333 0.568 0.501 
8,11,14-Eicosatrienoic 
acid (20:3Δ8,11,14) 
0.285 0.629 0.201 0.681 0.123 
4,7,10,13,16,19-
Docosahexaenoic acid 
(22:6Δ4,7,10,13,16,19) 
0.442 0.556 0.348 0.037 0.167 
7,10,13,16-
Docosatetraenoic acid 
(22:4Δ7,10,13,16) 
0.820 0.303 0.294 0.287 0.964 
a
 Number of carbons:degree of unsaturation 
b 
Represents a combination of dementia with Lewy body disease (DLB) and 
frontotemporal dementia (FTD) 
 
 
 
  
179 
 
Table 4.6.  Skewness test results for mitochondrial fatty acid composition between 
various disease states. 
Species 
(Structure)
a
 
Skewness value
b
 
Normal 
Control 
(NC) 
Mild 
cognitive 
impairment 
(MCI) 
Preclinical 
AD 
(PCAD) 
Late-
stage 
AD 
(LAD) 
Disease 
Control 
(DC)
c
 
Dodecanoic acid (12:0) 1.645 0.839 2.871 0.233 0.851 
Tetradecanoic acid (14:0) 0.651 0.209 1.682 0.805 1.124 
Pentadecanoic acid (15:0) 0.675 1.721 1.887 0.744 0.504 
9-Hexadecenoic acid 
(16:1Δ9) 
0.152 0.0926 1.193 0.0798 1.404 
Hexadecanoic acid (16:0) 0.819 0.530 0.448 0.528 -0.222 
Plasmalogen 16:0  
(P 16:0) 
0.217 1.150 0.760 0.438 0.854 
Heptadecanoic acid (17:0) 2.478 1.522 0.490 0.688 0.331 
9,12-Octadecadienoic acid 
(18:2Δ9,12) 
3.202 1.276 1.045 0.995 0.456 
9-Octadecenoic acid 
(18:1Δ9) 
1.473 0.811 0.381 0.431 0.281 
10-Octadecenoic acid 
(18:1Δ10)  
0.710 0.524 0.406 0.231 0.134 
Octadecanoic acid (18:0) 2.032 0.678 0.562 0.504 0.208 
Plasmalogen 18:1a  
(P 18:1a) 
1.009 0.514 0.411 0.802 0.855 
Plasmalogen 18:1b  
(P 18:1b) 
2.410 0.448 0.418 0.601 1.156 
Plasmalogen 18:0  
(P 18:0) 
2.583 0.943 0.257 0.619 -0.263 
5,8,11,14-Eicosatetraenoic 
acid (20:4Δ5,8,11,14) 
1.262 1.096 0.686 0.314 0.259 
8,11,14-Eicosatrienoic 
acid (20:3Δ8,11,14) 
0.111 1.414 0.579 1.105 0.667 
4,7,10,13,16,19-
Docosahexaenoic acid 
(22:6Δ4,7,10,13,16,19) 
0.741 0.393 0.795 0.948 0.776 
7,10,13,16-
Docosatetraenoic acid 
(22:4Δ7,10,13,16) 
1.003 1.836 0.723 0.906 0.619 
a
 Number of carbons:degree of unsaturation 
b
 Values represent data from CER, IPL and SMTG 
c 
Represents a combination of dementia with Lewy body disease (DLB) and 
frontotemporal dementia (FTD) 
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Table 4.7.  Skewness test results for mitochondrial fatty acid composition between 
various disease states for cerebellum (CER). 
Species 
(Structure)
a
 
Skewness value 
Normal 
Control 
(NC) 
Mild 
cognitive 
impairment 
(MCI) 
Preclinical 
AD 
(PCAD) 
Late-
stage 
AD 
(LAD) 
Disease 
Control 
(DC)
b
 
Dodecanoic acid (12:0) 1.749 0.184 0.528 0.797 -1.266 
Tetradecanoic acid (14:0) 0.306 -0.475 1.499 0.198 0.394 
Pentadecanoic acid (15:0) 0.226 0.453 1.842 0.796 -0.326 
9-Hexadecenoic acid 
(16:1Δ9) 
0.0794 0.444 1.681 0.770 -0.547 
Hexadecanoic acid (16:0) -0.0138 0.388 -0.413 -0.0524 0.914 
Plasmalogen 16:0  
(P 16:0) 
1.417 0.0489 0.774 0.0116 1.050 
Heptadecanoic acid (17:0) 0.255 0.854 0.153 0.418 0.423 
9,12-Octadecadienoic acid 
(18:2Δ9,12) 
0.326 1.096 1.390 1.189 -0.881 
9-Octadecenoic acid 
(18:1Δ9) 
0.805 -0.456 0.210 0.0248 1.112 
10-Octadecenoic acid 
(18:1Δ10)  
1.383 0.0848 0.571 0.0568 1.261 
Octadecanoic acid (18:0) 1.292 -0.0379 -0.189 -0.138 1.161 
Plasmalogen 18:1a  
(P 18:1a) 
0.260 -0.0833 0.976 0.208 0.747 
Plasmalogen 18:1b  
(P 18:1b) 
0.790 0.0460 0.682 0.234 -0.319 
Plasmalogen 18:0  
(P 18:0) 
-0.666 0.259 0.494 0.368 -0.776 
5,8,11,14-Eicosatetraenoic 
acid (20:4Δ5,8,11,14) 
0.970 0.328 -0.551 0.554 0.137 
8,11,14-Eicosatrienoic 
acid (20:3Δ8,11,14) 
0.584 0.407 0.790 -0.534 -0.666 
4,7,10,13,16,19-
Docosahexaenoic acid 
(22:6Δ4,7,10,13,16,19) 
-0.113 0.00404 -0.253 1.040 0.128 
7,10,13,16-
Docosatetraenoic acid 
(22:4Δ7,10,13,16) 
0.414 0.588 0.497 -0.253 -0.0928 
a
 Number of carbons:degree of unsaturation 
b 
Represents a combination of dementia with Lewy body disease (DLB) and 
frontotemporal dementia (FTD) 
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Table 4.8.  Skewness test results for mitochondrial fatty acid composition between 
various disease states for inferior parietal lobule (IPL). 
Species 
(Structure)
a
 
Skewness value 
Normal 
Control 
(NC) 
Mild 
cognitive 
impairment 
(MCI) 
Preclinical 
AD 
(PCAD) 
Late-
stage 
AD 
(LAD) 
Disease 
Control 
(DC)
b
 
Dodecanoic acid (12:0) 2.055 0.392 1.227 -0.0345 0.864 
Tetradecanoic acid (14:0) 0.535 -0.000203 1.613 0.207 -0.220 
Pentadecanoic acid (15:0) -0.0720 1.083 -0.277 1.404 0.727 
9-Hexadecenoic acid 
(16:1Δ9) 
-0.587 0.565 1.024 -0.186 1.956 
Hexadecanoic acid (16:0) 0.0588 0.929 0.960 1.077 -0.141 
Plasmalogen 16:0  
(P 16:0) 
0.624 0.379 -0.364 0.857 0.430 
Heptadecanoic acid (17:0) 2.390 1.779 -0.132 0.429 -1.082 
9,12-Octadecadienoic acid 
(18:2Δ9,12) 
3.301 -0.119 0.552 0.363 -0.0387 
9-Octadecenoic acid 
(18:1Δ9) 
1.896 1.541 0.453 0.230 0.193 
10-Octadecenoic acid 
(18:1Δ10)  
0.154 2.162 0.971 0.271 -0.321 
Octadecanoic acid (18:0) 0.0539 1.837 1.081 0.260 -0.0547 
Plasmalogen 18:1a  
(P 18:1a) 
-0.410 1.579 0.0961 -0.105 0.0394 
Plasmalogen 18:1b  
(P 18:1b) 
2.767 0.375 0.642 0.558 0.272 
Plasmalogen 18:0  
(P 18:0) 
3.134 2.298 0.262 0.944 -1.019 
5,8,11,14-Eicosatetraenoic 
acid (20:4Δ5,8,11,14) 
1.008 0.623 1.343 -0.398 -0.469 
8,11,14-Eicosatrienoic 
acid (20:3Δ8,11,14) 
0.165 0.904 0.238 0.874 -0.720 
4,7,10,13,16,19-
Docosahexaenoic acid 
(22:6Δ4,7,10,13,16,19) 
1.425 0.190 1.942 0.994 0.0473 
7,10,13,16-
Docosatetraenoic acid 
(22:4Δ7,10,13,16) 
0.851 0.145 1.901 1.962 -0.925 
a
 Number of carbons:degree of unsaturation 
b 
Represents a combination of dementia with Lewy body disease (DLB) and 
frontotemporal dementia (FTD) 
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Table 4.9.  Skewness test results for mitochondrial fatty acid composition between 
various disease states for superior and middle temporal gyri (SMTG). 
Species 
(Structure)
a
 
Skewness value 
Normal 
Control 
(NC) 
Mild 
cognitive 
impairment 
(MCI) 
Preclinical 
AD 
(PCAD) 
Late-
stage 
AD 
(LAD) 
Disease 
Control 
(DC)
b
 
Dodecanoic acid (12:0) 1.998 -0.283 1.217 0.533 1.002 
Tetradecanoic acid (14:0) -0.0870 -0.712 0.913 0.834 1.076 
Pentadecanoic acid (15:0) 0.455 1.715 1.405 0.313 -0.409 
9-Hexadecenoic acid 
(16:1Δ9) 
-0.790 -0.222 0.394 -0.876 0.343 
Hexadecanoic acid (16:0) -0.288 0.597 0.761 1.013 0.580 
Plasmalogen 16:0  
(P 16:0) 
-0.692 0.727 0.585 -0.324 0.513 
Heptadecanoic acid (17:0) 0.363 1.128 0.958 -0.354 0.777 
9,12-Octadecadienoic acid 
(18:2Δ9,12) 
0.229 0.649 -0.353 1.039 -0.0367 
9-Octadecenoic acid 
(18:1Δ9) 
0.0531 0.469 0.539 0.617 -0.0377 
10-Octadecenoic acid 
(18:1Δ10)  
0.496 -0.255 0.243 0.899 0.227 
Octadecanoic acid (18:0) 0.612 -0.655 0.757 0.846 1.163 
Plasmalogen 18:1a  
(P 18:1a) 
0.480 0.300 0.512 0.130 0.382 
Plasmalogen 18:1b  
(P 18:1b) 
0.422 0.653 0.315 -0.0965 0.799 
Plasmalogen 18:0  
(P 18:0) 
-0.269 0.482 0.295 0.618 -0.166 
5,8,11,14-Eicosatetraenoic 
acid (20:4Δ5,8,11,14) 
-0.220 0.771 0.980 0.464 0.410 
8,11,14-Eicosatrienoic 
acid (20:3Δ8,11,14) 
-0.911 1.094 0.612 0.559 0.430 
4,7,10,13,16,19-
Docosahexaenoic acid 
(22:6Δ4,7,10,13,16,19) 
-0.0839 1.074 1.023 1.032 1.326 
7,10,13,16-
Docosatetraenoic acid 
(22:4Δ7,10,13,16) 
0.0738 1.352 0.161 -0.776 -0.131 
a
 Number of carbons:degree of unsaturation 
b 
Represents a combination of dementia with Lewy body disease (DLB) and 
frontotemporal dementia (FTD) 
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The FA profile from the superior and middle temporal gyri (SMTG) exhibited the 
most change in skewness shifting (Table 4.9).  In total four species: P18:0, 20:4, 20:3 and 
22:6 altered negative to positive skewness from NC to LAD subjects.  Two other species 
(P18:1b and 22:4) had the reverse trend.  As with the IPL, data from SMTG disease states 
were compared to CER data.  Values from SMTG demonstrated less change from CER 
than with IPL, but again the change in the data population occurred within PCAD and 
LAD subjects.      
Correlation tests     
 Pearson product-moment tests were employed to determine possible relationships 
between various subject neuropathological characteristics and fatty acid species.  The 
Pearson correlation test provides a means of evaluating the association between multiple 
variables, without regard to dependence.  The reported data is given in terms of 
correlation coefficient and significance value (p-value).  A positive correlation coefficient 
and a p<0.050, signifies that the two variables increase together.  A negative correlation 
coefficient and a p<0.050, denotes that the variables decrease concurrently.  A p>0.050 
indicates that no significant relationship exists between the two variables.  Unlike other 
statistical treatments, for correlation studies, the data from individual disease states were 
pooled together to provide a single variable.  Data relating the subjects’ 
neuropathological demographics were first tested for possible correlations, among the 
different regions.  Age and Braak scores for mitochondria isolated from cerebellum 
exhibited no significant relationship between the two variables (Table 4.10).  For SMTG 
and IPL age, Braak score and neuritic plagues were compared (Tables 4.11 & 4.12).  The 
results from both regions yielded analogous results.  Age showed no relationship to either 
Braak score or neuritic plaques, however comparison of Braak scores and NP counts 
displayed a positive correlation.  
 Next, subject neuropathologic variables were compared to data for each fatty acid 
species.  Overall there seemed to be little correlation between fatty acid species and 
subject variables among the three brain regions.  Data from cerebellum demonstrated a 
negative correlation between dodecanoic acid (12:0) for age and Braak score (Table 
4.13).  In contrast, there was a positive correlation between Braak score and 8 of the 
unsaturated fatty acids, excluding 18:1Δ10, from cerebellum mitochondria. 
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Table 4.10.  Pearson product-moment correlation test for mitochondria from cerebellum 
(CER). 
Variables Braak score 
Age 0.128
a
 
0.325
b
 
a
 Correlation coefficient 
b
 p-value 
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Table 4.11.  Pearson product-moment correlation test for mitochondria from inferior 
parietal lobule (IPL). 
Variables Braak score Neuritic plagues 
Age 0.137
a
 
0.301
b
 
-0.243
 
 
0.0660 
Braak score  0.692
 
 
0.00000000173 
a
 Correlation coefficient 
b
 p-value 
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Table 4.12.  Pearson product-moment correlation test for mitochondria from superior and 
middle temporal gyri (SMTG). 
Variables Braak score Neuritic plagues 
Age 0.224
a
 
0.118
b
 
0.0327 
0.823 
Braak score  0.728 
0.00000000297 
a
 Correlation coefficient 
b
 p-value 
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Table 4.13.  Pearson product-moment correlation test for mitochondrial fatty acids from 
cerebellum (CER). 
Species 
(Structure)
a
 
Variables 
Age Braak score 
Dodecanoic acid (12:0) -0.487
b
 
0.000120
c
 
-0.418 
0.00123 
Tetradecanoic acid (14:0) -0.00120 
0.993 
0.143 
0.280 
Pentadecanoic acid (15:0) 0.0404 
0.765 
0.120 
0.375 
9-Hexadecenoic acid (16:1Δ9) 0.0278 
0.834 
0.325 
0.0120 
Hexadecanoic acid (16:0) -0.175 
0.196 
0.354 
0.00740 
Plasmalogen 16:0 (P 16:0) 0.0557 
0.675 
0.158 
0.231 
Heptadecanoic acid (17:0) 0.176 
0.187 
0.110 
0.411 
9,12-Octadecadienoic acid 
(18:2Δ9,12) 
0.255 
0.0536 
0.267 
0.0431 
9-Octadecenoic acid (18:1Δ9) -0.160 
0.233 
0.378 
0.00372 
10-Octadecenoic acid 
(18:1Δ10)  
-0.138 
0.296 
0.360 
0.00510 
Octadecanoic acid (18:0) -0.167 
0.219 
0.355 
0.00721 
Plasmalogen 18:1a  
(P 18:1a) 
0.0743 
0.586 
0.0670 
0.624 
Plasmalogen 18:1b  
(P 18:1b) 
-0.0774 
0.560 
0.184 
0.164 
Plasmalogen 18:0 (P 18:0) -0.165 
0.212 
0.398 
0.00180 
5,8,11,14-Eicosatetraenoic acid 
(20:4Δ5,8,11,14) 
-0.00624 
0.963 
0.403 
0.00153 
8,11,14-Eicosatrienoic acid 
(20:3Δ8,11,14) 
0.147 
0.265 
0.321 
0.0131 
4,7,10,13,16,19-
Docosahexaenoic acid 
(22:6Δ4,7,10,13,16,19) 
0.128 
0.335 
0.398 
0.00181 
7,10,13,16-Docosatetraenoic 
acid (22:4Δ7,10,13,16) 
0.0205 
0.879 
0.311 
0.0173 
a
 Number of carbons:degree of unsaturation 
b 
Correlation coefficient 
c
 p-value 
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The inferior parietal lobule mitochondrial fatty acid profile displayed random 
correlations between Braak scores and neuritic plaque counts, however no correlations 
between age and FAs were detected (Table 4.14).  Braak scores were found to have 
negative correlations between pentadecanoic (15:0) and heptadecanoic (17:0) acids, the 
only odd-carbon chain fatty acid species.  A positive correlation was found between 
18:1Δ9, 18:0, 20:4, 22:4 and neuritic plaques.  In addition, positive correlations were 
established between hexadecanoic (16:0), 10-octadecanoic (18:1Δ10), Braak scores and 
neuritic plaques. 
 The relationship between subject variables and mitochondria fatty acids from 
SMTG were more sparse than those in the inferior parietal lobule (Table 4.15).  Age was 
found to have a negative correlation with 9-hexadecenoic (16:1Δ9), plasmalogen 16:0, 
heptadecanoic (17:0) and plasmalogen 18:1a.  Neuritic plaques were only found to have a 
positive correlation with plasmalogen 16:0.  No relationship was found between Braak 
score and any fatty acid species from SMTG. 
Fatty acid distribution and disease state analysis 
Data on mitochondrial lipid species, cumulative from the three regions (CER, IPL 
and SMTG) were compared as a function of disease states.  Data are graphically 
represented by box-and-whisker plots (odd-numbered Figures 4.27-4.61).  Individual 
boxes for the five discrete neuropathological classifications, from left-to-right: age-
matched normal control (NC), mild cognitive impairment (MCI), preclinical AD 
(PCAD), late-stage AD (LAD) and disease control (DC). 
Fatty acid methyl esters were also analyzed as a function of disease state and 
region of isolation (even-numbered Figures 4.28-4.62).  Data are graphically represented 
by box-and-whisker plots segmented by region CER (a), IPL (b) and SMTG (c).  As with 
the preceding graphs, each graph consists of individual boxes for the five discrete 
neuropathologic classifications, from left-to-right: age-matched normal control (NC), 
mild cognitive impairment (MCI), preclinical AD (PCAD), late-stage AD (LAD) and 
disease control (DC). 
Methyl ester species, 18 total, were evaluated statistically by either a parametric 
one way ANOVA, for normally distributed data or a non-parametric Kruskal-Wallis one  
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Table 4.14.  Pearson product-moment correlation test for mitochondrial fatty acids from 
inferior parietal lobule (IPL). 
Species 
(Structure)
a
 
Variables 
Age Braak score 
Neuritic 
plagues 
Dodecanoic acid (12:0) -0.0790
b
 
0.555
c
 
-0.143 
0.286 
-0.0105 
0.938 
Tetradecanoic acid (14:0) 0.0944 
0.481 
0.129 
0.339 
0.0688 
0.611 
Pentadecanoic acid (15:0) -0.0829 
0.536 
-0.294 
0.0251 
-0.169 
0.209 
9-Hexadecenoic acid (16:1Δ9) 0.151 
0.258 
0.0148 
0.912 
0.0586 
0.665 
Hexadecanoic acid (16:0) -0.0907 
0.502 
0.281 
0.0342 
0.367 
0.00538 
Plasmalogen 16:0 (P 16:0) -0.156 
0.242 
0.0211 
0.875 
0.146 
0.279 
Heptadecanoic acid (17:0) -0.0775 
0.563 
-0.315 
0.0162 
-0.180 
0.180 
9,12-Octadecadienoic acid 
(18:2Δ9,12) 
-0.00291 
0.983 
-0.160 
0.226 
-0.116 
0.384 
9-Octadecenoic acid (18:1Δ9) -0.152 
0.253 
0.193 
0.146 
0.337 
0.0104 
10-Octadecenoic acid 
(18:1Δ10)  
0.0594 
0.658 
0.282 
0.0318 
0.278 
0.0361 
Octadecanoic acid (18:0) -0.108 
0.431 
0.201 
0.142 
0.307 
0.0241 
Plasmalogen 18:1a  
(P 18:1a) 
-0.193 
0.150 
-0.00972 
0.943 
0.177 
0.192 
Plasmalogen 18:1b  
(P 18:1b) 
-0.0666 
0.616 
0.0808 
0.543 
0.154 
0.247 
Plasmalogen 18:0 (P 18:0) -0.137 
0.302 
0.224 
0.0879 
0.215 
0.105 
5,8,11,14-Eicosatetraenoic acid 
(20:4Δ5,8,11,14) 
-0.135 
0.316 
0.189 
0.158 
0.324 
0.0150 
8,11,14-Eicosatrienoic acid 
(20:3Δ8,11,14) 
-0.0913 
0.500 
0.000380 
0.998 
0.111 
0.415 
4,7,10,13,16,19-
Docosahexaenoic acid 
(22:6Δ4,7,10,13,16,19) 
-0.199 
0.141 
0.0408 
0.765 
0.211 
0.121 
7,10,13,16-Docosatetraenoic 
acid (22:4Δ7,10,13,16) 
-0.191 
0.157 
0.165 
0.224 
0.285 
0.0349 
a
 Number of carbons:degree of unsaturation 
b 
Correlation coefficient 
c
 p-value 
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Table 4.15.  Pearson product-moment correlation test for mitochondrial fatty acids from 
superior and middle temporal gyri (SMTG). 
Species 
(Structure)
a
 
Variables 
Age Braak score 
Neuritic 
plagues 
Dodecanoic acid (12:0) -0.288
b
 
0.0610
c
 
0.146 
0.351 
0.0781 
0.623 
Tetradecanoic acid (14:0) -0.0804 
0.583 
-0.0701 
0.632 
0.152 
0.304 
Pentadecanoic acid (15:0) -0.252 
0.0809 
-0.142 
0.329 
0.121 
0.411 
9-Hexadecenoic acid (16:1Δ9) -0.326 
0.0222 
-0.0298 
0.839 
0.190 
0.195 
Hexadecanoic acid (16:0) 0.0845 
0.577 
0.240 
0.108 
0.173 
0.255 
Plasmalogen 16:0 (P 16:0) -0.284 
0.0480 
0.0521 
0.722 
0.293 
0.0433 
Heptadecanoic acid (17:0) -0.318 
0.0292 
-0.0770 
0.607 
0.181 
0.223 
9,12-Octadecadienoic acid 
(18:2Δ9,12) 
0.100 
0.492 
-0.0308 
0.834 
0.0590 
0.690 
9-Octadecenoic acid (18:1Δ9) 0.0260 
0.862 
0.202 
0.173 
0.131 
0.385 
10-Octadecenoic acid 
(18:1Δ10)  
-0.137 
0.350 
0.0979 
0.503 
0.129 
0.384 
Octadecanoic acid (18:0) 0.112 
0.440 
-0.0460 
0.751 
-0.0645 
0.660 
Plasmalogen 18:1a  
(P 18:1a) 
-0.339 
0.0173 
-0.0719 
0.623 
0.123 
0.404 
Plasmalogen 18:1b  
(P 18:1b) 
-0.210 
0.147 
-0.0658 
0.653 
0.0696 
0.638 
Plasmalogen 18:0 (P 18:0) -0.120 
0.412 
-0.0243 
0.868 
0.109 
0.462 
5,8,11,14-Eicosatetraenoic acid 
(20:4Δ5,8,11,14) 
0.0303 
0.838 
0.000328 
0.998 
0.0973 
0.515 
8,11,14-Eicosatrienoic acid 
(20:3Δ8,11,14) 
-0.189 
0.193 
0.00975 
0.947 
0.270 
0.0637 
4,7,10,13,16,19-
Docosahexaenoic acid 
(22:6Δ4,7,10,13,16,19) 
-0.00370 
0.980 
-0.0219 
0.881 
0.0497 
0.737 
7,10,13,16-Docosatetraenoic 
acid (22:4Δ7,10,13,16) 
0.0294 
0.841 
-0.0725 
0.621 
0.0540 
0.715 
a
 Number of carbons:degree of unsaturation 
b 
Correlation coefficient 
c
 p-value  
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Figure 4.27.  Distribution of 12:0 between disease states for 
combined neurological regions (normal control (NC), mild 
cognitive impairment (MCI), preclinical AD (PCAD) late-
stage AD (LAD) and disease control (DC)).  Significant 
differences (p<0.05) between disease states, compared to NC, 
are depicted by *. 
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Figure 4.29.  Distribution of 14:0 between disease states for 
combined neurological regions (normal control (NC), mild 
cognitive impairment (MCI), preclinical AD (PCAD) late-
stage AD (LAD) and disease control (DC)).  Significant 
differences (p<0.05) between disease states, compared to 
NC, are depicted by *. 
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Figure 4.31.  Distribution of 15:0 between disease states for 
combined neurological regions (normal control (NC), mild 
cognitive impairment (MCI), preclinical AD (PCAD) late-
stage AD (LAD) and disease control (DC)).  Significant 
differences (p<0.05) between disease states, compared to 
NC, are depicted by *. 
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Figure 4.33.  Distribution of 16:1 between disease states for 
combined neurological regions (normal control (NC), mild 
cognitive impairment (MCI), preclinical AD (PCAD) late-
stage AD (LAD) and disease control (DC)).  Significant 
differences (p<0.05) between disease states, compared to NC, 
are depicted by *. 
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Figure 4.35.  Distribution of 16:0 between disease states for 
combined neurological regions (normal control (NC), mild 
cognitive impairment (MCI), preclinical AD (PCAD) late-
stage AD (LAD) and disease control (DC)).  Significant 
differences (p<0.05) between disease states, compared to 
NC, are depicted by *. 
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Figure 4.37.  Distribution of P 16:0 between disease states 
for combined neurological regions (normal control (NC), 
mild cognitive impairment (MCI), preclinical AD (PCAD) 
late-stage AD (LAD) and disease control (DC)).  Significant 
differences (p<0.05) between disease states, compared to 
NC, are depicted by *. 
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Figure 4.39.  Distribution of 17:0 between disease states for 
combined neurological regions (normal control (NC), mild 
cognitive impairment (MCI), preclinical AD (PCAD) late-
stage AD (LAD) and disease control (DC)).  Significant 
differences (p<0.05) between disease states, compared to 
NC, are depicted by *. 
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Figure 4.41.  Distribution of 18:2Δ9,12 between disease 
states for combined neurological regions (normal control 
(NC), mild cognitive impairment (MCI), preclinical AD 
(PCAD) late-stage AD (LAD) and disease control (DC)).  
Significant differences (p<0.05) between disease states, 
compared to NC, are depicted by *. 
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Figure 4.43.  Distribution of 18:1Δ9 between disease states 
for combined neurological regions (normal control (NC), 
mild cognitive impairment (MCI), preclinical AD (PCAD) 
late-stage AD (LAD) and disease control (DC)).  
Significant differences (p<0.05) between disease states, 
compared to NC, are depicted by *. 
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Figure 4.45.  Distribution of 18:1Δ10 between disease 
states for combined neurological regions (normal control 
(NC), mild cognitive impairment (MCI), preclinical AD 
(PCAD) late-stage AD (LAD) and disease control (DC)).  
Significant differences (p<0.05) between disease states, 
compared to NC, are depicted by *. 
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Figure 4.47.  Distribution of 18:0 between disease states for 
combined neurological regions (normal control (NC), mild 
cognitive impairment (MCI), preclinical AD (PCAD) late-
stage AD (LAD) and disease control (DC)).  Significant 
differences (p<0.05) between disease states, compared to 
NC, are depicted by *. 
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Figure 4.49.  Distribution of P 18:1a between disease states 
for combined neurological regions (normal control (NC), 
mild cognitive impairment (MCI), preclinical AD (PCAD) 
late-stage AD (LAD) and disease control (DC)).  Significant 
differences (p<0.05) between disease states, compared to 
NC, are depicted by *. 
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Figure 4.51.  Distribution of P 18:1b between disease states 
for combined neurological regions (normal control (NC), 
mild cognitive impairment (MCI), preclinical AD (PCAD) 
late-stage AD (LAD) and disease control (DC)).  Significant 
differences (p<0.05) between disease states, compared to 
NC, are depicted by *. 
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Figure 4.53.  Distribution of P 18:0 between disease states 
for combined neurological regions (normal control (NC), 
mild cognitive impairment (MCI), preclinical AD (PCAD) 
late-stage AD (LAD) and disease control (DC)).  
Significant differences (p<0.05) between disease states, 
compared to NC, are depicted by *. 
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Figure 4.55.  Distribution of 20:4Δ5,8,11,14 between 
disease states for combined neurological regions (normal 
control (NC), mild cognitive impairment (MCI), 
preclinical AD (PCAD) late-stage AD (LAD) and disease 
control (DC)).  Significant differences (p<0.05) between 
disease states, compared to NC, are depicted by *. 
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Figure 4.57.  Distribution of 20:3Δ8,11,14 between disease 
states for combined neurological regions (normal control 
(NC), mild cognitive impairment (MCI), preclinical AD 
(PCAD) late-stage AD (LAD) and disease control (DC)).  
Significant differences (p<0.05) between disease states, 
compared to NC, are depicted by *. 
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Figure 4.59.  Distribution of 22:6Δ4,7,10,13,16,19 
between disease states for combined neurological regions 
(normal control (NC), mild cognitive impairment (MCI), 
preclinical AD (PCAD) late-stage AD (LAD) and disease 
control (DC)).  Significant differences (p<0.05) between 
disease states, compared to NC, are depicted by *. 
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Figure 4.61.  Distribution of 22:4Δ7,10,13,16 between 
disease states for combined neurological regions (normal 
control (NC), mild cognitive impairment (MCI), 
preclinical AD (PCAD) late-stage AD (LAD) and disease 
control (DC)).  Significant differences (p<0.05) between 
disease states, compared to NC, are depicted by *. 
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way ANOVA on ranks, for non-normally distributed data.  Significance was established 
by a Tukey post hoc test or Dunn’s test, if treatment groups were unequal in number. 
Comparisons were limited to equivalent fatty acids between brain regions and/or 
disease states, i.e. 12:0 NC (CER) vs. 12:0 NC (IPL) or 12:0 NC (CER) vs. 12:0 MCI 
(CER).  Significant differences (p<0.05) across disease states, within a particular or 
combined brain region, compared to NC for that region are depicted by *.  Significant 
differences (p<0.05) within equivalent disease states, across distinct brain regions 
compared to CER, are depicted by ‡.  Results of statistical analysis from each lipid 
species will be discussed in the subsequent paragraphs. 
Dodecanic acid (12:0) from disease control (DC) patients exhibited a significantly 
higher abundance within CER compared to other neuropathological demographics and 
regions (Figure 4.28).  The overall distribution of 12:0 for DC patients was dominated by 
the CER region (Figure 4.27).  Because of this disparity in 12:0, the three regional graphs 
are presented with different y-axes (Figure 4.28).  Dodecanic acid did not differ 
significantly from NC for the other two regions: IPL or SMTG.   
In contrast, tetradecanoic acid (14:0) and pentadecanoic acid (15:0) showed no 
statistical differences among disease states for combined regions (Figures 4.29 & 4.31).  
There were however a number of outliers across disease states for each FA species.  
Tetradecanoic acid demonstrated significant increases for NC patients in IPL and MCI 
subjects in SMTG, compared to CER levels (Figure 4.30).  Pentadecanoic acid displayed 
significant increases for LAD and DC in SMTG (Figure 4.32).  In addition pentadecanoic 
acid exhibited a negative correlation to Braak score, although no correlation was found 
for NP (Table 4.13). 
Overall, results for 9-hexadecenoic acid (16:1Δ9) were not significantly different 
for disease states when evaluated for the combined regions (Figure 4.33).  As with the 
two species prior, data from the combined regions yielded a number of outliers.  Results 
from individual regions for 9-hexadecenoic acid, both PCAD and LAD showed a 
significant increase compared to NC for CER (Figure 4.33).  In addition, CER quantities 
of 16:1Δ9 from NC subjects were appreciably lower than SMTG and IPL data.   
The global profile of hexadecanoic acid revealed that NC had a significantly 
lower abundance than all other disease states (Figure 4.35).  When the data was arranged 
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by region NC mitochondria were significantly lower in 16:0 than PCAD and LAD in 
CER, PCAD in IPL and MCI subjects from SMTG (Figure 4.36).  Data from MCI 
patients indicate a significant increase for 16:0 in SMTG.    
Quantitation of the dimethyl acetal of hexadecan-1-al, the product of 1-enyl-
hexadecenoic acid (P 16:0) from the combined mitochondrial pool was nearly uniform 
across disease states (Figure 4.37).  The regional analysis was similar with only LAD and 
DC exhibiting a significant increase in SMTG over CER (Figure 4.38).  Also, worth 
noting is that NC patients displayed a lower abundance of P 16:0 in each region, with the 
only exception of PCAD in SMTG. 
Results for heptadecanoic acid (17:0), appear almost identical to P 16:0.  The 
combined profile was nearly even across patient demographics (Figure 4.39).  Only  
significant increases in SMTG for late-stage AD and disease control patients over their 
corresponding CER levels were found (Figure 4.40).   
The overall abundance of 9,12-octadecadienoic or linoleic acid (18:2Δ9,12) did 
not change throughout the disease profile (Figure 4.41).  However, when data were 
analyzed by region, differences were present.  A significant difference was established 
for preclinical AD patients in cerebellum compared to normal control.  Also, normal 
control, mild cognitive impairment, late-stage AD and disease control subjects displayed 
a significant increase in SMTG linoleic abundance over their corresponding CER 
abundances (Figure 4.42).  Overall, PCAD subjects displayed higher levels of 18:2Δ9,12 
in CER and lower in SMTG than all other sample groups. 
Data from the two octadecanoic unsaturated fatty acids (18:1Δ9 & 18:1Δ10) 
displayed similar profiles amongst disease states and regions.  Normal control patients 
exhibited a lower combined regional abundance of both 9-octadecenoic (18:1Δ9) and 10-
octadenoic (18:1Δ10) than all other states (Figures 4.43 & 4.45).  This overall decreased 
abundance was statistically significant for MCI, PCAD and LAD subjects for 18:1Δ9 
(Figure 4.43) and for LAD patients for 18:1Δ10 (Figure 4.45).  Within CER 18:1Δ9 and 
18:1Δ10 were significantly lower for NC compared to PCAD and LAD (Figure 4.44).  
Mild cognitive impairment subjects had a significant increase in abundance within 
SMTG (Figure 4.44).  Normal control 10-octadenoic acid was also significantly increased 
in IPL compared to CER. 
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Octadecanoic acid (18:0) was found to be significantly higher with SMTG of MCI 
subjects compared to NC and other regions (Figure 4.48).  Mitochondria from NC 
patients had significantly lower amounts of 18:0 than IPL or SMTG, in addition to PCAD 
and LAD within CER.  The combined mitochondrial profile for 18:0 displayed 
significant increases from NC levels for MCI and LAD (Figure 4.47). 
The two unsaturated plasmalogen species, 1-enyl-1,-octadecadienoic acids (P 18:1 
a&b) exhibited similar profiles with neurological mitochondria.  Both were equally 
distributed among disease states when compared as a composite of regions (Figures 4.49 
& 4.51).  However, data from individual regions provided slight distinction.  Plasmalogen 
18:1a (P 18:1a) displayed significant differences in SMTG compared to CER for NC, 
MCI, LAD and DC patients (Figure 4.50).  Likewise, plasmalogen 18:1b (P 18:1b) had 
increases within SMTG for LAD and DC samples (Figure 4.52).  No significant changes 
were found in CER or IPL across disease states.   
The long-chain saturated plasmalogen species 1-enyl-octadecenoic acid (P 18:0) 
global expression found significant increases in PCAD, LAD and DC mitochondria 
compared to NC quantities (Figure 4.53).  The regional distribution revealed significant 
increases in PCAD and LAD mitochondria in cerebellum and LAD samples from inferior 
parietal lobule (Figure 4.54).  Superior and middle temporal gyri contained significantly 
higher quantities of P 18:0 for NC compared to CER.    
Arachidonic acid (ARA) or 5,8,11,14-eicosatetraenoic (20:4Δ5,8,11,14) globally 
had a significant increase for LAD mitochondria compared to NC (Figure 4.55).  The 
regional distribution of arachidonic acid found that SMTG contained a significant 
increase in 20:4 abundance for NC, MCI and DC over their respective CER quantities 
(Figure 4.56).  In addition PCAD and LAD subjects had a significant increase in ARA 
within CER tissue. 
The comprehensive distribution of 8,11,14-eicosatrienoic acid (20:3Δ8,11,14) 
within neurological mitochondria was consistant over disease states (Figure 4.57).  
Significant increases within the SMTG were found for LAD and DC patients compared 
to CER levels (Figure 4.58).   
As a whole the allocation of 4,7,10,13,16,19-docosahexaenoic acid or DHA 
(22:6Δ4,7,10,13,16,19) between disease states was uniform for combined regions (Figure 
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4.59).  Comparison of the areas led to several interesting observations (Figure 4.60).  
Within the cerebellum NC and DC mitochondria had the lowest DHA levels.  Among the 
three AD disease stages, MCI was slightly lower than LAD and both of these were less 
than preclinical AD subjects, which was significantly higher than NC.  The CER graph 
shape gives the appearance of a broad bell-curve.  Data from SMTG was nearly the 
inverse of the CER profile.  Preclinical subjects had the lowest detected DHA which was 
significantly lower than respective CER levels, followed closely by LAD, then DC and 
NC.  The MCI cases contained greater amounts of DHA than expected by this trend, 
however the increase was not significant.   
Finally, 7,10,13,16-docosatetraenoic or adrenic acid (22:4Δ7,10,13,16) was 
detected in lower quantities, for each disease state, within the CER and IPL than in 
SMTG (Figure 4.62).  In fact, with the exception of PCAD all other states had 
significantly higher adrenic acid quantities in SMTG compared to their analogous CER 
levels.  The inclusive comparison of the three regions found that only LAD patients were 
significantly different, lower, than NC (Figure 4.61).   
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Chapter 4.4.  Discussion 
The electron transport chain (ETC), housed in the mitochondrial membrane, is 
vital for cellular energy production.  Electrons leaking from mitochondria are the greatest 
source of ROS within a cell, thus mitochondria are the suspected cause and a potential 
target of oxidative stress.  Oxidative stress, a hallmark of many neurodegenerative 
diseases, leads to the development of ROS.  Common targets for ROS are lipid 
components, namely polyunsaturated fatty acids (PUFAs).  The high oxygen 
consumption rate of neurological cells and comparatively low levels of antioxidant 
capacity would be expected to cause compensatory changes to the fatty acid profile in 
order to minimize susceptibility to oxidative damage.  Neurological tissue has been 
reported to have an increased abundance of polyunsaturated fatty acids, namely 
docosahexaenoic acid (DHA) [118, 120, 132, 145].   
 Diversity in the mitochondrial fatty acid (FA) profile, could lead to a variety of 
innate responses as a consequence of detrimental ROS generated in vivo.  The previously 
conducted study with Sprague Dawley rats focused on a comparison of the mitochondrial 
membrane composition between tissues provided evidence of increased neurological 
susceptibly to ROS.  The appearance of unique PUFAs species in brain mitochondria 
provided greater potential susceptibility to ROS.   
  This project was designed to explore the variation in the mitochondrial fatty acid 
profile as a function of both disease progression and neurological region.  Subjects were 
chosen to represent four distinct groupings of AD pathology as determined by the 
University of Kentucky Alzheimer’s Disease Center (UK-ADC).  Demographics for AD 
samples consisted of mild cognitive impairment (MCI), preclinical Alzheimer’s disease 
(PCAD) and late-stage Alzheimer’s disease (LAD) patients.  Two additional sample 
populations, age-matched normal control (NC) and diseased control (DC) were added.  
Disease control were comprised of dementia with Lewy body disease (DLB) and 
frontotemporal dementia (FTD) patients.  The rationale for the DC demographic was to 
provide further confirmation that changes to the mitochondrial FA profile were specific 
to AD pathology.  
 
 
Tissue specimens from the superior and middle temporal gyri (SMTG), inferior 
parietal lobule (IPL), and cerebellum (CER) were collected from each patient employed 
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in the study.  The three regions were selected to provide distinct locales with differing 
neurological function that displayed various degrees of AD pathology during disease 
progression.  Cerebellum is the region that regulates the integration of sensory 
perception, coordination and motor control.  It displays minimal pathology throughout 
the AD pathology spectrum.  Data from the CER provides a comparison of lipid 
composition in an unaffected region across disease states and affected regions.  The 
inferior parietal lobule is involved in integration of sensory information functions.  
Typically the IPL shows little pathology, except during late-stage disease profiles.  
Lastly, the superior and middle temporal gyri are the most affected regions of the three 
studied.  The SMTG contains subdivisions involved in processing sound and visual 
cognition.  It displays pathology early in AD progression, frequently during the MCI 
stage.  
Subject neuropathological demographics 
Statistical comparison of subject demographic data provided a basis for distintion 
between the populations (Table 4.1).  Results from the one way ANOVA on the average 
age of subjects determined that no statistical differences existed between AD states 
compared to NC.  Age matching was carried out to eliminate age as a potential variable, 
thus isolating differences to disease state or region.  The diseased control subjects were 
found to be significantly younger (p<0.001) than the other neuropathological states 
studied.  This result is not entirely unanticipated, since on set of Lewy body disease 
(DLB) and frontotemporal dementia (FTD) occurs at a younger age than AD [154, 159].  
The post-mortem interval (PMI) data from each subject group showed no 
statistical differences between any of the samples, as determined by one way ANOVA.  
The PMI is critical because as the time interval between demise and autopsy increases 
degradation of biological analytes would be expected to occur.  As with age, eliminating 
differences in PMI assists in isolating justification for differences between subjects. 
 Statistical comparison of the median Braak scores and neuritic plaques (NP) 
counts among the disease states, imparted the main distinction between the subjects.  
Both features are used in the neuropathological classification of patients within the 
disease spectrum.  Therefore, it would be expected that both Braak scores and NP counts 
would be statistically different between disease states.  Braak scores are a measure of 
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intraneuronal neurofibrillary tangles (NFT) which are enriched in hyperphosphorylated 
tau [103].  Due to Braak scores being presented as median values, statistical analysis 
required the non-parametric Kruskal-Wallis one way ANOVA on ranks with a Dunn’s 
method post hoc test to establish significance.  Both NC and DC groups were 
significantly lower (p<0.05) than MCI, PCAD and LAD states.  This reaffirms that NC 
and DC contained less NFT pathology than later states.  
 Average neuritic plague (NP), or senile plaque (SP), counts were compared across 
disease states for IPL and SMTG regions, data for NP from CER were not available.  
Plaques are extracellular aggregates composed mainly of amyloid beta peptide (Aβ) 
resulting from the proteolytic cleavage of amyloid precursor protein (APP) [103].  Plaque 
counts were compared statistically, across disease states for SMTG and IPL, by one way 
ANOVA with a Tukey post hoc test to establish significance.  The inferior parietal lobule 
had a significant increase (p<0.001) in NP for LAD compared to all other disease states.  
This result confirms the notion that the IPL typically only displays AD pathology in late-
stage patients.  For SMTG the LAD samples had a significant increase (p<0.001) in NP 
compared to NC, PCAD and DC; however, comparison to MCI samples resulted in only 
a p<0.05 significant increase.  The results from SMTG confirm that this area is affected 
earlier in the pathogenesis of AD.  The highly significant difference (p<0.001) for NC 
and DC reinforces the concept that these demographics display minimal pathology 
associated with AD.  A lower level of significance found for MCI patients substantiates 
the idea that this stage is a critical marker between normal aging and rapid disease onset.  
Correlation tests     
Pearson product-moment correlation tests conducted on subject demographics 
compares the linear relationship between two variables.  The Pearson product-moment 
test allows a statistical measure of correlation between two variables without regard to 
variable dependence.  The advantage with this approach is that any relationship of 
correlation is symmetrical with regard to the axis.  In other words, establishment of 
variable dependence and independence is not required or calculated.  The disadvantage is 
that correlation statistics cannot determine the cause-and-effect of two variables.  Even 
though cause-and-effect statistics, through regression analysis, would be advantageous it 
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requires prior knowledge of variable dependence.  This would require further testing, 
such as with oxidative insults resulting in a subsequent change in fatty acid profile. 
Pearson product-moment correlation tests were performed on the subject 
population as a whole, segmented by region (Tables 4.10-4.12).  Calculations compared 
the variables of age, Braak score and neuritic plaques (NP).  For all three regions (CER, 
IPL and SMTG) no correlations were found between age and Braak score or NP.  Note, 
no data was available on NP from CER, therefore only Braak score was tested for this 
region.  No relationship was found between age and the two AD pathology markers is the 
result of age-matched normal control subjects.  As determined previously, the NC 
patients displayed no statistical difference in age between other patient demographics, but 
were statistically different (at least p<0.05) in Braak score and NP counts. 
 Patient data concerning Braak score and NP, from SMTG and IPL, found a strong 
positive correlation (p<3x10
-9
) between these two variables.  Being markers of AD 
progression, it is reasonable that these two variables would show a positive correlation.   
 Pearson product-moment correlation tests were also conducted on individual 
mitochondrial fatty acid methyl esters isolated from each region (Tables 4.13-4.15).  
Lipid species were tested for possible correlations to age, Braak score and NP (SMTG 
and IPL only) variables.  Results from these statistical tests will be discussed later 
alongside results from fatty acid distribution and disease state analyses. 
Mitochondria isolation 
To conduct studies of mitochondrial lipidomics from human tissue, required the 
development of an isolation procedure resulting in high-purity mitochondria in 
considerable yields.  There are numerous procedures for the isolation of mitochondria 
from tissue, which are mainly built around a foundation of mitochondrial isolation 
through differential centrifugation [109, 111-112, 114, 160-161].  The predominant 
differences between these procedures are generally variations to the isolation buffer, 
centrifugation times/speeds, and the type/percentages of density gradients utilized.  The 
majority of these techniques utilize a rapid isolation of mitochondria for enzymatic 
studies, sacrificing purity for viability needed for respiration based studies.  However, 
lipidomic based studies for this particular project required purity over viability.  
Therefore, the initial focus of the project was to adapt several previously established 
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isolation methods, maintaining the yields, while improving the purity, of mitochondria 
from a single neurological tissue section [109, 111-112, 114, 160].     
The tissue to buffer ratio employed during the initial homogenization was found 
to be important for maximizing mitochondria recoveries and minimizing contamination.  
A weight-to-volume ratio of less than 10% led to lower than expected recoveries, 
primarily believed to be the result of insufficient tissue homogenization or loses during 
the initial low-speed centrifugation steps.  Following the first low-speed centrifugation, 
re-homogenization of the nuclear pellet and a subsequent second low-speed 
centrifugation minimized possible mitochondrial loses.  Contamination of the 
mitochondria isolate, due to residual nuclear material, was ultimately removed by means 
of a third low-speed spin following crude mitochondrial isolation.   
 The use of two separate Percoll solutions, as opposed to a single discontinuous 
Percoll gradient traditional used in other procedures [109, 111-112, 114], provided a 
mitochondrial pellet instead of bands.  Formation of discrete Percoll interfaces by 
layering various percentage solutions can be problematic.  Failure to form sharp 
boundaries will ultimately reduce yields due to diffusion of bands.  The advantages of the 
proposed method and using two separate centrifugation steps each with a single Percoll 
concentration are that recoveries are not dependent on generation of sharp interfaces and 
formation of a mitochondrial pellet aids in the removal of excess Percoll which may 
hinder subsequent washing steps.  This approach was thought to aid in mitochondria 
recoveries, as formation of and removal of mitochondrial bands from between discrete 
Percoll interfaces can be problematic.   
The proposed method does not segregate synaptic and non-synaptic mitochondria 
isolation, however the procedure can easily be modified to accommodate this necessity.   
A 28% Percoll gradient can be run instead of a 19% to separate the two mitochondria 
species.  Upon centrifugation (19,600xg, 10 min) the non-synaptic mitochondria will 
form a pellet, while the synaptic mitochondria will remain in suspension, immediately 
below the myelin layer.  Synaptic mitochondrial isolation would proceed from the 
digitonin treatment step; whereas non-synaptic mitochondrial isolation could be finalized 
by washing with PBS. 
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Instead of necessitating different procedures based on the tissue wet weight, the 
developed method is directly applicable to a variety of tissue quantities [109, 114].  An 
additional advantage is the formation of a mitochondrial pellet during the Percoll steps 
that facilitate the utilization of smaller tissue quantities without incurring losses due to 
diffusion within a band.  Although the developed method herein may require additional 
centrifugation steps, over previously described separation procedures the increased 
isolation purity was necessary for lipidomic based studies [109, 111-112, 114, 160-161]. 
Fatty acid structure analysis 
Elucidation of unsaturation sites along the fatty acid backbone through 
transesterification to picolinyl esters was critical to understanding changes to 
mitochondrial fatty acids with AD progression.  The oxidative stress model of 
neurodegenerative disease correlates the generation of reactive oxygen species (ROS) and 
subsequent ROS mediated oxidative damage to the degradation of cellular 
biomacromolecules, especially lipids, during disease pathogenesis.  Current research has 
indicated that products of lipid peroxidation are dependent upon the sites of unsaturation 
[153].  The principal unsaturation site critical to determining the reactive aldehyde 
species generated from lipid peroxidation appears to be the omega (ω) double bond [119, 
131, 162].  The omega (ω) designation signifies the position of the furthermost double 
bond relative to the carbonyl group, or the most terminal site. 
Derivatization reactions to fatty acid picolinyl ester were successful in allowing 
the full elucidation of unsaturation sites from the mitochondrial fatty acid profile.  As 
previously determined the lipid profile of neurological mitochondria from Sprague 
Dawley rats, human mitochondria displayed an analogous lipid profile.  This is most 
apparent when comparing the relative distributions among the oleic acid series.  
Neurological mitochondria displayed a lower ratio of 9,12-octadecadienoic acid 
(18:2Δ9,12) to 9-octadecenoic acid (18:1Δ9) compared to other tissues.   
More relevant to the oxidative stress model of lipid peroxidation were data 
acquired on the unsaturation sites from polyunsaturated fatty acids (PUFAs).  Due to the 
increased functionality imparted from the double bond, these sites have increased 
vulnerability to ROS mediated oxidative damage.  The increase in unsaturation index for 
PUFAs, as a result of multiple double bonds, designates examination these species 
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critical to understanding the relationship between lipids, oxidative damage and products 
of oxidative stress. 
The mass spectrum for the picolinyl ester of 5,8,11,14-eicosatetraenoic acid 
(arachidonic acid, 20:4Δ5,8,11,14) illustrates a typical spectrum for an ω-6 fatty acid 
(Figure 4.12).  Interpretation of the spectrum reveals that the first gap of -26 amu from 
the molecular ion occurs at m/z 324.  The mass difference between the molecular ion and 
m/z 324 is 71 amu, which translates to loss of the terminal methyl group (15 amu) and 4 
methylene groups (14 amu).  Thus the ω-6 family of PUFAs has an unsaturation site 
beginning six carbons from the terminal methyl group.   
As with picolinyl arachidonate, the spectra from the picolinyl esters of 8,11,14-
eicosatrienoic acid (20:3Δ8,11,14) and 7,10,13,16-docosatetraenoic acid 
(22:4Δ7,10,13,16) provide fragmentation indicative of ω-6 fatty acids.  For eicosatrienoic 
acid the ω-6 double bond is revealed with the -26 amu gap between m/z 326 to m/z 300 
(Figure 4.13).  In actuality, the spectrum from picolinyl 8,11,14-eicosatrienoate is very 
similar to the spectrum from picolinyl arachidonate, the mass units are just shifted up two 
mass units to account for the lack of a double bond at the 5 position.  The spectrum for 
picolinyl 7,10,13,16-docosatetraenoate again displays an ω-6 pattern through loss -40 
amu from m/z 352 to m/z 312 (Figure 4.15). 
In total, three of the four mitochondrial long-chain PUFAs are comprised of three 
ω-6 fatty acids, with the only differing lipid being 4,7,10,13,16,19-docosahexaenoic acid 
(22:6Δ4,7,10,13,16,19).  The picolinyl docosahexaenoate spectrum indicates that the 
farthest double bond on carbon 19 results in the loss of 26 amu from m/z 390 to m/z 364 
(Figure 4.14).  Docosahexaenoic acid, a member of the ω-3 fatty acid family, is a chief 
component of neurological cellular membranes.  The increased proximity of the furthest 
double bond to the terminal methyl group imparts unique physical properties compared to 
ω-6 fatty acids. 
Fatty acid profile analysis 
Normality test 
The distribution of lipid species amongst each disease demographic was subjected 
to Shapiro-Wilk’s normality statistical test to analyze if the data diverges appreciably 
from a population with a normal Gaussian distribution.  Shapiro-Wilk’s normality tests 
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were conducted as a function of disease state for each individual neurological region: 
CER (Table 4.3), IPL (Table 4.4) and SMTG (Table 4.5).   
The distribution of short-chain FAs, 12:0-16:1Δ9, within the cerebellum for 
PCAD patients was overwhelming non-normally distributed (Table 4.3).  The analyte 
distributions of other disease states from cerebellum mitochondria exhibited only 
sporadic non-normal populations.   These data indicate that the lipid compositions of 
CER mitochondria PCAD subjects displayed a wide distribution of shorter chain FAs.  
Analytical reasons for these non-normal distributions might be due to minor variations in 
peak area between low abundant FA species.  These minor differences in area counts 
result in an exaggerated relative distribution.  A biological explanation for the non-
normal distribution might be rooted in the disease state designation of PCAD subjects.  
With proposed theory that PCAD might represent a prodromal stage in disease 
progression the PCAD population would be expected to exhibit a range of lipid variation.  
 The inferior parietal lobule (IPL) displayed the greatest number of non-normally 
distributed fatty acids across each of the disease states (Table 4.4).  The rationale for this 
might be that patient-to-patient variability of mitochondrial lipid composition is greater 
for this particular region, in contrast to CER.  The homogeneity found in CER FAs could 
possibly be the basis for the CER being largely immune from AD pathology. 
 Lastly, data from superior and middle temporal gyri exhibits the greatest degree 
of normally distributed FAs throughout each of the disease states, when compared to the 
other two regions (Table 4.5).  Analytically these results might be explained that most FA 
species displayed greater abundance in the SMTG that the other regions.  Therefore, 
minor differences in peak areas would not create large relative deviations between 
samples.  Of course a biological rational might be that the lipid composition of the SMTG 
is conserved compared to CER or IPL.  
Mitochondrial fatty acid compositions were also analyzed for normality as a 
composite of neurological areas (CER, SMTG and IPL) divided by the various disease 
states (Table 4.2).  The principle reason for presenting the data in this manner was to 
examine the distribution of FAs across the three regions within each disease state.  
Among this data there are two unique situations that deserve note.  The first being, FAs 
that were found to be non-normally distributed across the three regions, however data 
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from the individual regions indicated a normal distribution.  These data suggests that the 
region-to-region variability is great enough to create a multimodal distribution.  These 
lipid species are designated by † (Table 4.2).  The second unique situation, FAs that were 
normally distributed across the combined three regions, however regional data indicates 
that one or more regions were non-normally distributed.  This would imply that normality 
was unbalanced among the regions by outliers, and distributions from the additional 
regions fostered unification of the data.  Species falling into this category are denoted by 
# (Table 4.2). 
The inconsistent results from the Shapiro-Wilk’s normality tests indicate that this 
statistical treatment is best suited as a test for population distributions that would 
determine the use of non-parametric or parametric during further statistical analysis.  
Unfortunately, the results of normality testing does not indicate designation of disease 
state, proliferation of AD or degree of disease pathology by oxidative damage. 
Skewness test 
The interpretation of skewness data for the combined regions means that NC 
subjects contained higher-value outliers.  A change in positive to negative skewness, 
across the disease profile, implies that the outlier population is shifting causing it to occur 
above or below the mean, respectively.   
Data for IPL from each disease grouping was compared to CER data from the 
equivalent disease state.  As might be expected the two states with the most pronounced 
disease pathology, PCAD and LAD, exhibit the majority of deviations from the CER.  
The FA profile from the superior and middle temporal gyri (SMTG) exhibited a shift in 
skewness, especially because it occurs between NC and later disease stages might 
indicate a change in the mean for the disease population. 
Overall the statistical importance of skewness provides a measure of symmetry 
around a population mean.  A dramatic change in skewness polarity when compared 
across the disease states does indicate a shifting population mean.  As with normality, the 
skewness value does not impart evidence of lipid peroxidation or degradation.  Therefore, 
care must be taken not to over interpret the data as a diagnostic tool of disease 
progression.  The importance of the test however, allows evaluation of the sample 
population as a whole.   
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Fatty acid distribution and disease state analysis 
Methyl derivatizied species were treated as individual analytes, 18 in total, and 
subjected to a variety of statistically treatments.  The purpose of evaluating the lipid 
species by exhaustive statistics was an attempt to determine differences between disease 
groups or neurological regions.  In addition correlation tests were conducted in an effort 
to rationalize changes in relation to neuropathology markers.  The culmination of the 
project comes down to the comparison of fatty acids regionally and between disease 
states.  The statistical treatments employed either a parametric one way ANOVA, for 
normally distributed data as established by Shapiro-Wilk normality test; or a non-
parametric Kruskal-Wallis one way ANOVA on ranks, for non-normally distributed data.  
Significance was established by a Tukey post hoc test when comparing regional 
distributions for a particular disease state.  Dunn’s test established significance was used 
when comparing disease states within a region because treatment groups were unequal in 
number.  Discussion of regional, distribution and correlation statistical results from select 
lipid species analyzed will be covered in the subsequent paragraphs. 
The overwhelming abundance of dodecanoic acid (12:0) in CER of DC patients 
imparted a unique mitochondrial FA profile.  The lack of outliers within this particular 
sample set designates that patients, at least from this sample population, exhibiting Lewy 
body pathology have a significantly different mitochondrial FA profile than found with 
any demographic or region contained in this study.  This disproportion in CER resulted in 
a negative correlation between 12:0 vs. age and Braak score.  This correlation is likely 
due to DC patients having a slightly lower age than other subjects and lower Braak score 
than subjects with AD pathology.   
9-Hexadecenoic acid (16:1Δ9) is the shortest-chain unsaturated fatty acid detected 
in mitochondria.  A positive correlation was found in CER between 16:1Δ9 and Braak 
score, in addition to a negative correlation in SMTG with age.  These random, albeit 
statistically significant, correlations are probably the consequence of minor fluctuations 
within the sample population. 
Hexadecanoic or palmitic acid (16:0) is one of the most abundance lipids in the 
mitochondrial membrane.  It is the primary substrate used during desaturation and 
elongation reactions in the synthesis of other fatty acids [15].  Correlation statistics 
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established a positive link between 16:0 and Braak score in CER in addition to Braak 
score and NP in IPL.  These correlations are likely to be the result of significant increases 
in 16:0 from MCI, PCAD and LAD patients within various regions.  It is interesting that 
both 16:0 and 16:1Δ9 were in lower abundance for CER mitochondria from NC subjects.     
 Linoleic or 9,12-octadecadienoic acid (18:2Δ9,12) is a precursor for synthesis of 
long chain PUFAs.  As shown in the previous study (Chapter 3) neurological 
mitochondria contain a lower percentage of this particular fatty acid than other tissues 
studied.  The significant increase in 18:2Δ9,12 with SMTG mitochondria for every 
population demographic, except PCAD, is worth noting.  This is important because it 
relates to the potential for PUFAs synthesis.  An increase in 18:2Δ9,12 substrate could 
signify an alteration in the need for PUFAs within this region.  Preclinical AD subjects 
were found to have a significant increase in CER mitochondria, and a non-statistically 
significant decrease in SMTG mitochondria.  It is interesting that the two regions (CER 
and SMTG) at opposite ends of the AD pathology scale exhibited such dissimilarity in 
18:2Δ9,12 content, whereas IPL levels were seemingly unchanged.  However, if a 
reduction in 18:2Δ9,12 was linked to AD pathology in SMTG, presumably LAD patients 
would be expected to display similar results to PCAD.   The only correlation calculated 
was within CER between Braak score.    
The two octadecenoic fatty acids (18:1Δ9 and 18:1Δ10) exhibited similar 
distributions among disease populations within equivalent regions.  This might not be too 
surprising as a shift in one carbon for the double bond wouldn’t be expected to impart 
drastically different physical characteristic to the membrane.  The importance of 18:1 
fatty acids within the mitochondrial membrane is due to their association as fatty acids 
found in the cardiolipin backbone [163-167].  Cardiolipin is a class of lipid exclusively 
synthesized in the inner mitochondrial membrane and is believed to be involved in 
stabilizing membrane bound proteins involved in the ETP [168-170].  In addition, 
proteomic studies conducted on phospholipases, which function to directly regulate 
phospholipid concentrations, have documented an increased expression in mitochondrial 
fractions with progression of AD [171-174].  Furthermore, activity of phospholipase D 
has been implemented in being linked to amyloid precursor protein, which is the 
progenitor to amyloid beta (Aβ) [172-173, 175].  Current research has reported a 
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connection with lipid expression that indicates phospholipase D activity is in part 
regulated by oleic acid (18:1Δ9) [174].  An interesting distinction between the two is that 
10-octadecenoic acid was found to have a positive correlation to both Braak score and NP 
within the IPL. 
Results from the analysis of octadecanoic or stearic acid (18:0) were similar to 
those from the 18:1 fatty acids.  Again, this might not be entirely surprising due to the 
fact that 18:0 is substrate for both 18:1Δ9 and 18:1Δ10 syntheses.  As with the other 18-
length carbon fatty acids, stearic acid showed a positive correlation with Braak score 
within CER.  This is probably the consequence of CER levels for NC which were 
significantly lower than IPL and SMTG measurements and lower than PCAD and LAD 
CER samples.   
Finally, the two groups of lipid species to be discussed are the plasmalogens and 
polyunsaturated fatty acids (PUFAs).  These two groups represented a great deal of the 
literature concerned with the intersection of lipids and health.  Plasmalogens are of 
interest because they are considered to be inherent anti-oxidants of biological 
membranes, providing protection for PUFAs [16, 121-122, 136, 176].  Polyunsaturated 
fatty acids are of equal interest because of their susceptibility to ROS and the deleterious 
products formed from subsequent reactions [116-117, 119, 162, 177-178].  Because of 
PUFAs and plasmalogens presumed roles within the reactions oxidative damage 
comparison of these species across disease states and neurological regions is central to 
understanding changes in mitochondrial membrane components.      
First, a discussion of the various plasmalogen species results.  With regard to 
CER and IPL plasmalogens 16:0 and 18:1 a&b exhibited similar distributions among the 
disease states.  No statistically significant changes were found between the regions or 
compared to NC quantities within a region.  These results when viewed from the 
standpoint of plasmalogens role as anti-oxidants are not surprising being in two regions 
of limited pathology.  The last plasmalogen species, P 18:0, had a slightly different 
profile.  On the whole quantities of 1-enyl-octadecenoic acid (P 18:0) were greater in 
SMTG for each population compared to CER and IPL mitochondria.  In contrast to the 
other plasmalogens there was a slight increase of P 18:0 from NC to LAD subjects.  This 
increase was found to be significant for PCAD and LAD in CER and LAD in IPL.  A 
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positive correlation to Braak score within CER was probably a consequence of this 
increase.  As far as P 18:0 is concerned the increased abundance for later AD stages 
within pathology limited regions might provide anti-oxidant protection controlling the 
disease proliferation.   
Overall, all plasmalogen species displayed greater mean abundance in SMTG 
mitochondria when compared to CER and IPL.  For each plasmalogen in SMTG 
mitochondria the population distribution displayed a similar profile.  Normal control was 
slightly lower than MCI, followed by a drop in abundance for PCAD, then an increase for 
both LAD and DC patients.  For P 16:0 and P 18:1 a&b this increase was significant for 
LAD and DC, in addition to NC and MCI for P 18:1a.  As for P 18:0 mean abundances 
for disease populations were noticeable higher in SMTG, although the increase was not 
statistically significant, with the exception of NC patients.  The increased quantity of 
each plasmalogen species within SMTG mitochondrial membrane raises questions about 
their role with regards to oxidative stress.    
The imperative question is whether these species are synthesized as a response to 
an oxidative stress environment [143, 179].  An increased synthesis within an oxidative 
stress environment would make sense following the concept of homeoviscous adaptation.  
However, if increased synthesis was a consequence of oxidative stress then NC patients 
would be expected to contain consistent quantities across the three regions.  Of course the 
regional increase might be a preemptive modification to a potential oxidative stress 
environment.  The population outlier with both of these theories are data from PCAD 
subjects.  The statistically insignificant decrease of plasmalogen species for PCAD 
subjects in SMTG, compared to other regions, might make sense with the connection to 
increase AD pathology given the proposed mechanism of plasmalogens acting as 
antioxidants, [121-122, 134].  However, LAD data would be expected to display a similar 
if not greater reduction, and not a significant increase over CER levels [122-123, 134, 
176]. 
The last set of lipid species to be discussed are arguably the most central to 
research on neurodegenerative disease, these are the long-chain polyunsaturation fatty 
acids.  These PUFAs will be divided into two groups for discussion purposes.  The first 
group will be the ω-6 fatty acid family.  To begin with 5,8,11,14-eicosatetraenoic or 
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arachidonic acid (20:4) is one of the most abundant PUFAs found in neurological tissue.  
The cleavage and subsequent oxidation of arachidonic acid (ARA) from the 
phosphoglycerol background leads to the generation of isoprostanes and ensuing 
biomarkers of oxidative damage [119].  The expression of ARA is interesting being 
significantly higher in CER and reduced in SMTG, whereas the other disease populations 
were significantly higher within SMTG, compared to equivalent CER quantities.  It is 
notable that a lipid species associated with oxidative damage would be less prominent 
during the two later disease states within a region abundant in disease pathology.  These 
data implies that disease progression is associated with reduced ARA abundance within 
SMTG.  However, no statistically significant correlation was found between Braak score 
or NP with SMTG.    
The two FA, 8,11,14-eicosatrienoic (20:3) and 7,10,13,16-docosatetraenoic (22:4) 
exhibited comparable regional and disease state distributions, which are remarkable 
similar to ARA patterns.  The quantities between disease populations were relatively 
unchanged within IPL.  For mitochondria from CER both FAs were most abundant in 
PCAD patients, dropping in abundance for MCI and LAD, then again for NC and DC.  
Again, as seen with ARA the population expression was nearly opposite that of CER.  
Each of the three ω-6 FAs yielded a significant positive correlation in CER between 
Braak score and concentration.  This implies that a greater abundance of PUFAs are 
associated with a known biomarker of oxidative damage, at least within a region deficient 
disease pathology. 
The second set of PUFAs is the ω-3 family, 4,7,10,13,16,19-docosahexaenoic 
acid (22:6, DHA), which is unique being the only ω-3 FA detected in the mitochondrial 
membrane.  Docosahexaenoic acid is widely acknowledged as the most abundant PUFA 
in neurological gray matter, the source for all tissue used in this study [180].  As with 
arachidonic acid, the cleavage of DHA from the glycerol backbone and consequently 
oxidation leads to the development of biomarkers of oxidative stress.  These products, 
otherwise known as neuroprostanes, are the focus of research concerned with the 
products of oxidative stress from lipids [118, 120, 131-132, 145, 178, 181-184].  Overall, 
the regional and subject population distribution of DHA was nearly equivalent to each of 
the ω-6 FAs.  The difference for DHA was a general higher abundance in CER and 
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SMTG for most disease states.  In addition the disparity between higher PCAD and lower 
NC or DC abundances were more distinct.  Along the same lines the significant drop in 
SMTG abundance for PCAD patients was greater with DHA in comparison to ARA.  As 
with the ω-6 FAs DHA correlated positively with increasing Braak score. 
As mentioned earlier because of their proximity to the generation of, and the 
consequential formation of reactive products with, ROS lipids are a fundamental aspect 
to research of neurodegenerative disease [107, 116-117, 119-120, 162, 185].  Studies 
conducted on plasma membrane lipids have found regional differences during the 
progression of Alzheimer’s disease [140].  Further studies have detected regional 
differences in the form of biomarkers of lipid peroxidation when comparing AD patients 
to controls [120].  Literature such as these documenting variations of the lipid profile 
and/or products of lipid peroxidation on a regional scale within neurological tissue 
provided the basis for investigations for mitochondrial fatty acid regional dissimilarity, in 
addition to distinction among disease state. 
Regional and AD disease progression data established that differences are present 
in mitochondria fatty acid profiles which are consistent with the current literature and the 
principle of oxidized products in pathology affected regions [120, 177].  Proteomic 
studies conducted on phospholipases, which function to directly regulate phospholipid 
concentrations, have documented an increased expression in mitochondrial fractions with 
progression of AD [171-174].  Furthermore, activity of phospholipase D has been 
implemented in being linked to amyloid precursor protein, which is the progenitor to 
amyloid beta (Aβ) [172-173, 175].  In other words, lipids have the potential to have an 
affect on the activity of proteins.  The activated proteins, in turn, have the potential to 
employ lipids as substrates for the generation of further metabolic products [171, 174-
175]. 
As a whole, the goal of the project was to elucidate possible changes to 
mitochondrial FAs as a reflection of advanced AD stages, in addition to being more 
prevalent in regions displaying greater pathology.  When viewing the data of individual 
methyl derivatizied species, intra-regional changes were found among disease 
populations and inter-regional changes were found within equivalent disease populations.  
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Statistical evaluation of the data in this two-dimensional manner provided a substantial 
number of comparisons between associated groups.  
The lack of an overwhelming trend concerning the change in methyl derivatizied 
species across disease states can possibly be explained by population noise.  Variation in 
the sample population is natural and should be expected to occur for biological subjects.  
For evaluation of a human population some variables relating to a subject’s history can 
not be controlled and therefore greater differences should be expected to arise.  In 
addition, the designation of a subject’s disease state mostly likely increased sample 
variation.  Braak and Braak noted that pathology differences for classification were 
difficult to discern during transitional stages in disease progression [149].  The seemingly 
subjective nature of stage classification would contribute to variation within a disease 
state.  The range of disease expression within each classification state could be the cause 
of non-normally distributed data.  The ramifications of the non-normally distributions 
were the use of non-parametric statistical tests.  Non-parametric tests compare differences 
in the medians between to groups, thus they lack the statistical power to differentiate 
between minor variations.   
It is interesting to note that statistical differences appeared to be greater across 
neurological regions than found between disease states for a particular region.  Further 
studies would have to be conducted to examine the response of lipid expression in 
response to oxidative stress agents.  Although the current was successful in finding 
significant differences between disease states and regions, it was not possible to indicate 
whether changes were the result or cause of oxidative stress.    
The current project applied the concept of homeoviscous adaptation, adjusting the 
traditional perception of environmental stimuli in exchange for neurological region and 
disease state.  Overall, various FA and plasmalogen changes were found between disease 
states in both pathology affected and limited regions.  Correlation statistics conducted 
between methylated species and disease markers provided random associations, however 
no definite connections were possible to link particular lipid species with plaques or 
tangles.  Several of the changes, such as with PUFAs in SMTG, were unpredicted when 
considered in the context of disease progression and pathology.  Further studies are being 
developed to discern possible changes to the mitochondrial membrane as a result to 
247 
 
specific oxidative insults.  The data obtained from future studies and those obtained 
herein will hopefully provide further evidence for a link between mitochondrial lipid 
composition and AD pathology.     
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PART IV.  CONCLUSIONS 
Chapter 5.1.  Conclusions 
The concept of homeoviscous adaptation was a unifying theme between each of 
the research projects within this dissertation.  This theory was developed by Michael 
Sinensky (circa 1974) as a means to characterize the influence that changes in fatty acid 
(FA) composition have on membrane viscosity.  Sinensky’s experiments with 
Escherichia coli found that cultures grown at various temperatures modified their FA 
content which resulted in maintenance of membrane viscosities [1].  Being as the 
membrane provides protection from extracellular environmental contaminates and as 
structure for membrane-bound proteins, regulation of membrane integrity is critical for 
cellular function [1, 41, 70, 186].  This phenomenon is not relegated to E. coli, as 
temperature induced membrane modification of fatty acids has been documented across a 
range of microorganisms [71-74, 77-78, 187].  The concept of microorganism membrane 
adaptation has since expanded to include a variety of environmental insults, including 
cultures grown in the presence of organic solvents [35, 37, 76, 188].   
The initial research project (Chapter 2) was a multidisciplinary bio-fuels study 
concerned with FA analysis of Clostridium thermocellum strains [138].  The project 
centered on the comparison of membranes from wild-type and ethanol-adapted C. 
thermocellum strains.  A hypothesis was developed that ethanol adaptation could lead to 
modifications in the FA profile, as established by the concept of homeoviscous 
adaptation.  This hypothesis was tested by comparing the relative composition of FA 
between both strains.  Further analysis compared the change in physical properties of the 
membrane induced by ethanol exposure through steady-state fluorescence anisotropy. 
The combination of FA and anisotropy data, proved the hypothesis to be correct, that 
changes in FA profile had occurred as a result of ethanol exposure.  These data 
necessitated development of a model of ethanol adaptation for C. thermocellum cells 
[138].   
The homeoviscous adaptation concept as employed by prokaryotic organisms was 
utilized as a foundation to explore FA variations occurring as a result of non-traditional 
“environmental” factors [1, 39].  Factors such as growth temperature [36, 38, 42, 71-74, 
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77-78], pressure [47, 69, 189] and solvent insults [35, 37, 42, 76, 188] have been 
recognized to affect not only the lipid composition, but also metabolic pathways of 
microorganisms [79-80, 190].  The central concept of homeoviscous adaptation through 
FA modification was expanded beyond unicellular systems and the traditional perception 
of environmental factors (i.e. temperature) to include changes in the intracellular 
environment.   
Previous work from the Lynn group has involved research on mitochondrial based 
projects [191-193].  Mitochondria are of interest because of their involvement in an 
assortment of biomedical research endeavors including respiratory chain deficiencies 
[128, 194-196], age-related diseases [197-198], cancer [100, 196, 198] and 
neurodegenerative diseases [105, 154, 158, 199-200].  The role of mitochondria within 
cellular energy generating pathways, associates them with the development of ROS, 
which have been proposed as casual in the theories of oxidative stress and aging [103, 
141, 198].  With prior group experience and the proposed evolutionary link between 
bacteria and mitochondria, allowed for a logical transition from prokaryotic to eukaryotic 
systems [151].   
The concept of homeoviscous adaptation is generally applied to unicellular 
organisms, and not thought of on the scale of multicellular systems or subcellular 
organelles.  Research conducted in the field of proteomics has documented variations in 
the protein expression between tissues within the same animal [99, 174, 201].  This 
provided motivation to investigate possible differences in the mitochondrial fatty acid 
profiles from various tissues within Sprague Dawley rats (Chapter 3).  A hypothesis was 
formulated that changes in the extracellular environment could cause intracellular 
changes affecting the lipid composition of subcellular organelles.  In order to test the 
hypothesis, mitochondria were isolated from kidney, liver, heart and brain of Sprague 
Dawley rats and derivatizied FAs were compared as a function of tissue.  These results 
confirmed the hypothesis that variations in FA species and relative distributions existed 
between mitochondria isolated from various tissues.  These data indicated that FAs 
within neurological mitochondria provide the potential for increased vulnerability to 
oxidative damage.   
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Data identifying the unique FA profile of neurological mitochondria generated 
interest in investigation of mitochondrial fatty acid modification in human brain regions 
during progression of neurological disease (Chapter 4).  A hypothesis was developed that 
changes to mitochondrial FAs will be reflected during advanced stages of Alzheimer’s 
disease (AD), in addition to being more prevalent in regions displaying greater pathology.  
To test this theory mitochondria were isolated from three regions of neurological tissue 
representing AD progression and compared to control samples.  Although, the hypothesis 
was technically proven by observing statistically significant differences in the 
mitochondrial FA profile among regions and disease populations, the results did not 
provide distinctions as originally predicted.  Therefore, the original hypothesis should be 
revised to more accurately identify dissimilarity between mitochondria.  In keeping with 
advances in instrumental development further testing could be conducted to increase the 
volume of data obtained from mitochondria samples and fine-tune the hypothesis.  
With the advent of electrospray ionization (ESI) the study of lipids has undergone 
a radical change in recent years [202-203].  The traditional method of derivatization prior 
to analysis has in large part been replaced by direct lipid analysis following a Folch style 
extraction [204].  The coupling of ESI to a mass analyzer allows the analysis of intact 
phospholipids following membrane extraction [9-10, 205-207].  The advantage with this 
technique is the ability to discern fatty acid acyl chain pairings and bonding geometries 
along the glycerol backbone in addition to phosphate polar head group determination 
[205, 208].  Data on glycerol associated fatty acid species are valuable to understanding 
the relationship of plasmalogens and PUFAs in an oxidative stress environment [177, 
179, 209].  Analysis of polar head group designation is equally important for studying 
variations among phospholipids with respect to disease expression as these groups are 
involved in signal regulation [93, 97, 140].   
The advantages afforded by ESI allow the acquisition of phospholipid data not 
possible with methyl derivatization techniques.  However, data on individual FA species, 
such as sites of unsaturation are typically lost.  Therefore, to get a complete lipidomics 
representation of a system and changes that occur in response to environmental stimuli 
both types of analysis would be necessary. 
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In keeping with current trends in lipid research and in an effort to acquire data lost 
during the derivatization process, method development for the analysis of neurological 
mitochondria phospholipid profiles were initiated using ESI techniques.  The goal is to 
analyze mitochondria isolated during Chapter 4.  Therefore, data can be obtained on FAs 
and phospholipids on the exactly the same sample set.  The expectation is that intact 
phospholipid data will provide further differentiation between region and disease state 
mitochondria.   
For the application of lipidomics and their involvement in neurodegenerative 
health, I would propose additional future experiments.  With the current study isolated 
mitochondria were obtained from tissues obtained during autopsy.  This means that both 
mitochondria and disease state classification represent the comparison of end-points.  
Data obtained do not provide an indication of whether the lipid profile influences disease 
progression or vise-versa.  Obviously, isolation of tissue samples from living patients is 
not possible; however studies with cell cultures would alleviate this hurdle.  Experiments 
with neurological cell cultures and the exposure to oxidative insults would provide data 
on the potential mitochondrial, or cellular, lipid response to a simulated disease state 
environment.    
Going further with mitochondrial lipidomics, current research has proposed a link 
between disease and phospholipid expression along the outer-layer of the lipid bilayer 
[210-211].  Although the separation of inner and outer mitochondrial membranes has 
been documented, the method is probably not amendable to high-throughput analysis 
[212].  An alternative procedure would be to react intact mitochondria with a ligand that 
specifically binds to the phosphotidyl head group.  Phospholipid isolation could then 
precede by established isolation methods following by ESI analysis.  Phospholipids 
tagged with the ligand can be identified by mass shifts and the neutral loss of the tagged 
head-group through MS/MS spectra would be known to originate from the external layer 
of the outer membrane.  The advantage with this technique is that it can be used in 
conjunction with established instrumental methods, complimenting acquisition by 
supplying additional information alongside previously acquired data.  
The concept of homeoviscous adaptation was shown to be integral to each 
research project within this dissertation.  The catalyst for environmental adaptation 
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evolved from an organic solvent to changes in extracellular environment, such as tissue 
and regional origin, and finally to neurodegenerative pathology.  Adaptation of lipids at 
its best can be a process for cellular survival, as in the case with C. thermocellum, or at its 
worst create the potential for propagation of deleterious products resulting in 
macrocellular repercussions.  
The field of lipid research has evolved over the years keeping pace with current 
trends in instrument development, facilitating research into biological systems.  Still 
considerable challenges remain for the progression of lipidomics into high-throughput 
research endeavors [213-214].  The future of lipidomics seems boundless as 
chromatographic and mass spectral method developments are pushing the scientific 
envelope and allowing application into countless aspects of cellular and systems biology 
[4-5, 11, 13, 97, 129, 215-217].       
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